A Dormant Microbial Component in the Development of Preeclampsia

Abstract

Preeclampsia (PE) is a complex, multisystem disorder that remains a leading cause of morbidity and mortality in pregnancy. Four main classes of dysregulation accompany PE and are widely considered to contribute to its severity. These are abnormal trophoblast invasion of the placenta, anti-angiogenic responses, oxidative stress, and inflammation. What is lacking, however, is an explanation of how these themselves are caused. We here develop the unifying idea, and the considerable evidence for it, that the originating cause of PE (and of the four classes of dysregulation) is, in fact, microbial infection, that most such microbes are dormant and hence resist detection by conventional (replication-dependent) microbiology, and that by occasional resuscitation and growth it is they that are responsible for all the observable sequelae, including the continuing, chronic inflammation. In particular, bacterial products such as lipopolysaccharide (LPS), also known as endotoxin, are well known as highly inflammagenic and stimulate an innate (and possibly trained) immune response that exacerbates the inflammation further. The known need of microbes for free iron can explain the iron dysregulation that accompanies PE. We describe the main routes of infection (gut, oral, and urinary tract infection) and the regularly observed presence of microbes in placental and other tissues in PE. Every known proteomic biomarker of “preeclampsia” that we assessed has, in fact, also been shown to be raised in response to infection. An infectious component to PE fulfills the Bradford Hill criteria for ascribing a disease to an environmental cause and suggests a number of treatments, some of which have, in fact, been shown to be successful. PE was classically referred to as endotoxemia or toxemia of pregnancy, and it is ironic that it seems that LPS and other microbial endotoxins really are involved. Overall, the recognition of an infectious component in the etiology of PE mirrors that for ulcers and other diseases that were previously considered to lack one.

Introduction

Preeclampsia

Preeclampsia is a multisystem disorder of pregnancy, characterized and indeed defined by the presence of hypertension after 20 weeks’ gestation and before the onset of labor, or postpartum, with either proteinuria or any multisystem complication (1–9). It is a common condition, affecting some 3–5% of nulliparous pregnant women (8, 10) and is characterized by high mortality levels (11–14). There is no known cure other than delivery, and consequently, preeclampsia (PE) also causes significant perinatal morbidity and mortality secondary to iatrogenic prematurity. There are a variety of known risk factors (Table 1) that may be of use in predicting a greater likelihood of developing PE, albeit there are so many, with only very modest correlations, that early-stage (especially the first-trimester) prediction of late-stage PE remains very difficult (8, 15–17).

It is striking that most of the “risk factors” of Table 1 are, in fact, risk factors for multiple vascular or metabolic diseases, i.e., they merely pre-dispose the individual to a greater likelihood of manifesting the disease or syndrome (in this case PE). Indeed, some of them are diseases. This would be consistent with the well-known comorbidities, e.g., between PE and later cardiovascular disease [e.g., Ref. (55–65)], between PE and intracerebral hemorrhage during pregnancy [OR 10.39 (66)], and between PE and stroke postpartum (67, 68). The penultimate row of Table 1 lists a series of diseases that amount to comorbidities, although our interest was piqued by the observation that one-third of patients with antiphospholipid syndrome have PE, and infectious agents with known cross-reacting antigens are certainly one original (external) source of the triggers that cause the antiphospholipid antibodies (43, 44, 47, 69) (and see below). Similarly, in the case of urinary tract infection (UTI), the “risk” factor is a genuine external trigger, a point [following the call by Mignini and colleagues (70) for systematic reviews] that we shall expand on considerably here. [A preprint has been lodged at bioRxiv (71).]

In recent decades, intense investigation has led to the development of a two-stage etiological model for PE, first proposed by Redman (72), in which inadequate remodeling of the spiral arteries in early gestation results in poor placental development (stage one) and the resultant ischemia/reperfusion injury and oxidative stress (73) eventually leads to maternal vascular endothelial cell dysfunction and the maternal manifestations of the disease (stage 2) (72, 74–77). However, many clinical inconsistencies challenge the simplicity of this model. For example, while the association between poor placentation and PE is well established, it is not specific. Poor placentation and fetal growth restriction (FGR) frequently present without maternal signs of PE. Moreover, FGR is not a consistent feature of PE. While it is commonly seen in PE presenting at earlier gestations, in PE presenting at term, neonates are not growth restricted and may even be large for dates (78).

Thus, the two-stage model has been further refined by Roberts and others (77, 79, 80) to take into account the heterogeneous nature of PE and the varying contribution from mother and infant to the disorder. We now appreciate that normal pregnancy is characterized by a low-grade systemic inflammatory response and specific metabolic changes, and that virtually all of the features of normal pregnancy are simply exaggerated in PE (81–83). There is also widespread acceptance that maternal constitutional and environmental factors (such as obesity) can interact to modulate the risk of PE. Thus, with profoundly reduced placental perfusion (or significant “placental loading”), the generation of stage 2 may require very little contribution from the mother to provide sufficient stress to elicit the maternal syndrome. In this setting, almost any woman will develop PE. Conversely, the woman with extensive predisposing constitutional sensitivity could develop PE with very little reduced perfusion, or minimal “placental loading.” As with many complex disorders, multiple factors can affect disease development positively or negatively, with a convenient representation of the two main negative sources (fetal and maternal) being that of a see-saw (84), as in Figure 1.

Figure 1

While this explains the inconsistencies of the two-stage model, the precise mechanisms (1) underlying the initial poor placentation and (2) linking placental stress and the maternal syndrome have still not been fully elucidated.

Much recent research in PE has focused on various angiogenic factors, including the pro-angiogenic factors vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) and the two anti-angiogenic proteins, such as soluble endoglin (sEng) and soluble fms-like tyrosine kinase 1 (sFlt-1). Recent data suggest that alterations in circulating angiogenic factors play a pathogenic role in PE. These angiogenic factors tightly regulate angiogenesis and are also essential for maintenance of normal vessel health. Consequently, the synthesis and action of these factors and their receptors in the uterine bed and placenta are essential for normal placental development and pregnancy (85, 86). In PE, increased levels of the anti-angiogenic sFlt-1 and sEng trap circulating VEGF, PlGF, and transforming growth factor-β (TGF-β), respectively. A myriad of data support the idea that circulating levels of these factors alone, or in combination, can be used to predict PE (87–89) (and see below under PE biomarkers), but in line with the heterogeneous nature of PE, these data are somewhat inconsistent and their performance as biomarkers seems limited to disease with significant placental loading (8). Therefore, angiogenic dysregulation would appear unlikely to be the sole link between the stressed placenta and endothelial dysfunction and the clinical manifestations of the disease.

Notwithstanding these many inconsistencies, the central role of the placenta as a source of “toxin,” in a condition regarded, and indeed often named, as “toxemia of pregnancy” (90–92) cannot be refuted. The uncertainty regarding the nature of the toxin continues, and other placental sources of endothelial dysfunction include syncytiotrophoblast basement membrane fragments (STBM) (93) and endothelial progenitor cells (EPC) (94); an increase of reactive oxygen species over scavenging by antioxidants (95, 96) has also been promoted.

The Bradford Hill criteria for causation of a disease Y by an environmental factor X (97) are as follows: (1) strength of association between X and Y, (2) consistency of association between X and Y, (3) specificity of association between X and Y, (4) experiments verify the relationship between X and Y, (5) modification of X alters the occurrence of Y, and (6) biologically plausible cause and effect relationship.

In general terms (98), if we see that two things (A and B) co-vary in different circumstances, we might infer that A causes B, that B causes A, or that something else (C) causes both B and A, whether in series or parallel. To disentangle temporal relations requires a longitudinal study. The job of the systems biologist doing systems medicine is to uncover the chief actors and the means by which they interact (99), in this way fulfilling the Bradford Hill postulates, a topic to which we shall return at the end.

In infection microbiology, and long predating the Bradford Hill criteria, the essentially equivalent metrics are known [widely, but somewhat inaccurately (100)] as the Koch or Henle–Koch postulates (i.e., criteria). They involve assessing the correlation of a culturable organism with the presence of a disease, the cure of the disease (and its symptoms) upon removal of the organism, and the development of the disease with (re)inoculation of the organism. They are of great historical importance but present us with three main difficulties here. The first is that we cannot apply the third of them to humans for obvious ethical reasons. The second (see also below) and related one is that we cannot usefully apply them in animal models because none of the existing models recapitulates human PE well. Finally, as widely recognized (100–107), they cannot be straightforwardly applied when dealing with dormant bacteria or bacteria that are otherwise refractory to culture.

Our solution to this is twofold: (i) we can assess the first two using molecular methods if culturing does not work and (ii) we exploit the philosophy of science principle known as “coherence” (108–112). This states that if a series of ostensibly unrelated findings are brought together into a self-consistent narrative and that narrative is thereby strengthened. Our systems approach purposely represents a “coherence” in the sense given.

Overall, known biochemical associations with PE come into four main categories, such as abnormal trophoblast invasion, oxidative stress, inflammation and altered immune response, and anti-angiogenic responses (Figure 2). Each of these can contribute directly to PE, and although they can interact with each other (black arrows), no external or causal source is apparent. Figure 2 has been redrawn from a very nice review by Pennington and colleagues (113), which indicates four main generally accepted “causes” (or at least accompaniments) of PE as the four outer colored circles. As illustrated with the black two-way arrows, many of these also interact with each other. What is missing, in a sense, is then what causes these causes, and that is the nub of our argument here. Since we now know (and describe below) that microbes can affect each of these four general mechanisms, we have added these routes to Figure 1 (using pink arrows) where dormant, resuscitating, or growing microbes are known to contribute.

Figure 2

In a similar vein, Magee and colleagues (114) have nicely set down their related analysis of the causes and consequences of PE, with a central focus (redrawn in Figure 3) on endothelial cell activation. While bearing much similarity in terms of overall content to the analysis of Pennington and colleagues (113), and ours above, it again lacks a microbial or infection component as a causative element, but importantly does note that infection and/or inflammation can serve to lower the threshold for PE in cases of inadequate placentation. In our view, microbes can also enter following normal placentation if their dormant microbiome begins to wake up and/or to shed inflammagens.

Figure 3

Heritability

The question of the extent of heritability of PE (susceptibility) is of interest. Although this seems to vary widely in different studies (Table 1), a number of candidate gene studies (37, 115–118) imply that a susceptibility to PE is at least partly heritable, consistent with the variance in all the other “risk factors” of Table 1 [and see Ref. (6)]. As with all the other gene association studies where phenotypic (“lifestyle”) information is absent (119–121), it is not possible to ascribe the heritability to genetics alone, as opposed to an interaction of a genetic susceptibility (e.g., in the HLA system) with environmental factors (117), such as cytomegalovirus infection (122).

Inflammation

Preeclampsia is accompanied by oxidative stress (123, 124) and inflammation and, thus, shares a set of observable properties with many other (and hence related) inflammatory diseases, be they vascular (e.g., atherosclerosis), neurodegenerative (e.g., Alzheimer’s, Parkinson’s), or “metabolic” (type 1 and 2 diabetes). It is thus at least plausible that they share some common etiologies, as we argue here, and that knowledge of the etiology of these diseases may give us useful clues for PE.

As well as raised levels of inflammatory cytokines that constitute virtually a circular definition of inflammation, we and others have noted that all of these diseases are accompanied by dysregulation of iron metabolism (84, 125, 126), hypercoagulability and hypofibrinolysis (127, 128), blood microparticles (126), and changes in the morphology of fibrin fibers [e.g., Ref. (129–134)] and of erythrocytes [e.g., Ref. (127, 132–137)].

In addition, we and others have recognized the extensive evidence for the role of a dormant blood and/or tissue microbiome in these (138–143) and related (144–147) diseases, coupled in part with the shedding of highly inflammagenic bacterial components such as Gram-negative lipopolysaccharide (LPS) and their Gram-positive cell wall equivalents such as lipoteichoic acids (148). (We shall often use the term “LPS” as a “shorthand,” to be illustrative of all of these kinds of highly inflammagenic molecules.)

The purpose of this review, outlined as a “mind map” in Figure 4, is thus to summarize the detailed and specific lines of evidence suggesting a very important role of a dormant microbial component in the etiology of PE [and see also Ref. (138)]. To do this, we must start by rehearsing what is meant by microbial dormancy.

Figure 4

Bacterial Viability

In microbiology, we usually consider microbes as being in one of the three “physiological macrostates” (Figure 5). The definition of a “viable” bacterium is normally based on its ability to replicate, i.e., “viability” = culturability (149–151). In this sense, classical microbiology has barely changed since the time of Robert Koch, with the presence of a “viable” microorganism in a sample being assessed via its ability to form a visible colony on an agar plate containing suitable nutrients. However, it is well known, especially in environmental microbiology [“the great plate count anomaly” (152)], that only a small percentage of cells observable microscopically is typically culturable on agar plates. In principle, this could be because they are/were “irreversibly” non-culturable (operationally “dead”), or because our culture media either kill them (153) or such media lack nutrients or signaling molecules necessary for their regrowth (154, 155) from an otherwise dormant state (156, 157). These statements are true even for microbes that appear in culture collections and (whose growth requirements) would be regarded as “known.”

Figure 5

However, it is common enough in clinical microbiology that we detect the existence or presence of “novel” microbial pathogens with obscure growth requirements before we learn to culture them; this is precisely what happened in the case of Legionella pneumophila (158–161), Tropheryma whipplei [Whipple’s disease (162, 163)], and Coxiella burnetii [the causative agent of Q fever (164, 165)]. Even Helicobacter pylori was finally brought into culture on agar plates only because an unusually long Easter holiday break meant that the plates were incubated for an extended period of 5 days (rather than the normal 2) before being thrown out (166, 167)! Consequently, there is ample precedent for the presence of “invisible” microbes to go unremarked before they are discovered as the true cause of a supposedly non-infectious disease, even when they are perfectly viable (culturable) according to standard analyses.

Dormancy

Dormancy for a microbe is defined operationally as a state, commonly of low metabolic activity, in which the organism appears not to be viable in that it is unable to form a colony but where it is not dead in that it may revert to a state in which it can do so, via a process known as resuscitation (156, 157). However, an important issue (and see above) is that dormant bacteria do not typically fulfill the Koch–Henle postulates (100–103), and in order for them to do so it is necessary that they be grown or resuscitated. This is precisely what was famously done by Marshall and Warren when they showed that the supposedly non-infectious disease of gastric ulcers was, in fact, caused by a “novel” organism called H. pylori (168, 169). One of the present authors showed in laboratory cultures of actinobacteria that these too could enter a state of true dormancy (170, 171) [as is well known for Mycobacterium tuberculosis, e.g., Ref. (172–176)], and could be resuscitated by a secreted growth factor called Rpf (177–181). This RPF family has a very highly conserved motif that is extremely immunogenic (182, 183), and it is presently under trials as a vaccine against M. bovis.

Prevalence of Dormant, Persistent, or Latent Bacteria in Infection Microbiology

It is worth stressing here that the presence of dormant or latent bacteria in infection microbiology is well established; one-third of humans carry dormant M. tuberculosis [e.g., Ref. (175, 184–187)], most without reactivation, while probably 50–100% are infected with H. pylori, most without getting ulcers or worse (188, 189). As with the risk factors in Table 1, the organisms are merely or equivalently “risk factors” for these infectious diseases and are effectively seen as causative only when the disease is actually manifest.

In a similar vein, so-called persisters are phenotypic variants of infectious microbes that resist antibiotics and can effectively lie in hiding to resuscitate subsequently. This is also very well established [e.g., Ref. (139, 190–203)]. In many cases, they can hide intracellularly (204), where antibiotics often penetrate poorly (205) because the necessary transporters (206–209) are absent. This effectively provides for reservoirs of reinfection, e.g., for Staphylococcus aureus (210), Bartonella spp. (211), and – most pertinently here – for the Escherichia coli involved in urinary tract (re)infection (212–215). The same intracellular persistence is true for parasites such as Toxoplasma gondii (216).

Thus, the main point of the extensive prevalence of microbial dormancy and persistence is that microbes can appear to be absent when they are, in fact, present at high concentrations. This is true not only in cases where infection is recognized as the cause of disease but, as we here argue, such microbes may be an important part of diseases presently thought to lack an infectious component.

Iron and Inflammation

It is well known that [with the possible exception of Borrelia (217, 218)] a lack of free iron normally limits microbial growth in vivo [e.g., Ref. (219–243)], and we have reviewed previously (84, 125, 126) the very clear iron dysregulation accompanying PE [e.g., Ref. (90, 244–256)].

This has led to the recognition (128, 139, 141) that the source of the continuing inflammation might be iron-based resuscitation of dormant microbes that could release well known and highly potent inflammagens such as LPS. Indeed, we have shown that absolutely tiny (highly substoichiometric) amounts of LPS can have a massive effect on the blood clotting process (257), potentially inducing β-amyloid formation directly (258, 259) [something, interestingly, that can be mimicked in liquid crystals (260, 261)]. The overall series of interactions envisaged [see also Kell et al. (139)] is shown in Figure 6.

Figure 6

As pointed out by a referee, worldwide, iron deficiency anemia is associated with increased perinatal morbidity and mortality, predominantly in low resource settings. This is most recently and comprehensively reviewed by Rahman and colleagues (262). This meta-analysis (262) found that in low- and middle-income countries, maternal hemoglobin concentrations <10 or <11 g dL⁻¹ or hematocrit values <33 or <34% accounted for 12% of low birth weight, 19% of preterm births (PTBs), and 18% of perinatal mortality. However, the independent contribution of iron deficiency is difficult to define, especially since in low resource settings anemia is often not found in isolation but as part of a wider spectrum of nutritional insufficiencies (especially vitamins and folic acid) or as a result of parasitic infection. These can increase susceptibility to other insults such a hemorrhage or infection, also common in low resources settings. In addition, the exact speciation and hence availability of iron may be important (not just the total amount). Thus, the hypothesis presented here is that iron in excess or under certain physiological conditions can be, and indeed is, equally detrimental to maternal health. There is a likely a “Goldilocks” concentration of iron which is optimal for maternal and neonatal health, and the authors are proposing the selected use of treatments such as statins or iron chelators in the at-risk population, rather than as a broad panacea. Furthermore, the use of statins to prevent pregnancy complications is far from controversial (see also below). There are at least two registered current trials of statins to prevent PE (ISRCTN17787139 and ISRCTN23410175).

Detecting Dormant Microbes

By definition, dormant bacteria escape detection by classical methods of assessing viability that involve replication on agar plates. Other growth-associated methods include measurements involving changes in turbidity (263), including an important but now rather uncommon technique referred to as the “most probable number” (MPN). The MPN involves diluting samples serially and assessing by turbidity changes in the presence of growth/no growth. Look-up tables based on Poisson statistics enable estimation of the number of cells or propagules that were present. A particular virtue is that they allow dormant and “initially viable” cells to be discriminated via “dilution to extinction” (171), thereby avoiding many artifacts (157). As mentioned earlier, preincubation in a weak nutrient broth (171, 264) was instrumental in allowing the discovery (177) of an autocrine “wake-up” molecule necessary for the growth of many actinobacteria.

Other more classical means of detecting microbes, but not whether they were culturable, involved microscopy (190, 265–268) or flow cytometry (269) with or without various stains that reflected the presence or otherwise of an intact cell wall/membrane (170, 270–277). These stains are sometimes referred to as “viability” stains, but this is erroneous as they do not measure “culturability.” Readers may also come upon the term “viable-but-not-culturable”; however, since viable = culturable, this is an oxymoron that we suggest is best avoided (157). Other methods involved measurement of microbial products, e.g., CO₂ (278, 279), or changes in the conductivity or impedance of the growth medium (263, 280–282).

Most importantly, however, dormant (as well as culturable) cells may be detected by molecular means, nowadays most commonly through PCR and/or sequencing of the DNA encoding their small subunit ribosomal RNA (colloquially “16S”) (283–297) or other suitable genes. It is clear that such methods will have a major role to play in detecting, identifying, and quantifying the kinds of microbes that we argue lie at the heart of PE etiology.

A Dormant Blood Microbiome

Of course, actual bacteremia, the presence of replicable bacteria in blood, is highly life-threatening (298), but – as emphasized – viability assays do not detect dormant bacteria. When molecular detection methods are applied to human blood, it turns out that blood does indeed harbor a great many dormant bacteria [e.g., Ref. (299–309)]; they may also be detected ultramicroscopically [e.g., Ref. (139–141, 190, 267, 300, 310)] or by flow cytometry (311), and dormant blood and tissue microbes probably underpin a great many chronic, inflammatory diseases normally considered to lack a microbial component (139–141, 144–147, 190, 267, 268, 302, 312–321). Multiple arguments serve to exclude “contaminants” as the source of the bacterial DNA (141): (1) there are significant differences between the blood microbiomes of individuals harboring disease states and nominally healthy controls, despite the fact that samples are treated identically; (2) the morphological type of organism (e.g., coccus vs. bacillus) seems to be characteristic of particular diseases; (3) in many cases, relevant organisms lurk intracellularly, which is hard to explain by contamination; (4) there are just too many diseases where bacteria have been found to play a role in the pathogenesis, that all of them may be caused by contamination; (5) the actual numbers of cells involved seem far too great to be explicable by contamination; given that blood contains ~5 × 10⁹ erythrocytes mL⁻¹, if there was just one bacterial cell per 50,000 erythrocytes this will equate to 10⁵ bacteria mL⁻¹. These are big numbers, and if the cells were culturable, that number of cells would be the same as that ordinarily defining bacteriuria.

A recent study by Damgaard and colleagues (306) is of particular interest here. Recognizing the strong mismatch between the likelihood of an infection post-transfusion [very high (306)] and the likelihood of detecting culturable microbes in blood bank units (negligible, ca. 0.1%) (306, 322), Damgaard et al. reasoned that our methods of detecting and culturing these microbes might be the problem. Certainly, taking cells from a cooled blood bag and placing them onto an agar plate at room temperature that is directly exposed to atmospheric levels of gaseous O₂ is a huge stress leading to the production of “reactive oxygen species” (125, 323), that might plausibly kill any dormant, injured, or even viable microbes. Thus, they incubated samples from blood on a rich medium (trypticase soy agar) for a full week, both aerobically and anaerobically. Subsequent PCR and sequencing allowed them to identify specific microbes in some 35–53% of the samples. Thus, very careful methods need to be deployed to help resuscitate bacteria from physiological states that normally resist culture, even when these bacteria are well-established species. This is very much beginning to happen in environmental microbiology [e.g., Ref. (154, 324–326)], and such organisms are rightly seen as important sources of novel bioactives (327, 328).

As reviewed previously (139–143), the chief sources of these blood microbes are the gut microbiome, the oral microbiome [periodontitis (329)], and via UTIs. Consequently, if we are to argue that there is indeed a microbial component to PE, we should expect to see some literature evidence for it (53, 54, 138, 330–332). In what follows we shall rehearse the fact that it is voluminous.

Direct Evidence for a Role of Infectious Agents in PE

Although we recognize that many of the more molecular methods cannot distinguish culturable from dormant microbes, quite a number of studies have explicitly identified infection as a cause of PE (Table 2). The commonest microbe seems to be H. pylori; while it is most famously associated with gastric ulcers (168, 169, 333), there are many other extragastric manifestations [e.g., Ref. (334–342)]. The odds ratio of no less than 26 in PE vs. controls when the strains can produce CagA antigens is especially striking, not least because it provides a mechanistic link to poor trophoblast invasion via a mechanism involving host antibodies to CagA cross-reacting with trophoblasts (343, 344), and circulating (345) in microparticles (346) or endosomes (347, 348).

In contrast to the situation in PE, albeit severe PE is associated with iatrogenic PTBs, there is a widespread recognition [e.g., Ref. (383–410)] that infection is a common precursor to PTB in the absence of PE. The failure of antibiotics to help can be ascribed to their difficulty of penetrating to the trophoblasts and placental regions. Unfortunately, no proteomic biomarkers have yet been observed as predictive of PTB (411, 412). In a similar vein, and if we are talking about a time of parturition that is very much more “preterm,” we are in the realm of miscarriages and spontaneous abortions and stillbirths, where infection again remains a major cause (413–416). Here, we note that early or pre-emptive antibiotic therapy has also proved of considerable value in improving outcomes after multiple spontaneous abortions (417).

Vaginal, Placental, and Amniotic Fluid Microbiomes in PE

It might be natural to assume that the placenta is a sterile organ, like blood is supposed to be. However, various studies [modulo the usual issues of contamination (418)] have shown the presence of microbes in tissues including the placenta (400, 409, 419–432), vagina (393, 433–440), uterus (391, 441, 442), amniotic fluid (430, 443–448), and follicular fluid (449, 450), and how these may vary significantly in PE [we do not discuss other pregnancy disorders such as small for gestational age (SGA) and intrauterine growth restriction (IUGR)]. We list some of these in Table 3.

Origins of a Blood and Tissue Microbiome

As assessed previously (139–141) over a large literature, the chief source of blood microbes is the gut (426), with another major entry point being via the oral microbiome (especially in periodontitis, see below). For rheumatoid arthritis (142, 458–460) and diseases of pregnancy, UTI (see below and Table TT) also provides a major source.

Gut Origins of Blood Microbes and LPS

We have recently rehearsed these issues elsewhere (139–141), so a brief summary will suffice. Clearly, the gut holds trillions of microbes, with many attendant varieties of LPS (461), so even low levels of translocation [e.g., Ref. (462–464)], typically via Peyer’s patches and M cells, provide a major source of the blood microbiome. This may be exacerbated by intra-abdominal hypertension and overeating (465–467) that can indeed stimulate the translocation of LPS (468). For reasons of space and scope, we do not discuss the origins and translocation of microbes in breast milk (469) nor the important question of the establishment of a well-functioning microbiome in the fetus and neonate (470), and the physiological role of the mother therein.

Preeclampsia and Periodontal Disease

One potential origin of microbes that might be involved in, or represent a major cause of, PE is the oral cavity, and in particular when there is oral disease (such as periodontitis and gum bleeding) that can allow microbes to enter the bloodstream. If this is a regular occurrence one would predict that PE would be much more prevalent in patients with pre-existing periodontitis [but cf. Ref. (471) for those in pregnancy] than in matched controls; this is indeed the case (Table 4). As with many of the tables herein, the odds ratios are far beyond anything that might weakly be referred to as an “association.”

Urinary Tract Infections

A particular feature of UTIs is the frequency of reinfection (497–504). This is because the organisms can effectively “hide” in bladder epithelial cells as the so-called “quiescent intracellular reservoirs” (212, 501, 503, 505–509) of (presumably) dormant cells that can resuscitate. This is why reinfection is often from the same strains that caused the original infection (510–514). Other complications can include renal scarring (515). Bacteriuria (often asymptomatic) is a frequent occurrence in pregnancy [e.g., Ref. (373, 375, 473, 516–522)], and the frequency of UTI as a source of microbes causing PE is clear from Table 2.

From Blood to and from the Placenta: A Role for Microparticles

We and others have noted the fact that many chronic, inflammatory disease are accompanied by the shedding of various antigens and other factors; typically they pass through the bloodstream as microparticles (126, 140, 523–530), sometimes known as endosomes (345, 347, 348, 524, 531) [and see later under microRNAs (miRNAs)]. Similarly, LPS is normally bound to proteins such as the LPS-binding protein and apoE (140). Given their prevalence, their role in simply finding their way from maternal blood to placenta, and the fact that we discussed them extensively in two previous reviews (126, 140), we do not discuss them further here.

Evidence from Antibiotic Therapies

Antibiotic drug prescriptions (532–534) may be seen as a proxy for maternal infection, so if dormant (and resuscitating and growing) bacteria are a major part of PE etiology one might imagine an association between antibiotic prescriptions and PE. According to an opposite argument, antibiotics and antibiotic prescriptions given for nominally unrelated infections (UTI, chest, etc., and in particular diseases requiring long-term anti-infective medication that might even last throughout a pregnancy) might have the beneficial side-effect of controlling the proliferation of dormant cells as they seek to resuscitate. There is indeed some good evidence for both of these, implying that it is necessary to look quite closely at the nature, timing, and duration of the infections and of the anti-infective therapy relative to pregnancy. A summary is given in Table 5. A confounding factor can be that some (e.g., the antiretroviral) therapies are themselves quite toxic (535, 536); while the OR for avoiding PE was 15.3 in one study of untreated HIV-infected individuals vs. controls, implying (as is known) a strong involvement of the immune system in PE, the “advantage” virtually disappeared upon triple-antiretroviral therapy (537). Overall, it is hard to draw conclusions from antiretrovirals (538, 539). However, we have included one HIV study in the table. Despite a detailed survey, we found no reliable studies with diseases such as Lyme disease or tuberculosis, where treatment regimens are lengthy, that allowed a fair conclusion as to whether antibiotic treatment was protective against PE. However, we do highlight the absolutely stand-out study of Todros and colleagues (540), who noted that extended spiramycin treatment (of patients with T. gondii) gave a greater than 10-fold protection against PE, when the parasite alone had no effect (541). This makes such an endeavor (assessing the utility of early or pre-emptive antibiotics in PE) potentially highly worthwhile.

Role of LPS in PE

It is exceptionally well known that LPS (sensu lato) is highly inflammagenic, and since one of us recently reviewed that literature in extenso (140) this is not directly rehearsed here. However, since we are arguing that it has a major role in PE naturally or in vivo, we do need to ask whether the literature is consistent with this more focused question. The answer is, of course, a resounding “yes.” Notwithstanding that only primates, and really only humans, are afflicted by “genuine” PE, so the genuine utility of rodent models is questionable (543), even if some can recapitulate elements of the disease (544, 545). Hence, it is somewhat ironic that there are a number of animal models in which LPS (also known as “endotoxin”) is used experimentally to induce a condition resembling PE [e.g., Ref. (546–551) and also see Ref. (552)]. We merely argue that it is not a coincidence that exogenous administration of LPS has these effects, because we consider that it is, in fact, normally one of the main mediators of PE. Also note, in the context of gestational diabetes, that serum levels of LPS are raised significantly in both type 1 (466, 553) and type 2 (554–556) diabetes.

The standard sequelae of LPS activation, e.g., TLR signaling and cytokine production, also occur in PE (557–559), bolstering the argument that this is precisely what is going on. In a similar vein, double-stranded RNA-mediated activation of TLR3 and TLR7/8 can play a key role in the development of PE (560–562). What is new here is our recognition that LPS and other inflammagens [e.g., Ref. (563–565)] may continue to be produced and shed by dormant and resuscitating bacteria that are generally invisible to classical microbiology.

Effects of LPS and Other Microbial Antigens on Disrupting Trophoblast Invasion and/or Stimulating Parturition

As with other cases of cross-reactivity such as that of various antigens in Proteus spp. that can cause disease in rheumatoid arthritis (458–460), the assumption is that various microbial antigens can lead to the production of (auto-)antibodies that attack the host, in the present case of interest by stopping the placentation by trophoblasts. This is commonly referred to as “molecular mimicry” [e.g., Ref. (566–569)] and may extend between molecular classes, e.g., peptide/carbohydrate (570, 571). Table 6 shows some molecular examples where this has been demonstrated.

In many cases, the actual (and possibly microbial) antigens are unknown, and clearly the microbial elicitation of antibodies to anything that might contribute to PE points to multiple potential origins. To this end, we note that PE has also been associated with antibodies to angiotensin receptors (577–590), to smooth muscle (591, 592) [such blocking may be anti-inflammatory (593–595)], to adrenoceptors (596), to the M2 muscarinic receptor (597), and to Th17 (598) [and see Ref. (599)]. It is not unreasonable that epitope scanning of the antibody targets coupled with comparative sequence analysis of potential microbes might light up those responsible. In the case of angiotensin II type 1 receptor antibodies, the epitope is considered (600) to be AFHYESQ, an epitope that also appears on parvovirus B19 capsid proteins; in the event, parvoviruses seem not to be the culprits here (601). However, the role of these antibodies in activating the angiotensin receptor is also considered to underpin the lowering of the renin–angiotensin system that is commonly seen in PE (602–605), but which is typically raised during normal pregnancy.

Th-17 is of especial interest here, since these are the helper T (Th)-cell subset that produces IL-17. IL-17 is probably best known for its role in inflammation and autoimmunity (599, 606–610). However, it also has an important role in induction of the protective immune response against extracellular bacteria or fungal pathogens at mucosal surfaces (608, 611–623). Th17 cells seem to participate in successful pregnancy processes and can be lower in PE (624–626), although more studies show them as higher (599, 627–635) or unchanged (636, 637). One interpretation, consistent with the present thesis, is that the antimicrobial effects of placental IL-17 relative to T_reg cells are compromised during PE (599, 633, 638).

A Note on the Terminology of Sepsis

As one may suppose from the name, sepsis (and the use of words like “antiseptic”) was originally taken to indicate the presence of culturable organisms in (or in a sample taken from) a host, e.g., as in bacteremia. Recognizing that it is the products of bacteria, especially cell wall components, that cause the cytokine storms that eventually lead to death from all kinds of infection (639–643), “sepsis” nowadays has more come to indicate the latter, as a stage (in the case of established infection) on a road that leads to septic shock and (eventually) to death [with a shockingly high mortality, and many failures of initially promising treatments, e.g., Ref. (644, 645), and despite the clear utility of iron chelation (84, 125, 646–648)]. In most cases, significant numbers of culturable microbes are either unmeasured or absent, and like most authors, we shall use “sepsis” to imply the results of an infection whether the organisms are detected or otherwise. Overall, it is possible to see the stages of PE as a milder form of the sepsis cascade on the left-hand side of Figure 7. Figure 7 compares the classical route of sepsis-induced death with the milder versions that we see in PE; they are at least consistent with the idea that PE is strongly related to the more classical sepsis in degree rather than in kind.

Figure 7

Preeclampsia and Neonatal Sepsis

If PE is really based on infectious agents, it is reasonable that one might expect to see a greater incidence of neonatal sepsis (i.e., infection) following PE. While there are clearly other possible explanations (e.g., simply a weakened immune system, sometimes expressed as neutropenia, after PE), there is certainly evidence that this is consistent with this suggestion (649–653).

PE Biomarkers and Infection

Because of the lengthy development of PE during pregnancy, there has long been a search for biomarkers (somewhat equivalent to the “risk factors” discussed earlier) that might have predictive power, and some of these, at both metabolome (15, 654–661) and proteome (662–667) level, are starting to come forward. The typical experimental design is a case–control, in which markers that are raised or lowered significantly relative to the age-matched controls are considered to be candidate markers of PE. However, just as noted with leukocyte markers (81) and polycystic ovary syndrome (PCOS) (668) that does not mean that they might not also be markers for other things too, such as infection (669)!

Thus, one prediction is that if dormant and resuscitating bacteria are responsible for PE then at least some of these biomarkers should also be (known to be) associated with infection. However, one obvious point is that the markers may appear only after infection, and this may itself be after the first-trimester; clearly then these would not then be seen as “first-trimester” biomarkers! There are many well-known inflammatory biomarkers that are part of the innate [and possibly trained (670)] immune response, such as the inflammatory cytokines CRP [cf. Ref. (671, 672)], IL-6 (673), IL-1β (674), TNF-α (675), and macrophage migration inhibitory factor (MIF) (676), which are also all biomarkers of infection (677–681). Certainly, the fact that these increase in PE is consistent with a role for an infectious component. However, we shall mainly look at other biomarkers that are known to increase with PE, and see if they are also known to be biomarkers for (or at least changed in the presence of) infection (and see Th17/IL-17 above), and we next examine this. We shall see that pretty well every biomarker that is changed significantly in PE is also known to be changed following infection, a series of findings that we consider adds very strong weight to our arguments.

Proteomic and Similar Biomarkers – Circulating and Placental

What is really needed is a full systems biology strategy [see, e.g., Ref. (99, 682–684)] that brings together the actors that interact then parametrizes the nature of these interactions in a suitable encoding [e.g., SBML (685)] that permits their modeling, at least as an ODE model using software such as CellDesigner (686), COPASI (687), or Cytoscape (688). Thus, to take a small example, “agonistic autoantibodies against the angiotensin II type 1 receptor autoantibodies (AT1-AA) are described. They induce NADPH oxidase and the MAPK/ERK pathway leading to NF-κB and tissue factor activation. AT1-AA are detectable in animal models of PE and are responsible for elevation of soluble fms-related tyrosine kinase-1 (sFlt1) and soluble endoglin (sEng), oxidative stress, and endothelin-1, all of which are enhanced in pre-eclamptic women. AT1-AA can be detected in pregnancies with abnormal uterine perfusion” (589). Many such players have been invoked, and we next list some.

Activin A

Activin A is a member of the TGF-β superfamily. Its levels are raised significantly in PE (118, 689–691). However, activin A is also well established as a biomarker of infection (692–695).

Calretinin

In a proteomic study of preclamptic vs. normal placentas (696), calretinin was one of the most differentially upregulated proteins (p = 1.6 × 10⁻¹³ for preterm PE vs. controls, p = 8.9 × 10⁻⁷ for term PE vs. controls), and in a manner that correlated with the severity of disease. While calretinin [normally more expressed in neural tissue and mesotheliomas (697)] is not normally seen as a marker of infection, it is, in fact, raised significantly when Chlamydia pneumoniae infects human mesothelial cells (698).

Chemerin

Chemerin is a relatively recently discovered adipokine, whose level can increase dramatically in the first-trimester of preeclamptic pregnancies (699), and beyond (700). Its levels are related to the severity of the PE (701–703). Specifically, an ROC curve (704) analysis showed that a serum chemerin level >183.5 ng mL⁻¹ predicted PE with 87.8% sensitivity and 75.7% specificity (AUC, 0.845; 95% CI, 0.811–0.875) (699). Papers showing that chemerin is also increased by infection (hence inflammation) include (705, 706); it even has antibacterial properties (707, 708) and was protective in a skin model of infection (709, 710). In a study of patients with sepsis (711), circulating chemerin was increased 1.69-fold compared with controls (p = 0.012) and was also protective as judged by survival. These seem like particularly potent argument for a role of chemerin as a marker of infection rather than of PE per se, and for the consequent fact that PE follows infection and not vice versa.

Copeptin

Copeptin, a glycosylated polypeptide consisting of the 39 C-terminal amino acids of arginine vasopressin, has been suggested as “a new biomarker that is specific for preeclampsia” (712), and certainly changes during its development (713). However, it turns out that it is also essentially a measure of all kinds of stresses and adverse events (714–719), including those caused by infection (720–729).

Cystatin C

Not least because kidney function is impaired in PE, low molecular weight (MW) proteins may serve as biomarkers for it. To this end, cystatin C (13 kDa) has been found to be raised significantly in PE (730–736); it also contributed to the marker set in the SCOPE study (8, 17). Notably, although it certainly can be raised during infection (737), it seems to be more of a marker of inflammation or kidney function (738, 739).

d-Dimer

“d-dimer” is a term used to describe quite varying forms of fibrin degradation products (740). Given that PE is accompanied by coagulopathies, it is probably not surprising that d-dimer levels are raised in PE (741–745), although this is true for many conditions (746), and some of the assays would bear improvement (747, 748). Needless to say, however, raised d-dimer levels are also a strong marker for infection (749, 750).

Endocan

Endothelial cell-specific molecule-1 (ESM-1), known as endocan, is a cysteine-rich dermatan sulfate proteoglycan expressed (and sometimes released) by endothelial cells. It has been suggested to be a new biomarker for endothelial dysfunction and PE (751, 752). It would appear, however, to be a rather less specific inflammatory biomarker (753, 754) and is associated with a variety of diseases, including chronic kidney disease (755, 756) and cardiovascular disease (755). Most pertinently from our perspective, it is also raised strongly during sepsis (757–760).

Endoglin

Endoglin is the product of a gene implicated (761, 762) in the rare disease Hereditary Hemorrhagic Telangiectasia. The role of endoglin remains somewhat enigmatic (763). However, endoglin levels were 2.5-fold higher in preeclamptic placentas compared to normal pregnancies (15.4 ± 2.6 vs. 5.7 ± 1.0, p < 0.01). After the onset of clinical disease, the mean serum level of sEng in women with preterm PE was 46.4 ng mL⁻¹, as compared with 9.8 ng mL⁻¹ in controls (p < 0.001) (88). Women with a particular endoglin polymorphism (AA) were 2.29 times more likely to develop PE than those with the GG genotype (p = 0.008) (764), and endoglin is seen as a reasonably good marker for PE (88, 691, 765–768) [cf. Ref. (769)]. Again, endoglin levels are raised following infection by a variety of organisms (770–773), with a particularly clear example that it is a marker of infection coming from the fact that there is raised endoglin only in infected vs. aseptic loosening in joints following arthroplasty (774). In general, it seems likely that these circulating (anti)angiogenic factors are more or less markers of endothelial cell damage, just as we have described for serum ferritin (126).

Ferritin

The natural iron transporter in blood is transferrin [e.g., Ref. (775–780)], present at ca. 1–2 g L⁻¹, with ferritin being an intracellular iron storage molecule, so one is led to wonder why there is even any serum ferritin at all (126, 781). The answer is almost certainly that it is a leakage molecule from damaged cells (126), and when in serum it is found to have lost its iron content (782–785). Serum ferritin is, as expected, raised during PE (244, 246, 249, 253, 255, 786, 787) and in many other inflammatory diseases (126), including infection [e.g., Ref. (788, 789) and above].

microRNAs

microRNAs are a relatively novel and highly important class of ~22 nt non-coding, regulatory molecules (790–793). Some are placenta specific, and those in the circulation [often in endo/exosomes (794–796)] can be identified during pregnancy (797–800), potentially providing a minimally invasive readout of placental condition (801–803). There is aberrant expression of placenta-specific miRNAs in PE including miR-517a/b and miR-517c (804–810) and miR-1233 (811). C19MC is one of the largest miRNA gene clusters in humans, maps to chromosome 19q13.41, and spans a ~100 kb long region. C19MC miRNAs are processed from the cluster (812), are primate-specific, conserved in humans, and comprise 46 miRNA genes, including the miR-517 family (813). miR-517 is known to be antiviral (814, 815), while miR-517a overexpression is apoptotic (816) and can inhibit trophoblast invasion (817). Importantly for our argument, miR-517 molecules are overexpressed following infection (818, 819).

Neuropeptide Y

Although, as its name suggests, neuropeptide Y is a neurotransmitter, it is also correlated with stress. Certainly, it is related to noradrenaline (see below) that may itself be responsible for the raised blood pressure (BP) in PE (820). It is also raised in sepsis, where it is considered to counterbalance the vasodilation characteristic of septic shock [e.g., Ref. (821, 822)]. The apparent paradox of a raised BP in PE and a lowered one in septic shock is considered to be related to the very different concentrations of endotoxin involved (Figure 7).

NGAL (Lipocalin 2, Siderocalin)

Neutrophil gelatinase-associated lipocalin (NGAL) is a lipocalin that is capable of binding catecholate-based siderophores (125, 823, 824). As such it is antimicrobial and is also an inflammatory or sepsis biomarker (825, 826). Given our interest in iron, it is not surprising that it is changed during PE. While one study suggested it to be decreased in PE (827), a great many other studies showed it to be increased significantly in PE, and typically in a manner that correlated with PE severity (735, 828–837). Pertinently to PE, it is also well established as an early biomarker of acute kidney injury (AKI) (838–841). However, it is not a specific biomarker for AKI vs. sepsis (839, 842–850) and its origin in sepsis differs (851, 852). Of course, it can be the sepsis that leads to the AKI (853, 854). Fairly obviously, while it does tend to be increased during PE, we again see its direct role as an antimicrobial and marker of sepsis as highly supportive of our present thesis.

Placental Growth Factor

This is a member of the VEGF Family that despite its name has a great many activities (855). It is often considered in parallel with endoglin and sFlt, with a high sFlt:PlGF ratio being considered as especially discriminatory for PE (89, 856–869), i.e., a lower PlGF can be diagnostic of PE (769, 870–873). PlGF tends to be raised in sepsis unrelated to pregnancy (874, 875), while its lowering in PE may be due to the excess sFLT that decreases it (855, 876, 877). In one study of a patient with CMV infection and PE, it was, in fact, raised (878), while, in the case of IUGR, it was massively lowered (879). PlGF alone is thus probably not a useful general marker for either PE or sepsis if one is trying to disentangle them, although it has clear promise when PE is superimposed on CKD (872, 880).

Procalcitonin

Procalcitonin is the 116 amino acid polypeptide precursor of calcitonin, a calcium regulatory hormone. It is another marker that has been observed to be raised (according to severity) in preeclamptics (742, 881, 882) [but cf. Ref. (713)]. However, it is also a known marker of bacterial infections or sepsis (881, 883–891).

Serum Amyloid A

This is an inflammatory biomarker, which was shown to increase fourfold in PE in one study (892), was significantly raised in another (882), but not in a third (893). However, it is a well-established (and potent) biomarker for infection/sepsis [e.g., Ref. (894–907)]. Defective amyloid processing may be a hallmark of PE more generally (908), and of course amyloid can be induced by various microbes (317, 319, 909, 910) and their products (257).

Soluble fms-Like Tyrosine Kinase 1

The sFlt receptor is a splice variant of the VEGF receptor (766). It is raised considerably in PE (691, 767, 856, 862, 864, 911–914) and may be causal (545, 590, 915–918). Needless to say, by now, we can see that it is also a very clear marker of infection (767, 919, 920), whose levels even correlate with the severity of sepsis (921–923). Of particular note is the fact that sFLT is actually anti-inflammatory (922).

Thrombomodulin

Soluble thrombomodulin was recognized early as an endothelial damage biomarker and is raised in PE (924–934). Interestingly, it has been found to have significant efficacy in the treatment of sepsis [-based disseminated intravascular coagulation (DIC)] (935–943).

TLR4

TLR4 upregulation in preeclamptic placentas (944) is entirely consistent with infection and the “danger model” as applied to PE (945). As well as LPS activation [reviewed in Kell and Pretorius (140)], the heat shock protein 60 of Chlamydia also activates TLR4 (138).

Visfatin

Visfatin is another adipokine that is raised in PE, approximately 2-fold in the study of Fasshauer and colleagues (946), and 1.5-fold in that of Adali and colleagues (947). However, it was little different in a third study (948), while in a different study, it was rather lower in PE than in controls (949). This kind of phenomenon rather lights up the need for excellent quality studies, including ELISA reagents, when making assessments of this type.

Fairly obviously, the conclusion that this long list of biomarkers that are raised in PE might be specific “PE” biomarkers is challenged very strongly by the finding that they are, in fact, all known markers of infection, a finding that in our view strongly bolsters the case for an infectious component in PE.

In a similar vein, there are a number of other sepsis markers (where sepsis is varied via, or occurs as, an independent variable) that we would predict are likely to be visible as raised in PE patient. These might include (680, 950) PAI-1, sE-selectin (951), and sVCAM-1 (921). In particular, Presepsin looks like a potentially useful marker for sepsis (888, 889, 952–961), but we can find no literature on its use as a PE biomarker, where we predict that it may also be raised.

Metabolomic Biomarkers

For fundamental reasons connected with metabolic control and its formal, mathematical analysis (962–966), changes in the metabolome are both expected (967) and found (968–971) to be amplified relative to those in the transcriptome and proteome. For similar reasons, and coupled with evolution’s selection for robustness (972–978) (i.e., homeostasis) in metabolic networks, we do not normally expect to find single metabolic biomarkers for a complex disease or syndrome. Since our initial metabolomic analyzes (654), the technology has improved considerably (979–982), a full human metabolic network reconstruction has been published (978, 983–985) in the style of that done for yeast (986), and a number of candidate metabolomics biomarkers for PE have been identified reproducibly on an entirely separate validation set (15, 655).

This latter, LC-MS-based, study (15) found a cohort of 14 metabolites from the first-trimester that when combined gave an OR of 23 as being predictive of third-trimester PE. For convenience, we list them in Table 7. Note that because they were characterized solely via their mass, there are some uncertainties in the exact identification in some cases, and that untargeted metabolomics of this type has a moderately high limit of detection (maybe 10 μM) such that many potentially discriminatory metabolites are below the limit of detection.

As well as the non-targeted metabolomics noted above, a number of other small molecule biomarkers have been turned up by more conventional measurements.

Noradrenaline (Norepinephrine)

An interesting early study (1002) found that venous plasma noradrenaline was raised by 67% in preeclamptics vs. controls. Similar data were found by others (1003). This is of particular interest in the present context since noradrenaline is well established as highly growth stimulatory to Gram-negative microorganisms [e.g., Ref. (1004–1008)], in part by acting as a siderophore (1009–1011). It also raises the levels of neuropeptide Y (820), and as a stress hormone (1012), is of course well known for its role in raising BP, a hallmark of PE.

There is relatively little metabolomics work in sepsis, but in one study, carnitine and sphingolipid metabolism were also modified during sepsis (1013), while in another (1014), a suite of molecules were decreased during acute sepsis. However, the patients involved here were quite close to death, so it is not clear that comparisons between the metabolome in PE and in dying patients are that worthwhile.

We also note a recent and rather interesting suggestion by Eggers (1015) that the maternal release of adrenaline (rather than noradrenaline) may have an important etiological role in PE, although as with the rest of our thesis here it is not there indicated as to what causes the adrenaline to rise (although infection and inflammation can of course do so).

Uric Acid

Hyperuricemia is a moderately common finding in preeclamptic pregnancies and may even be involved in its pathogenesis [see, e.g., Ref. (1016–1022)]. However, it does not seem to be very specific (1023–1027) and is seemingly not an early biomarker [and it did not appear in our own study (15)]. Its lack of specificity is illustrated by the fact that there is considerable evidence for the roles of purinergic signaling (1028), and especially the role of uric acid, in Alzheimer’s and Parkinson’s disease (1029–1031), as well as in a variety of other kinds of inflammatory processes, including pro-inflammatory cytokine production (1032, 1033), the Plasmodium falciparum-induced inflammatory response (1034), the mechanistic basis for the action of alum as an adjuvant (1035), and even peanut allergy (1036–1038). As is common in case–control studies when just one disease (e.g., PE) is studied, artificially high levels of sensitivity and (especially) specificity may appear when other patients with other diseases are not considered.

Clotting, Coagulopathies, and Fibrinogen in PE

In much of our previous work [e.g., Ref. (126–134)], we have noted that each of these chronic, inflammatory diseases is accompanied by changes in fibrin fiber morphologies, coagulopathies, and changes in erythrocytes that are both substantial and characteristic. They can variously be mimicked by adding unliganded iron or LPS. As is well known, LPS itself is a strong inducer of coagulation, whether via tissue factor or otherwise [e.g., Ref. (1039–1048)], and will bind to fibrin strongly (259, 1049). The morphological methods have not yet, to our knowledge, been performed on blood from preeclamptics, whether as a diagnostic or a prognostic, although we note that clotting factors came top in one GWAS looking for gene–PE associations (117). Fibrinogen itself is a TLR4 ligand (1050), is raised in PE (1051–1055), and we note the extensive evidence for coagulopathies during pregnancies with PE [e.g., Ref. (64, 128, 527, 741, 1056–1068)]. In the worst cases, these are the very frightening DIC (1047, 1069–1073) that can, of course, also emerge as a consequence of sepsis (1074–1080). Variations in the plasminogen activator inhibitor-1 may contribute to the hypofibrinolysis observed (1081–1083).

We recently showed that LPS can potently induce amyloid formation in fibrin (258, 259, 1084, 1085). Thus, in addition, we note the increasing recognition that amyloid proteins themselves, that may occur as a result of coagulopathies, are themselves both inflammatory [e.g., Ref. (565, 669, 1086–1091)] and cytotoxic [e.g., Ref. (257, 1092–1096)], and that this can of itself contribute strongly to the death of, e.g., trophoblasts.

Related to clotting parameters are three other “old” but easily measured variables that probably reflect inflammation (1097), that have been suggested to differ in PE from normotensives, and may have some predictive power. The first two are the erythrocyte sedimentation rate (ESR) (1098, 1099) and the red cell distribution width (RDW) (1100) [but cf. Ref. (1101)]. Interestingly, the former was the only variable that was predictive of a subsequent stroke following sub-arachnoid hemorrhage (1102). The third relates to the morphology of erythrocytes (that may in part underpin the other two). We and others have shown in a series of studies [e.g., Ref. (134–136, 1103–1106)] that erythrocyte morphology diverges very considerably from that “classical” discoid shape adopted by normal healthy cells, and that this can be a strong indicator of disease (137). In extreme cases [e.g., Ref. (133, 1107–1112)], including following infection (1113), this results in eryptosis, the suicidal death of erythrocytes. It is of interest that ceramide, a precursor of sphingosine-1-phosphate (S1P) (Table 7), is raised in various diseases such as Parkinson’s and may serve to stimulate eryptosis (1114). Although we know of no direct measurements to date, there is evidence that eryptosis may play a significant role in PE (1115).

Prevention Strategies

Apart from low-dose aspirin [that may have little effect (1116–1119) unless initiated relatively early in pregnancy (1120–1124)], and low-dose calcium (1125), there are relatively few treatment options in present use (1126–1129). [Magnesium sulfate (1130–1132) has been used as a treatment for eclampsia and, interestingly, prevents LPS-induced cell death in an in vitro model of the human placenta (1133).]

In the history of science or medicine, some treatments are empirical, while others are considered to have a mechanistic basis. The general assumption is that the more we know about the originating etiology of a disease or syndrome the more likely we are to be able to treat its causes effectively, and not just its symptoms. Clearly, also, clinicians are rightly loth to give complex and potentially teratogenic treatments to pregnant women when this can be avoided (1134–1137). However, the surprising lack of systematic data with antibiotics (1138), modulo one particularly spectacular success (540), suggests that we ought to be performing trials with safe antibiotics on women at special risk (1139). These must take care to avoid any Jarisch–Herxheimer reaction (1140–1143) due to the release from microbes induced by antibiotics of inflammagens such as LPS (1144–1147). A related strategy recognizes that some FDA-approved drugs can actually exert powerful antibiotic effects in vivo (but not on petri plates) by modifying the host (1148).

Because of the known oxidative stress accompanying PE, it had been assumed that antioxidants such as vitamin C (ascorbate) might be preventive; however, this turned out not to be the case (even the opposite) for ascorbate (1118, 1149). Probably, this is because in the presence of unliganded iron, ascorbate is, in fact, pro-oxidant (125). However, polyphenolic antioxidants that actually act by chelating iron (84, 125) seem to be more effective (1150).

Another area that we and others have previously highlighted recognizes the ability of non-siderophoric iron chelators to act as iron-withholding agents and thereby limit the growth of bacteria. Again, a prediction is that women with iron overload diseases should be more susceptible to PE, a prediction that is borne out for α-thalassemia (1151, 1152) though not apparently for hereditary hemochromatosis (1153). However, the extent of use of chelators and degree of control of free iron, thereby obtained is rarely recorded in any detail, so in truth it is difficult to draw conclusions.

The general benefits of nutritional iron chelators such as blueberries and other fruits and vegetables containing anthocyanins have been discussed elsewhere [e.g., Ref. (84, 125, 1154)].

How significant coagulopathies are to the etiology of PE development (as opposed to providing merely an accompaniment) is not entirely clear, but on the basis that they are then anticoagulants would potentially assist, just as thrombomodulin does in DIC accompanying sepsis (942, 943, 1079, 1080). Of course, one of many effects of low-dose aspirin is to act as an anticoagulant. There is also evidence for the efficacy of heparin (6, 1127, 1155–1160), which is especially interesting given our highlighting of the role of coagulopathies in PE. These anticoagulants that avoid bleeding (1161) are obviously of particular interest, while anything stopping the fibrin forming β-amyloid (258, 259) should serve as an especially useful anti-inflammatory anticoagulant.

With a change in focus from function-first to target-first-based drug discovery (976), there has been an assumption that because a drug is (i) found to bind potently to a molecular target and (ii) has efficacy at a physiological level in vivo, the first process is thus responsible for the second. This has precisely no basis in logic [it is a logical fault known variously as “affirming the consequent” or “post hoc ergo propter hoc” (1162)]. This is because the drug might be acting physiologically by any other means, since drug binding to proteins is typically quite promiscuous [e.g., Ref. (1163–1167)]. Indeed, the average known number of binding sites for marketed drugs is six (208, 1168). In particular, it is likely, from a network or systems pharmacology perspective [e.g., Ref. (978, 1169–1172)], that successful drugs (like aspirin) are successful precisely because they hit multiple targets. The so-called “statins” provide a particularly good case in point (125).

It had long been known that the enzyme HMGCoA reductase exerted strong control on the biosynthetic flux to cholesterol, and that inhibiting it might lower the flux and steady-state cholesterol levels (as indeed it does). Notwithstanding that cholesterol alone is a poor predictor of cardiovascular disease (1173–1175), especially in the normal range, HMGCoA reductase inhibitors have benefits in terms of decreasing the adverse events of various types of cardiovascular disease (1176). Following an original discovery of natural products such as compactin (mevastatin) and lovastatin containing a group related to hydroxymethylglutaric acid (rather than a CoA version) that inhibited the enzyme (1177), many variants with this (hydroxyl)methylglutaric substructure came to be produced, with the much larger “rest” of the molecule being considerably divergent [see Figure 8, where the MW values vary from 390.5 (mevastatin) to 558.6 (atorvastatin)]. Despite this wide structural diversity (Figure 8), they are still collectively known as “statins,” and despite the wildly illogical assumption that they might all work in the same way(s). The fact that different statins can cause a variety of distinct expression profiles (1178) is anyway utterly inconsistent with a unitary mode of action. In particular, in this latter study, statins clustered into whether they were (fluvastatin, lovastatin, and simvastatin) or were not (atorvastatin, pravastatin, and rosuvastatin) likely to induce the side-effect of rhabdomyolysis or any other myopathy. Clearly, any choice of “statin” should come from the latter group, with pravastatin and rosuvastatin being comparatively hydrophilic.

Figure 8

The epidemiological fact of improved survival despite the comparative irrelevance of cholesterol levels to atherosclerotic plaque formation and heart disease in the normal range provides an apparent paradox (1179). This is easily solved by the recognition [e.g., Ref. (1180–1193), and many other references and reviews] that “statins” are, in fact, anti-inflammatory. They may also be antimicrobial/antiseptic, whether directly or otherwise (1194–1198), and we also note the role of cholesterol in mopping up endotoxin (1199). Finally, here, it needs to be recognized that statins do themselves serve to lower iron levels (1200–1202), and (while oddly this seems not to have been tested directly) simple inspection of their structures (Figure 8) implies that the better ones (with their multiple OH groups) might, in fact, chelate iron directly.

In consequence, a number of authors have indicated the potential utility of statins in treating PE (113, 545, 1203–1213), and pravastatin has been the subject of a number of favorable studies (545, 1204, 1206, 1209, 1211, 1214, 1215), including in humans (1204, 1216–1218). Pravastatin seems more than ripe for a proper, randomized clinical trial (1203).

Another “vascular” class of drugs that has been proposed for treating PE is represented by those of the family of vasodilatory phosphodiesterase 5 inhibitors such as sildenafil (Viagra) and vardenafil (Levitra), as it is reasonable that they might improve endothelial function, especially if started early in pregnancy (1219). Thus, vardefanil restores endothelial function by increasing PlGF (1220), and sildenafil has shown promise in a number of animal studies (1221–1226) and in human tissues (1227, 1228), with a clinical trial ongoing (1229). In particular (1226), it was able to normalize the metabolomics changes observed in a mouse model (the COMT^−/− model) of PE.

Anti-hypertensive therapy for PE has been reviewed by Abalos and colleagues (1230) and Magee and colleagues (114). Anti-hypertensives did halve the incidence of hypertension but had no effect on PE. Methyldopa is one of the most commonly used anti-hypertensives in pregnancy, but it may also stimulate eryptosis (1231); alternative drugs were considered to be better (1230) for hypertension. Nifedipine (1232) and labetalol (1233) are considered a reasonable choice. There was also a slight reduction in the overall risk of developing proteinuria/PE when beta blockers and calcium channel blockers considered together (but not alone) were compared with methyldopa (1230). In mice, olmesartan (together with captopril) proved usefully anti-hypertensive (1234); this is of interest because olmesartan is also an agonist of the vitamin D receptor (1235). However, it was not mentioned in either Ref. (1230) or Ref. (114).

Lipopolysaccharide itself has long been recognized as a target of inflammatory diseases. Unfortunately, despite initially promising trials of an anti-LPS antibody known as centoxin (1236), it was eventually withdrawn, apparently because of a combination of ineffectiveness (1237, 1238) and toxicity (1239, 1240). LPS is rather hydrophobic, and thus it is hard to make even monoclonal antibodies very selective for such targets, such that the toxicity was probably because of its lack of specificity between lipid A and other hydrophobic ligands (1241). Other possible treatments based on LPS, such as “sushi peptides” (1242–1249) [or variants (1250, 1251)], and LPS-binding protein were covered elsewhere (140).

If an aberrant or dysbiotic gut microbiome is the source of the microbes that underpin PE, it is at least plausible that the gut microbiome should be predictive of PE (378), but we know of no suitably powered study that has been done to assess this, and this would clearly be worthwhile. However, in a study of primiparous women, the OR for getting severe PE was only 0.6 if probiotic milk drinks containing lactobacilli were consumed daily (1252). This is a very significant effects, such that this too seems an area well worth following up.

From a metabolomics point of view, the molecules seen to be raised in PE may either be biomarkers of the disease etiology or of the body’s attempts to respond to the disease [and this is true generally (1253)]. Thus, it is of great interest that S1P was raised in PE [see Kenny (15) and Table 7]. S1P is mainly vasoconstrictive (1254, 1255), but agonists of the S1P-1 receptor (that is involved in endothelial cell function) seemed to have considerable value in combatting the cytokine storm that followed infection-driven sepsis (1256–1261). The detailed mechanism seems not to be known, but in the context of infection, a need for S1P and other sphingolipids for successful pregnancies (1262, 1263) [see also Parkinson’s (1001)], and the induction of PE by its disruption (1000, 1264–1268), some serious investigation of the potential protective effects of S1PR1 agonists seems highly warranted.

Among other small molecules, melatonin has shown some promise in the treatment of septic shock, by lowering inflammatory cytokine production (1269) [and see Gitto et al. (1270) for neonatal oxidative stress], and a trial is in prospect for PE (1271).

Lipoxin A₄ (LXA₄) is considered to be an endogenous stop signal in inflammation. While recognizing the difficulties with rodent PE models (above), we note that in one study, the effect of BML-111 (a synthetic analog of LXA₄) was tested on experimental PE induced in rats by low-dose endotoxin (LPS), and showed highly beneficial effects (549).

Coda – A Return to the Bradford Hill Criteria

Other Predictions

Classical clinical microbiology, involving mainly replication-based methods, is evolving rapidly to assess the microbial content of samples on the basis of DNA sequences (296, 1272), including 16S rDNA (287, 288, 290, 292, 293, 295, 297, 1273), suitable protein-encoding housekeeping genes [e.g., Ref. (1274–1279)], and, increasingly, full genome sequences (1280). In the future, we can thus expect a considerable increase in molecular assessments of the microbiological content of blood, urine, and tissues, and this will obviously be a vital part of the experimental assessment and development of the ideas presented here. Molecular methods will also be used to assess maternal circulating DNA (1281–1283) and RNA (1284) in terms of both its presence and sequencing, as well as the use of digital PCR (1285).

Since PE has such a strong vascular component, we also predict that measurements designed to detect coagulopathies will increase in importance, for both diagnosis and prognosis, and for assessing treatments.

New drugs designed to kill non-growing bacteria (1286–1290) or to overcome amyloid coagulopathies (1291–1295) will be needed and will come to the fore.

Finally, we consider that real progress in understanding PE from a systems biology perspective means that it must be modeled accordingly, and this must be a major goal.

Concluding Remarks

Any and all of these provide powerful strategies for testing whether PE is, in fact, such as gastric ulcers (166, 168, 169, 1296), essentially initiated as an infectious disease.

Author Notes

This is the paper number 8 of the series “The dormant blood microbiome in chronic, inflammatory diseases”. The other articles of the series can be found in the reference list with the numbers 141; 139; 140; 257; 147; 143; 1084; 258; 142.

References

• 1

  GrillSRusterholzCZanetti-DällenbachRTercanliSHolzgreveWHahnSet alPotential markers of preeclampsia – a review. Reprod Biol Endocrinol (2009) 7:70.10.1186/1477-7827-7-70

  • CrossRef
  • Google Scholar
  • View reference in article

• 2

  SteegersEAPVon DadelszenPDuvekotJJPijnenborgR. Pre-eclampsia. Lancet (2010) 376:631–44.10.1016/S0140-6736(10)60279-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 3

  NorthRAMccowanLMDekkerGAPostonLChanEHStewartAWet alClinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ (2011) 342:d1875.10.1136/bmj.d1875

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 4

  UzanJCarbonnelMPiconneOAsmarRAyoubiJM. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag (2011) 7:467–74.10.2147/VHRM.S20181

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 5

  KennyL. Improving diagnosis and clinical management of pre-eclampsia. MLO Med Lab Obs (2012) 44(12):14.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 6

  DesaiP. Obstetric Vasculopathies. New Delhi: Jaypee (2013).

  • Google Scholar
  • View reference in article

• 7

  ChaiworapongsaTChaemsaithongPYeoLRomeroR. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol (2014) 10:466–80.10.1038/nrneph.2014.102

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 8

  KennyLCBlackMAPostonLTaylorRMyersJEBakerPNet alEarly pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the screening for pregnancy endpoints (SCOPE) international cohort study. Hypertension (2014) 64:644–52.10.1161/HYPERTENSIONAHA.114.03578

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 9

  SircarMThadhaniRKarumanchiSA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens (2015) 24:131–8.10.1097/MNH.0000000000000105

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 10

  AbalosECuestaCGrossoALChouDSayL. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol (2013) 170:1–7.10.1016/j.ejogrb.2013.05.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 11

  KhanKSWojdylaDSayLGulmezogluAMVan LookPF. WHO analysis of causes of maternal death: a systematic review. Lancet (2006) 367:1066–74.10.1016/S0140-6736(06)68397-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 12

  DuleyL. The global impact of pre-eclampsia and eclampsia. Semin Perinatol (2009) 33:130–7.10.1053/j.semperi.2009.02.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 13

  GhulmiyyahLSibaiB. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol (2012) 36:56–9.10.1053/j.semperi.2011.09.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 14

  AbalosECuestaCCarroliGQureshiZWidmerMVogelJPet alPre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG (2014) 121(Suppl 1):14–24.10.1111/1471-0528.12629

  • CrossRef
  • Google Scholar
  • View reference in article

• 15

  KennyLCBroadhurstDIDunnWBrownMFrancis-McintyreSNorthRAet alRobust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension (2010) 56:741–9.10.1161/HYPERTENSIONAHA.110.157297

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 16

  BartschEMedcalfKEParkALRayJGHigh Risk of Pre-Eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ (2016) 353:i1753.10.1136/bmj.i1753

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 17

  KarumanchiSAGrangerJP. Preeclampsia and pregnancy-related hypertensive disorders. Hypertension (2016) 67:238–42.10.1161/HYPERTENSIONAHA.115.05024

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 18

  DuckittKHarringtonD. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. Br Med J (2005) 330:565–7.10.1136/bmj.38380.674340.E0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 19

  BakerPNKennyLC. Obstetrics by Ten Teachers. Boca Raton, FL: CRC Press (2011).

  • Google Scholar
  • View reference in article

• 20

  AnanthCVKeyesKMWapnerRJ. Pre-eclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ (2013) 347:f6564.10.1136/bmj.f6564

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 21

  BdolahYElchalalUNatanson-YaronSYechiamHBdolah-AbramTGreenfieldCet alRelationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. Hypertens Pregnancy (2014) 33:250–9.10.3109/10641955.2013.858745

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 22

  SaftlasAFOlsonDRFranksALAtrashHKPokrasR. Epidemiology of preeclampsia and eclampsia in the United-States, 1979-1986. Am J Obstet Gynecol (1990) 163:460–5.10.1016/0002-9378(90)91176-D

  • CrossRef
  • Google Scholar
  • View reference in article

• 23

  ZhangJZeislerJHatchMCBerkowitzG. Epidemiology of pregnancy-induced hypertension. Epidemiol Rev (1997) 19:218–32.10.1093/oxfordjournals.epirev.a017954

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24

  LamminpääRVehvilainen-JulkunenKGisslerMHeinonenS. Preeclampsia complicated by advanced maternal age: a registry-based study on primiparous women in Finland 1997-2008. BMC Pregnancy Childbirth (2012) 12:47.10.1186/1471-2393-12-47

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 25

  CarolanM. Maternal age >= 45 years and maternal and perinatal outcomes: a review of the evidence. Midwifery (2013) 29:479–89.10.1016/j.midw.2012.04.001

  • CrossRef
  • Google Scholar
  • View reference in article

• 26

  TrogstadLMagnusPStoltenbergC. Pre-eclampsia: risk factors and causal models. Best Pract Res Clin Obstet Gynaecol (2011) 25:329–42.10.1016/j.bpobgyn.2011.01.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 27

  CoonrodDVHickokDEZhuKMEasterlingTRDalingJR. Risk-factors for preeclampsia in twin pregnancies – a population-based cohort study. Obstet Gynecol (1995) 85:645–50.10.1016/0029-7844(95)00049-W

  • CrossRef
  • Google Scholar
  • View reference in article

• 28

  CampbellDMMacGillivrayI. Preeclampsia in twin pregnancies: incidence and outcome. Hypertens Pregnancy (1999) 18:197–207.10.3109/10641959909016193

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 29

  BdolahYLamCRajakumarAShivalingappaVMutterWSachsBPet alTwin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?Am J Obstet Gynecol (2008) 198:428.e1–6.10.1016/j.ajog.2007.10.783

  • CrossRef
  • Google Scholar
  • View reference in article

• 30

  BodnarLMNessRBHargerGFRobertsJM. Inflammation and triglycerides partially mediate the effect of prepregnancy body mass index on the risk of preeclampsia. Am J Epidemiol (2005) 162:1198–206.10.1093/aje/kwi334

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 31

  RobertsJMBodnarLMPatrickTEPowersRW. The role of obesity in preeclampsia. Pregnancy Hypertens (2011) 1:6–16.10.1016/j.preghy.2010.10.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 32

  JeyabalanA. Epidemiology of preeclampsia: impact of obesity. Nutr Rev (2013) 71:S18–25.10.1111/nure.12055

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 33

  SugermanHJ. Effect of obesity on incidence of preeclampsia. Am J Obstet Gynecol (2014) 210:375–375.10.1016/j.ajog.2013.10.014

  • CrossRef
  • Google Scholar
  • View reference in article

• 34

  ThorntonJGMacDonaldAM. Twin mothers, pregnancy hypertension and pre-eclampsia. Brit J Obstet Gynaecol (1999):570–5.10.1111/j.1471-0528.1999.tb08326.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 35

  RosHSLichtensteinPLipworthLCnattingiusS. Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. Am J Med Genet (2000) 91:256–60.10.1002/(SICI)1096-8628(20000410)91:4<256::AID-AJMG3>3.0.CO;2-T

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 36

  WilliamsPJBroughton PipkinF. The genetics of pre-eclampsia and other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol (2011) 25:405–17.10.1016/j.bpobgyn.2011.02.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 37

  ValenzuelaFJPerez-SepulvedaATorresMJCorreaPRepettoGMIllanesSE. Pathogenesis of preeclampsia: the genetic component. J Pregnancy (2012) 2012:632732.10.1155/2012/632732

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 38

  BoydHATahirHWohlfahrtJMelbyeM. Associations of personal and family preeclampsia history with the risk of early-, intermediate- and late-onset preeclampsia. Am J Epidemiol (2013) 178:1611–9.10.1093/aje/kwt189

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 39

  RotenLTThomsenLCVGundersenASFenstadMHOdlandMLStrandKMet alThe Norwegian preeclampsia family cohort study: a new resource for investigating genetic aspects and heritability of preeclampsia and related phenotypes. BMC Pregnancy Childbirth (2015) 15:319.10.1186/s12884-015-0754-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 40

  AshersonRAShoenfeldY. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome – molecular mimicry?J Rheumatol (2000) 27:12–4.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 41

  AshersonRACerveraR. Antiphospholipid antibodies and infections. Ann Rheum Dis (2003) 62:388–93.10.1136/ard.62.5.388

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 42

  BlankMAshersonRACerveraRShoenfeldY. Antiphospholipid syndrome infectious origin. J Clin Immunol (2004) 24:12–23.10.1023/B:JOCI.0000018058.28764.ce

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 43

  HarelMAron-MaorAShererYBlankMShoenfeldY. The infectious etiology of the antiphospholipid syndrome: links between infection and autoimmunity. Immunobiology (2005) 210:743–7.10.1016/j.imbio.2005.10.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 44

  ShoenfeldYBlankMCerveraRFontJRaschiEMeroniPL. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis (2006) 65:2–6.10.1136/ard.2005.045443

  • CrossRef
  • Google Scholar
  • View reference in article

• 45

  ClarkEASilverRMBranchDW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?Curr Rheumatol Rep (2007) 9:219–25.10.1007/s11926-007-0035-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 46

  EspinosaGCerveraRAshersonRA. Catastrophic antiphospholipid syndrome and sepsis. A common link?J Rheumatol (2007) 34:923–6.

  • Pubmed Abstract
  • Google Scholar

• 47

  SèneDPietteJCCacoubP. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev (2008) 7:272–7.10.1016/j.autrev.2007.10.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 48

  ZingerHShererYGoddardGBerkunYBarzilaiOAgmon-LevinNet alCommon infectious agents prevalence in antiphospholipid syndrome. Lupus (2009) 18:1149–53.10.1177/0961203309345738

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49

  KuttehWH. Antiphospholipid antibody syndrome and reproduction. Curr Opin Obstet Gynecol (2014) 26:260–5.10.1097/Gco.0000000000000086

  • CrossRef
  • Google Scholar

• 50

  KuttehWHHinoteCD. Antiphospholipid antibody syndrome. Obstet Gyn Clin N Am (2014) 41:113–32.10.1016/j.ogc.2013.10.004

  • CrossRef
  • Google Scholar

• 51

  O’GormanNWrightDSyngelakiAAkolekarRWrightAPoonLCet alCompeting risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol (2016) 214:103.e1–12.10.1016/j.ajog.2015.08.034

  • CrossRef
  • Google Scholar

• 52

  SchieveLAHandlerAHershowRDavisF. Urinary-tract infection during pregnancy – its association with maternal morbidity and perinatal outcome. Am J Public Health (1994) 84:405–10.10.2105/Ajph.84.3.405

  • CrossRef
  • Google Scholar

• 53

  Conde-AgudeloAVillarJLindheimerM. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol (2008) 198:7–22.10.1016/j.ajog.2007.07.040

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54

  RustveldLOKelseySFSharmaR. Association between maternal infections and preeclampsia: a systematic review of epidemiologic studies. Matern Child Health J (2008) 12:223–42.10.1007/s10995-007-0224-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 55

  IrgensHUReisaeterLIrgensLMLieRT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ (2001) 323:1213–7.10.1136/bmj.323.7323.1213

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56

  BellamyLCasasJPHingoraniADWilliamsDJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ (2007) 335:974.10.1136/bmj.39335.385301.BE

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 57

  CraiciIMWagnerSJHaymanSRGarovicVD. Pre-eclamptic pregnancies: an opportunity to identify women at risk for future cardiovascular disease. Womens Health (Lond Engl) (2008) 4:133–5.10.2217/17455057.4.2.133

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58

  RomundstadPRMagnussenEBSmithGDVattenLJ. Hypertension in pregnancy and later cardiovascular risk: common antecedents?Circulation (2010) 122:579–84.10.1161/CIRCULATIONAHA.110.943407

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 59

  PoweCELevineRJKarumanchiSA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 123:2856–69.10.1161/CIRCULATIONAHA.109.853127

  • CrossRef
  • Google Scholar

• 60

  SkjaervenRWilcoxAJKlungsøyrKIrgensLMVikseBEVattenLJet alCardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study. BMJ (2012) 345:e7677.10.1136/bmj.e7677

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61

  AnanthCVLawrence ClearyK. Pre-eclampsia and cardiovascular disease: more questions than answers?BJOG (2013) 120:920–3.10.1111/1471-0528.12215

  • CrossRef
  • Google Scholar

• 62

  BrennanLJMortonJSDavidgeST. Vascular dysfunction in preeclampsia. Microcirculation (2014) 21:4–14.10.1111/micc.12079

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 63

  ChenCWJaffeIZKarumanchiSA. Pre-eclampsia and cardiovascular disease. Cardiovasc Res (2014) 101:579–86.10.1093/cvr/cvu018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 64

  TannettaDSHuntKJonesCIDavidsonNCoxonCHFergusonDet alSyncytiotrophoblast extracellular vesicles from pre-eclampsia placentas differentially affect platelet function. PLoS One (2015) 10:e0142538.10.1371/journal.pone.0142538

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65

  MolBWJRobertsCTThangaratinamSMageeLADe GrootCJMHofmeyrGJ. Pre-eclampsia. Lancet (2016) 387:999–1011.10.1016/S0140-6736(15)00070-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 66

  BatemanBTSchumacherHCBushnellCDPile-SpellmanJSimpsonLLSaccoRLet alIntracerebral hemorrhage in pregnancy: frequency, risk factors, and outcome. Neurology (2006) 67:424–9.10.1212/01.wnl.0000228277.84760.a2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 67

  KajantieEErikssonJGOsmondCThornburgKBarkerDJP. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. Stroke (2009) 40:1176–80.10.1161/STROKEAHA.108.538025

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 68

  TangCHWuCSLeeTHHungSTYangCYLeeCHet alPreeclampsia-eclampsia and the risk of stroke among peripartum in Taiwan. Stroke (2009) 40:1162–8.10.1161/STROKEAHA.108.540880

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69

  ShererYBlankMShoenfeldY. Antiphospholipid syndrome (APS): where does it come from?Best Pract Res Clin Rheumatol (2007) 21:1071–8.10.1016/j.berh.2007.09.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70

  MigniniLEVillarJKhanKS. Mapping the theories of preeclampsia: the need for systematic reviews of mechanisms of the disease. Am J Obstet Gynecol (2006) 194:317–21.10.1016/j.ajog.2005.08.065

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71

  KellDBKennyLC. A dormant microbial component in the development of pre-eclampsia. BioRxiv preprint. bioRxiv (2016) 057356.10.1101/057356

  • CrossRef
  • Google Scholar

• 72

  RedmanCWG. Current topic: pre-eclampsia and the placenta. Placenta (1991) 12:301–8.10.1016/0143-4004(91)90339-H

  • CrossRef
  • Google Scholar

• 73

  GencHUzunHBenianASimsekGGelisgenRMadazliRet alEvaluation of oxidative stress markers in first trimester for assessment of preeclampsia risk. Arch Gynecol Obstet (2011) 284:1367–73.10.1007/s00404-011-1865-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 74

  BurtonGJJauniauxE. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig (2004) 11:342–52.10.1016/j.jsgi.2004.03.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75

  RedmanCWGSargentIL. Latest advances in understanding preeclampsia. Science (2005) 308:1592–4.10.1126/science.1111726

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 76

  RobertsJMBellMJ. If we know so much about preeclampsia, why haven’t we cured the disease?J Reprod Immunol (2013) 99:1–9.10.1016/j.jri.2013.05.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77

  RedmanCWSargentILStaffAC. IFPA Senior Award Lecture: making sense of pre-eclampsia – two placental causes of preeclampsia?Placenta (2014) 35(Suppl):S20–5.10.1016/j.placenta.2013.12.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78

  XiongXDemianczukNNSaundersLDWangFLFraserWD. Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol (2002) 155:203–9.10.1093/aje/155.3.203

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 79

  RobertsJMHubelCA. The two stage model of preeclampsia: variations on the theme. Placenta (2009) 30(Suppl A):S32–7.10.1016/j.placenta.2008.11.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 80

  RedmanCWG. The six stages of pre-eclampsia. Pregnancy Hypertens (2014) 4:246.10.1016/j.preghy.2014.04.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81

  SacksGPStudenaKSargentKRedmanCWG. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol (1998) 179:80–6.10.1016/S0002-9378(98)70254-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82

  RedmanCWGSargentIL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response – a review. Placenta (2003) 24(Suppl A):S21–7.10.1053/plac.2002.0930

  • CrossRef
  • Google Scholar

• 83

  HubelCA. Dyslipidemia and pre-eclampsia. In: BelfortMALydallF, editors. Pre-Eclampsia-Aetiology and Clinical Practice. Cambridge: Cambridge University Press (2006). p. 164–82.

  • Google Scholar

• 84

  KellDB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol (2010) 577:825–89.10.1007/s00204-010-0577-x

  • CrossRef
  • Google Scholar

• 85

  YancopoulosGDDavisSGaleNWRudgeJSWiegandSJHolashJ. Vascular-specific growth factors and blood vessel formation. Nature (2000) 407:242–8.10.1038/35025215

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 86

  MaynardSEpsteinFHKarumanchiSA. Preeclampsia and angiogenic imbalance. Annu Rev Med (2008) 59:61–78.10.1146/annurev.med.59.110106.214058

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87

  LevineRJMaynardSEQianCLimKHEnglandLJYuKFet alCirculating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 350:672–83.10.1056/NEJMoa031884

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 88

  LevineRJLamCQianCYuKFMaynardSESachsBPet alSoluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 355:992–1005.10.1056/NEJMoa055352

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 89

  PalomakiGEHaddowJEHaddowHRSalahuddinSGeahchanCCerdeiraASet alModeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenat Diagn (2015) 35:386–93.10.1002/pd.4554

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90

  EntmanSSRichardsonLD. Clinical applications of the altered iron kinetics of toxemia of pregnancy. Am J Obstet Gynecol (1983) 146:568–74.10.1016/0002-9378(83)90804-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91

  MacDonaldAB. Human fetal borreliosis, toxemia of pregnancy, and fetal death. Zentralbl Bakteriol Mikrobiol Hyg A (1986) 263:189–200.

  • Google Scholar

• 92

  LoudonI. Some historical aspects of toxaemia of pregnancy. A review. Br J Obstet Gynaecol (1991) 98:853–8.10.1111/j.1471-0528.1991.tb13505.x

  • CrossRef
  • Google Scholar

• 93

  MezianiFTesseADavidEMartinezMCWangesteenRSchneiderFet alShed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. Am J Pathol (2006) 169:1473–83.10.2353/ajpath.2006.051304

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94

  SugawaraJMitsui-SaitoMHayashiCHoshiaiTSenooMChisakaHet alDecrease and senescence of endothelial progenitor cells in patients with preeclampsia. J Clin Endocrinol Metab (2005) 90:5329–32.10.1210/jc.2005-0532

  • CrossRef
  • Google Scholar

• 95

  WangYWalshSW. Placental mitochondria as a source of oxidative stress in pre-eclampsia. Placenta (1998) 19:581–6.10.1016/S0143-4004(98)90018-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96

  SchumackerPT. Current paradigms in cellular oxygen sensing. Adv Exp Med Biol (2003) 543:57–71.10.1007/978-1-4419-8997-0_5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 97

  Bradford HillA. Environment and disease: association or causation?Proc R Soc Med (1965) 58:295–300.

  • Google Scholar

• 98

  KarmonAPilpelY. Biological causal links on physiological and evolutionary time scales. Elife (2016) 5:e14424.10.7554/eLife.14424

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99

  KellDB. Metabolomics, modelling and machine learning in systems biology: towards an understanding of the languages of cells. The 2005 Theodor Bücher lecture. FEBS J (2006) 273:873–94.10.1111/j.1742-4658.2006.05136.x

  • CrossRef
  • Google Scholar

• 100

  GradmannC. A spirit of scientific rigour: Koch’s postulates in twentieth-century medicine. Microbes Infect (2014) 16:885–92.10.1016/j.micinf.2014.08.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 101

  FalkowS. Molecular Koch’s postulates applied to microbial pathogenicity. Rev Infect Dis (1988) 10(Suppl 2):S274–6.10.1093/cid/10.Supplement_2.S274

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 102

  FredricksDNRelmanDA. Sequence-based identification of microbial pathogens – a reconsideration of Koch’s postulates. Clin Microbiol Rev (1996) 9:18–33.

  • Google Scholar

• 103

  FalkowS. Molecular Koch’s postulates applied to bacterial pathogenicity – a personal recollection 15 years later. Nat Rev Microbiol (2004) 2:67–72.10.1038/nrmicro799

  • CrossRef
  • Google Scholar

• 104

  LoweAMYansouniCPBehrMA. Causality and gastrointestinal infections: Koch, Hill, and Crohn’s. Lancet Infect Dis (2008) 8:720–6.10.1016/S1473-3099(08)70257-3

  • CrossRef
  • Google Scholar

• 105

  SealJBMorowitzMZaborinaOAnGAlverdyJC. The molecular Koch’s postulates and surgical infection: a view forward. Surgery (2010) 147:757–65.10.1016/j.surg.2010.03.008

  • CrossRef
  • Google Scholar

• 106

  SegreJA. What does it take to satisfy Koch’s postulates two centuries later? Microbial genomics and Propionibacteria acnes. J Invest Dermatol (2013) 133:2141–2.10.1038/jid.2013.260

  • CrossRef
  • Google Scholar

• 107

  ByrdALSegreJA. Adapting Koch’s postulates. Science (2016) 351:224–6.10.1126/science.aad6753

  • CrossRef
  • Google Scholar

• 108

  ThagardP. Explanatory coherence. Behav Brain Sci (1989) 12:435–502.10.1017/S0140525X00057046

  • CrossRef
  • Google Scholar

• 109

  ThagardPVerbeurgtK. Coherence as constraint satisfaction. Cogn Sci (1998) 22:1–24.10.1207/s15516709cog2201_1

  • CrossRef
  • Google Scholar

• 110

  ThagardP. How Scientists Explain Disease. Princeton, NJ: Princeton University Press (1999).

  • Google Scholar

• 111

  ThagardP. Coherence, truth, and the development of scientific knowledge. Philos Sci (2007) 74:28–47.10.1086/520941

  • CrossRef
  • Google Scholar

• 112

  ThagardP. Explanatory coherence. Reasoning: Studies of Human Inference and Its Foundations. (2008). p. 471–513.

  • Google Scholar

• 113

  PenningtonKASchlittJMJacksonDLSchulzLCSchustDJ. Preeclampsia: multiple approaches for a multifactorial disease. Dis Model Mech (2012) 5:9–18.10.1242/dmm.008516

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 114

  MageeLAPelsAHelewaMReyEVon DadelszenPCanadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens (2014) 4:105–45.10.1016/j.preghy.2014.01.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 115

  GoddardKAGTrompGRomeroROlsonJMLuQXuZet alCandidate-gene association study of mothers with pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum Hered (2007) 63:1–16.10.1159/000097926

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 116

  JebbinkJWoltersAFernandoFAfinkGvan der PostJRis-StalpersC. Molecular genetics of preeclampsia and HELLP syndrome – a review. Biochim Biophys Acta (2012) 1822:1960–9.10.1016/j.bbadis.2012.08.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 117

  FongFMSahemeyMKHamediGEyitayoRYatesDKuanVet alMaternal genotype and severe preeclampsia: a HuGE review. Am J Epidemiol (2014) 180:335–45.10.1093/aje/kwu151

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 118

  WilliamsonRDO’KeeffeGWKennyLC. Activin signalling and pre-eclampsia: from genetic risk to pre-symptomatic biomarker. Cytokine (2015) 71:360–5.10.1016/j.cyto.2014.11.017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 119

  MaherB. The case of the missing heritability. Nature (2008) 456:18–21.10.1038/456018a

  • CrossRef
  • Google Scholar

• 120

  ManolioTACollinsFSCoxNJGoldsteinDBHindorffLAHunterDJet alFinding the missing heritability of complex diseases. Nature (2009) 461:747–53.10.1038/nature08494

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 121

  ZukOHechterESunyaevSRLanderES. The mystery of missing heritability: genetic interactions create phantom heritability. Proc Natl Acad Sci U S A (2012) 109:1193–8.10.1073/pnas.1119675109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 122

  CarreirasMMontagnaniSLayrisseZ. Preeclampsia: a multifactorial disease resulting from the interaction of the feto-maternal HLA genotype and HCMV infection. Am J Reprod Immunol (2002) 48:176–83.10.1034/j.1600-0897.2002.01076.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 123

  McCarthyCMKennyLC. Immunostimulatory role of mitochondrial DAMPs: alarming for pre-eclampsia?Am J Reprod Immunol (2016) 76:341–7.10.1111/aji.12526

  • CrossRef
  • Google Scholar

• 124

  McCarthyCMKennyLC. Mitochondrial [dys]function; culprit in pre-eclampsia?Clin Sci (Lond) (2016) 130:1179–84.10.1042/CS20160103

  • CrossRef
  • Google Scholar

• 125

  KellDB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2:2.10.1186/1755-8794-2-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 126

  KellDBPretoriusE. Serum ferritin is an important disease marker, and is mainly a leakage product from damaged cells. Metallomics (2014) 6:748–73.10.1039/C3MT00347G

  • CrossRef
  • Google Scholar

• 127

  PretoriusEKellDB. Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases. Integr Biol (2014) 6:486–510.10.1039/c4ib00025k

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 128

  KellDBPretoriusE. The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen). Integr Biol (2015) 7:24–52.10.1039/c4ib00173g

  • CrossRef
  • Google Scholar

• 129

  PretoriusEOberholzerHMvan der SpuyWJSwanepoelACSomaP. Qualitative scanning electron microscopy analysis of fibrin networks and platelet abnormalities in diabetes. Blood Coagul Fibrinol (2011) 22:463–7.10.1097/MBC.0b013e3283468a0d

  • CrossRef
  • Google Scholar

• 130

  PretoriusESteynHEngelbrechtMSwanepoelACOberholzerHM. Differences in fibrin fiber diameters in healthy individuals and thromboembolic ischemic stroke patients. Blood Coagul Fibrinolysis (2011) 22:696–700.10.1097/MBC.0b013e32834bdb32

  • CrossRef
  • Google Scholar

• 131

  PretoriusESwanepoelACOberholzerHMvan der SpuyWJDuimWWesselsPF. A descriptive investigation of the ultrastructure of fibrin networks in thrombo-embolic ischemic stroke. J Thromb Thrombolysis (2011) 31:507–13.10.1007/s11239-010-0538-5

  • CrossRef
  • Google Scholar

• 132

  PretoriusEDu PlooyJSomaPGasparyanAY. An ultrastructural analysis of platelets, erythrocytes, white blood cells, and fibrin network in systemic lupus erythematosus. Rheumatol Int (2014) 34:1005–9.10.1007/s00296-013-2817-x

  • CrossRef
  • Google Scholar

• 133

  PretoriusESwanepoelACBuysAVVermeulenNDuimWKellDB. Eryptosis as a marker of Parkinson’s disease. Aging (2014) 6:788–819.10.18632/aging.100695

  • CrossRef
  • Google Scholar

• 134

  PretoriusEBesterJVermeulenNAlummoottilSSomaPBuysAVet alPoorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics. Cardiovasc Diabetol (2015) 13:30.10.1186/s12933-015-0192-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 135

  BesterJBuysAVLipinskiBKellDBPretoriusE. High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer’s disease. Front Aging Neurosci (2013) 5:00088.10.3389/fnagi.2013.00088

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 136

  PretoriusEBesterJVermeulenNLipinskiBGerickeGSKellDB. Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents. PLoS One (2014) 9:e85271.10.1371/journal.pone.0085271

  • CrossRef
  • Google Scholar

• 137

  PretoriusEOlumuyiwa-AkeredoluOOMbotweSBesterJ. Erythrocytes and their role as health indicator: using structure in a patient-orientated precision medicine approach. Blood Rev (2016) 30:263–74.10.1016/j.blre.2016.01.001

  • CrossRef
  • Google Scholar

• 138

  TodrosTVasarioECardaropoliS. Preeclampsia as an infectious disease. Exp Rev Obstet Gynecol (2007) 2:735–41.10.1586/17474108.2.6.735

  • CrossRef
  • Google Scholar

• 139

  KellDBPotgieterMPretoriusE. Individuality, phenotypic differentiation, dormancy and ‘persistence’ in culturable bacterial systems: commonalities shared by environmental, laboratory, and clinical microbiology. F1000Research (2015) 4:179.10.12688/f1000research.6709.1

  • CrossRef
  • Google Scholar

• 140

  KellDBPretoriusE. On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death. Integr Biol (2015) 7:1339–77.10.1039/C5IB00158G

  • CrossRef
  • Google Scholar

• 141

  PotgieterMBesterJKellDBPretoriusE. The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol Rev (2015) 39:567–91.10.1093/femsre/fuv013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 142

  PretoriusEAkeredoluO-OSomaPKellDB. Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability. Exp Biol Med (Forthcoming 2016).

  • Google Scholar

• 143

  PretoriusEBesterJKellDB. A bacterial component to Alzheimer-type dementia seen via a systems biology approach that links iron dysregulation and inflammagen shedding to disease. J Alzheimers Dis (2016) 53:1237–56.10.3233/JAD-160318

  • CrossRef
  • Google Scholar

• 144

  ProalADAlbertPJMarshallTG. The human microbiome and autoimmunity. Curr Opin Rheumatol (2013) 25:234–40.10.1097/BOR.0b013e32835cedbf

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 145

  ManginMSinhaRFincherK. Inflammation and vitamin D: the infection connection. Inflamm Res (2014) 63:803–19.10.1007/s00011-014-0755-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 146

  ProalADAlbertPJMarshallTG. Inflammatory disease and the human microbiome. Discov Med (2014) 17:257–65.

  • Pubmed Abstract
  • Google Scholar

• 147

  ItzhakiRFLatheRBalinBJBallMJBraakHBearerELet alMicrobes and Alzheimer’s disease. J Alzheimers Dis (2016) 51:979–84.10.3233/JAD-160152

  • CrossRef
  • Google Scholar

• 148

  MorathSGeyerAHartungT. Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J Exp Med (2001) 193:393–7.10.1084/jem.193.3.393

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 149

  PostgateJR. Viability measurements and the survival of microbes under minimum stress. Adv Micro Physiol (1967) 1:1–23.10.1016/S0065-2911(08)60248-9

  • CrossRef
  • Google Scholar

• 150

  PostgateJR. Viable counts and viability. Methods Microbiol (1969) 1:611–28.10.1016/S0580-9517(08)70149-1

  • CrossRef
  • Google Scholar

• 151

  PostgateJR. Death in microbes and macrobes. In: GrayTRGPostgateJR, editors. In the Survival of Vegetative Microbes. Cambridge: Cambridge University Press (1976). p. 1–19.

  • Google Scholar

• 152

  StaleyJTKonopkaA. Measurement of in situ activities of nonphotosynthetic microorganisms in aquatic and terrestrial habitats. Annu Rev Microbiol (1985) 39:321–46.10.1146/annurev.mi.39.100185.001541

  • CrossRef
  • Google Scholar

• 153

  TanakaTKawasakiKDaimonSKitagawaWYamamotoKTamakiHet alA hidden pitfall in the preparation of agar media undermines microorganism cultivability. Appl Environ Microbiol (2014) 80:7659–66.10.1128/AEM.02741-14

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 154

  NicholsDCahoonNTrakhtenbergEMPhamLMehtaABelangerAet alUse of ichip for high-throughput in situ cultivation of “uncultivable” microbial species. Appl Environ Microbiol (2010) 76:2445–50.10.1128/AEM.01754-09

  • CrossRef
  • Google Scholar

• 155

  BrowneHPForsterSCAnonyeBOKumarNNevilleBAStaresMDet alCulturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature (2016) 533:543–6.10.1038/nature17645

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 156

  KaprelyantsASGottschalJCKellDB. Dormancy in non-sporulating bacteria. FEMS Microbiol Rev (1993) 10:271–86.10.1111/j.1574-6968.1993.tb05871.x

  • CrossRef
  • Google Scholar

• 157

  KellDBKaprelyantsASWeichartDHHarwoodCLBarerMR. Viability and activity in readily culturable bacteria: a review and discussion of the practical issues. Antonie Van Leeuwenhoek (1998) 73:169–87.10.1023/A:1000664013047

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 158

  SaitoARolfeRDEdelsteinPHFinegoldSM. Comparison of liquid growth media for Legionella pneumophila. J Clin Microbiol (1981) 14:623–7.

  • Pubmed Abstract
  • Google Scholar

• 159

  MeyerRD. Legionella infections – a review of 5 years of research. Rev Infect Dis (1983) 5:258–78.10.1093/clinids/5.2.258

  • CrossRef
  • Google Scholar

• 160

  BarkerJFarrellIDHutchisonJG. Factors affecting growth of Legionella pneumophila in liquid media. J Med Microbiol (1986) 22:97–100.10.1099/00222615-22-2-97

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 161

  MolinariJ. Legionella and human disease: part 1: a path of scientific and community discovery. Compend Contin Educ Dent (1997) 18:556–9.

  • Google Scholar

• 162

  MaiwaldMSchuhmacherFDittonHJVonherbayA. Environmental occurrence of the Whipple’s disease bacterium (Tropheryma whippelii). Appl Environ Microbiol (1998) 64:760–2.

  • Google Scholar

• 163

  MaiwaldMRelmanDA. Whipple’s disease and Tropheryma whippelii: secrets slowly revealed. Clin Infect Dis (2001) 32:457–63.10.1086/318512

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 164

  OmslandACockrellDCHoweDFischerERVirtanevaKSturdevantDEet alHost cell-free growth of the Q fever bacterium Coxiella burnetii. Proc Natl Acad Sci U S A (2009) 106:4430–4.10.1073/pnas.0812074106

  • CrossRef
  • Google Scholar

• 165

  OmslandA. Axenic growth of Coxiella burnetii. Adv Exp Med Biol (2012) 984:215–29.10.1007/978-94-007-4315-1_11

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 166

  MarshallBJ. One hundred years of discovery and rediscovery of Helicobacter pylori and its association with peptic ulcer disease. In: MobleyHLTMendzGLHazellSL, editors. Helicobacter pylori: Physiology and Genetics. Washington, DC: ASM Press (2001). p. 19–24.

  • Google Scholar

• 167

  MarshallB. Helicobacter connections. ChemMedChem (2006) 1:783–802.10.1002/cmdc.200600153

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 168

  MarshallBJWarrenJR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet (1984) 1:1311–5.10.1016/S0140-6736(84)91816-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 169

  MarshallBJArmstrongJAMcgechieDBGlancyRJ. Attempt to fulfil Koch’s postulates for pyloric Campylobacter. Med J Aust (1985) 142:436–9.

  • Pubmed Abstract
  • Google Scholar

• 170

  KaprelyantsASKellDB. Dormancy in stationary-phase cultures of Micrococcus luteus: flow cytometric analysis of starvation and resuscitation. Appl Environ Microbiol (1993) 59:3187–96.

  • Pubmed Abstract
  • Google Scholar

• 171

  KaprelyantsASMukamolovaGVKellDB. Estimation of dormant Micrococcus luteus cells by penicillin lysis and by resuscitation in cell-free spent medium at high dilution. FEMS Microbiol Lett (1994) 115:347–52.10.1111/j.1574-6968.1994.tb06662.x

  • CrossRef
  • Google Scholar

• 172

  WayneLG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis (1994) 13:908–14.10.1007/BF02111491

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 173

  KanaBDGordhanBGDowningKJSungNVostroktunovaGMachowskiEEet alThe resuscitation-promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro. Mol Microbiol (2008) 67:672–84.10.1111/j.1365-2958.2007.06078.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 174

  GengenbacherMKaufmannSHE. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev (2012) 36:514–32.10.1111/j.1574-6976.2012.00331.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 175

  AlnimrAM. Dormancy models for Mycobacterium tuberculosis: a minireview. Braz J Microbiol (2015) 46:641–7.10.1590/S1517-838246320140507

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 176

  ShleevaMKondratievaTRubakovaEVostroknutovaGKaprelyantsAAptA. Reactivation of dormant “non-culturable” Mycobacterium tuberculosis developed in vitro after injection in mice: both the dormancy depth and host genetics influence the outcome. Microb Pathog (2015) 78:63–6.10.1016/j.micpath.2014.11.016

  • CrossRef
  • Google Scholar

• 177

  MukamolovaGVKaprelyantsASYoungDIYoungMKellDB. A bacterial cytokine. Proc Natl Acad Sci U S A (1998) 95:8916–21.10.1073/pnas.95.15.8916

  • CrossRef
  • Google Scholar

• 178

  MukamolovaGVTurapovOAKazarianKTelkovMKaprelyantsASKellDBet alThe rpf gene of Micrococcus luteus encodes an essential secreted growth factor. Mol Microbiol (2002) 46:611–21.10.1046/j.1365-2958.2002.03183.x

  • CrossRef
  • Google Scholar

• 179

  MukamolovaGVTurapovOAYoungDIKaprelyantsASKellDBYoungM. A family of autocrine growth factors in Mycobacterium tuberculosis. Mol Microbiol (2002) 46:623–35.10.1046/j.1365-2958.2002.03184.x

  • CrossRef
  • Google Scholar

• 180

  MukamolovaGVMurzinAGSalinaEGDeminaGRKellDBKaprelyantsASet alMuralytic activity of Micrococcus luteus Rpf and its relationship to physiological activity in promoting bacterial growth and resuscitation. Mol Microbiol (2006) 59:84–98.10.1111/j.1365-2958.2005.04930.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 181

  MukamolovaGVTurapovOMalkinJWoltmannGBarerMR. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am J Respir Crit Care Med (2010) 181:174–80.10.1164/rccm.200905-0661OC

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 182

  YeremeevVVKondratievaTKRubakovaEIPetrovskayaSNKazarianKATelkovMVet alProteins of the Rpf family: immune cell reactivity and vaccination efficacy against tuberculosis in mice. Infect Immun (2003) 71:4789–94.10.1128/IAI.71.8.4789-4794.2003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 183

  ZviAArielNFulkersonJSadoffJCShaffermanA. Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Med Genomics (2008) 1:18.10.1186/1755-8794-1-18

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 184

  DyeCScheeleSDolinPPathaniaVRaviglioneRC. Global burden of tuberculosis – estimated incidence, prevalence, and mortality by country. JAMA (1999) 282:677–86.10.1001/jama.282.7.677

  • CrossRef
  • Google Scholar

• 185

  FlynnJLChanJ. Tuberculosis: latency and reactivation. Infect Immun (2001) 69:4195–201.10.1128/IAI.69.7.4195-4201.2001

  • CrossRef
  • Google Scholar

• 186

  WayneLGSohaskeyCD. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol (2001) 55:139–63.10.1146/annurev.micro.55.1.139

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 187

  GomezJEMcKinneyJD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) (2004) 84:29–44.10.1016/j.tube.2003.08.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 188

  AmievaMREl-OmarEM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology (2008) 134:306–23.10.1053/j.gastro.2007.11.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 189

  CoverTLBlaserMJ. Helicobacter pylori in health and disease. Gastroenterology (2009) 136:1863–73.10.1053/j.gastro.2009.01.073

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 190

  DomingueGJWoodyHB. Bacterial persistence and expression of disease. Clin Microbiol Rev (1997) 10:320–44.

  • Google Scholar

• 191

  YoungDStarkJKirschnerD. Systems biology of persistent infection: tuberculosis as a case study. Nat Rev Microbiol (2008) 6:520–8.10.1038/nrmicro1919

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 192

  LewisK. Persister cells. Annu Rev Microbiol (2010) 64:357–72.10.1146/annurev.micro.112408.134306

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 193

  AmatoSMFazenCHHenryTCMokWWKOrmanMASandvikELet alThe role of metabolism in bacterial persistence. Front Microbiol (2014) 5:70.10.3389/Fmicb.2014.00070

  • CrossRef
  • Google Scholar

• 194

  ConlonBP. Staphylococcus aureus chronic and relapsing infections: evidence of a role for persister cells: an investigation of persister cells, their formation and their role in S. aureus disease. Bioessays (2014) 36:991–6.10.1002/bies.201400080

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 195

  KesterJCFortuneSM. Persisters and beyond: mechanisms of phenotypic drug resistance and drug tolerance in bacteria. Crit Rev Biochem Mol Biol (2014) 49:91–101.10.3109/10409238.2013.869543

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 196

  LevinBRConcepción-AcevedoJUdekwuKI. Persistence: a copacetic and parsimonious hypothesis for the existence of non-inherited resistance to antibiotics. Curr Opin Microbiol (2014) 21:18–21.10.1016/j.mib.2014.06.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 197

  MaisonneuveEGerdesK. Molecular mechanisms underlying bacterial persisters. Cell (2014) 157:539–48.10.1016/j.cell.2014.02.050

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 198

  RankRGYeruvaL. Hidden in plain sight: chlamydial gastrointestinal infection and its relevance to persistence in human genital infection. Infect Immun (2014) 82:1362–71.10.1128/IAI.01244-13

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 199

  HoldenDW. Persisters unmasked. Science (2015) 347:30–2.10.1126/science.1262033

  • CrossRef
  • Google Scholar

• 200

  OrmanMAMokWWKBrynildsenMP. Aminoglycoside-enabled elucidation of bacterial persister metabolism. Curr Protoc Microbiol (2015) 36:1–14.10.1002/9780471729259.mc1709s36

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 201

  StepanyanKWenseleersTDuéñez-GuzmánEAMuratoriFVan Den BerghBVerstraetenNet alFitness trade-offs explain low levels of persister cells in the opportunistic pathogen Pseudomonas aeruginosa. Mol Ecol (2015) 24:1572–83.10.1111/mec.13127

  • CrossRef
  • Google Scholar

• 202

  GerdesKSemseyS. Pumping persisters. Nature (2016) 534:41–2.10.1038/nature18442

  • CrossRef
  • Google Scholar

• 203

  PuYZhaoZLiYZouJMaQZhaoYet alEnhanced efflux activity facilitates drug tolerance in dormant bacterial cells. Mol Cell (2016) 62:284–94.10.1016/j.molcel.2016.03.035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 204

  DehioCBerryCBartenschlagerR. Persistent intracellular pathogens. FEMS Microbiol Rev (2012) 36:513.10.1111/j.1574-6976.2012.00336.x

  • CrossRef
  • Google Scholar

• 205

  PrideauxBViaLEZimmermanMDEumSSarathyJO’BrienPet alThe association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med (2015) 21:1223–7.10.1038/nm.3937

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 206

  DobsonPDKellDB. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?Nat Rev Drug Discov (2008) 7:205–20.10.1038/nrd2438

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 207

  KellDBDobsonPDOliverSG. Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. Drug Discov Today (2011) 16:704–14.10.1016/j.drudis.2011.05.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 208

  KellDBDobsonPDBilslandEOliverSG. The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. Drug Discov Today (2013) 18:218–39.10.1016/j.drudis.2012.11.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 209

  KellDBOliverSG. How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Front Pharmacol (2014) 5:231.10.3389/fphar.2014.00231

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 210

  ThwaitesGEGantV. Are bloodstream leukocytes Trojan horses for the metastasis of Staphylococcus aureus?Nat Rev Microbiol (2011) 9:215–22.10.1038/nrmicro2508

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 211

  SeubertASchuleinRDehioC. Bacterial persistence within erythrocytes: a unique pathogenic strategy of Bartonella spp. Int J Med Microbiol (2002) 291:555–60.10.1078/1438-4221-00167

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 212

  MysorekarIUHultgrenSJ. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci U S A (2006) 103:14170–5.10.1073/pnas.0602136103

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 213

  BlangoMGMulveyMA. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother (2010) 54:1855–63.10.1128/AAC.00014-10

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 214

  ChenSLWuMHendersonJPHootonTMHibbingMEHultgrenSJet alGenomic diversity and fitness of E. coli strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection. Sci Transl Med (2013) 5:184ra160.10.1126/scitranslmed.3005497

  • CrossRef
  • Google Scholar

• 215

  GoneauLWHannanTJMacpheeRASchwartzDJMacklaimJMGloorGBet alSubinhibitory antibiotic therapy alters recurrent urinary tract infection pathogenesis through modulation of bacterial virulence and host immunity. MBio (2015) 6:e00356–15.10.1128/mBio.00356-15

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 216

  SullivanWJJrJeffersV. Mechanisms of Toxoplasma gondii persistence and latency. FEMS Microbiol Rev (2012) 36:717–33.10.1111/j.1574-6976.2011.00305.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 217

  PoseyJEGherardiniFC. Lack of a role for iron in the Lyme disease pathogen. Science (2000) 288:1651–3.10.1126/science.288.5471.1651

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 218

  AguirreJDClarkHMMcilvinMVazquezCPalmereSLGrabDJet alA manganese-rich environment supports superoxide dismutase activity in a Lyme disease pathogen, Borrelia burgdorferi. J Biol Chem (2013) 288:8468–78.10.1074/jbc.M112.433540

  • CrossRef
  • Google Scholar

• 219

  WeinbergED. Nutritional immunity. Host’s attempt to withold iron from microbial invaders. JAMA (1975) 231:39–41.10.1001/jama.1975.03240130021018

  • CrossRef
  • Google Scholar

• 220

  WeinbergED. Iron withholding: a defense against infection and neoplasia. Physiol Rev (1984) 64:65–102.

  • Google Scholar

• 221

  MarxJJM. Iron and infection: competition between host and microbes for a precious element. Best Pract Res Clin Haematol (2002) 15:411–26.10.1053/beha.2002.0001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 222

  FischbachMALinHNLiuDRWalshCT. How pathogenic bacteria evade mammalian sabotage in the battle for iron. Nat Chem Biol (2006) 2:132–8.10.1038/nchembio771

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 223

  WeinbergEDMiklossyJ. Iron withholding: a defense against disease. J Alzheimers Dis (2008) 13:451–63.

  • Pubmed Abstract
  • Google Scholar

• 224

  ReidDWAndersonGJLamontIL. Role of lung iron in determining the bacterial and host struggle in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol (2009) 297:L795–802.10.1152/ajplung.00132.2009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 225

  WeinbergED. Iron availability and infection. Biochim Biophys Acta (2009) 1790:600–5.10.1016/j.bbagen.2008.07.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 226

  ChuBCGarcia-HerreroAJohansonTHKrewulakKDLauCKPeacockRSet alSiderophore uptake in bacteria and the battle for iron with the host; a bird’s eye view. Biometals (2010) 23:601–11.10.1007/s10534-010-9361-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 227

  NairzMSchrollASonnweberTWeissG. The struggle for iron – a metal at the host-pathogen interface. Cell Microbiol (2010) 12:1691–702.10.1111/j.1462-5822.2010.01529.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 228

  SkaarEP. The battle for iron between bacterial pathogens and their vertebrate hosts. PLoS Pathog (2010) 6:e1000949.10.1371/journal.ppat.1000949

  • CrossRef
  • Google Scholar

• 229

  HoodMISkaarEP. Nutritional immunity: transition metals at the pathogen-host interface. Nat Rev Microbiol (2012) 10:525–37.10.1038/nrmicro2836

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 230

  CassatJESkaarEP. Iron in infection and immunity. Cell Host Microbe (2013) 13:509–19.10.1016/j.chom.2013.04.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 231

  DeriuELiuJZPezeshkiMEdwardsRAOchoaRJContrerasHet alProbiotic bacteria reduce Salmonella typhimurium intestinal colonization by competing for iron. Cell Host Microbe (2013) 14:26–37.10.1016/j.chom.2013.06.007

  • CrossRef
  • Google Scholar

• 232

  LealSMJrRoySVareechonCCarrionSClarkHLopez-BergesMSet alTargeting iron acquisition blocks infection with the fungal pathogens Aspergillus fumigatus and Fusarium oxysporum. PLoS Pathog (2013) 9:e1003436.10.1371/journal.ppat.1003436

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 233

  Silva-GomesSVale-CostaSAppelbergRGomesMS. Iron in intracellular infection: to provide or to deprive?Front Cell Infect Microbiol (2013) 3:96.10.3389/fcimb.2013.00096

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 234

  ArmitageAEDrakesmithH. The battle for iron. Science (2014) 346:1299–300.10.1126/science.aaa2468

  • CrossRef
  • Google Scholar

• 235

  BeckerKWSkaarEP. Metal limitation and toxicity at the interface between host and pathogen. FEMS Microbiol Rev (2014) 38:1235–49.10.1111/1574-6976.12087

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 236

  Diaz-OchoaVEJellbauerSKlausSRaffatelluM. Transition metal ions at the crossroads of mucosal immunity and microbial pathogenesis. Front Cell Infect Microbiol (2014) 4:2.10.3389/fcimb.2014.00002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 237

  PotrykusJBallouERChildersDSBrownAJP. Conflicting interests in the pathogen-host tug of war: fungal micronutrient scavenging versus mammalian nutritional immunity. PLoS Pathog (2014) 10:e1003910.10.1371/journal.ppat.1003910

  • CrossRef
  • Google Scholar

• 238

  BarberMFEldeNC. Buried treasure: evolutionary perspectives on microbial iron piracy. Trends Genet (2015) 31:627–36.10.1016/j.tig.2015.09.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 239

  NairzMFerring-AppelDCasarrubeaDSonnweberTViatteLSchrollAet alIron regulatory proteins mediate host resistance to Salmonella infection. Cell Host Microbe (2015) 18:254–61.10.1016/j.chom.2015.06.017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 240

  RaymondKNAllredBESiaAK. Coordination chemistry of microbial iron transport. Acc Chem Res (2015) 48:2496–505.10.1021/acs.accounts.5b00301

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 241

  SubashchandraboseSMobleyHLT. Back to the metal age: battle for metals at the host-pathogen interface during urinary tract infection. Metallomics (2015) 7:935–42.10.1039/c4mt00329b

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 242

  Wessling-ResnickM. Nramp1 and other transporters involved in metal withholding during infection. J Biol Chem (2015) 290:18984–90.10.1074/jbc.R115.643973

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 243

  XiaYFarahNMaxanAZhouJLehmannC. Therapeutic iron restriction in sepsis. Med Hypotheses (2016) 89:37–9.10.1016/j.mehy.2016.01.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 244

  EntmanSSRichardsonLDKillamAP. Elevated serum ferritin in the altered ferrokinetics of toxemia of pregnancy. Am J Obstet Gynecol (1982) 144:418–22.10.1016/0002-9378(82)90247-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 245

  SamuelsPMainEKMennutiMTGabbeSG. The origin of increased serum iron in pregnancy-induced hypertension. Am J Obstet Gynecol (1987) 157:721–5.10.1016/S0002-9378(87)80037-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 246

  RamanLPawasheABYasodharaP. Hyperferritinemia in pregnancy induced hypertension and eclampsia. J Postgrad Med (1992) 38:65–7.

  • Pubmed Abstract
  • Google Scholar

• 247

  HubelCAKozlovAVKaganVEEvansRWDavidgeSTMcLaughlinMKet alDecreased transferrin and increased transferrin saturation in sera of women with preeclampsia: implications for oxidative stress. Am J Obstet Gynecol (1996) 175:692–700.10.1053/ob.1996.v175.a74252

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 248

  LaoTTTamKFChanLY. Third trimester iron status and pregnancy outcome in non-anaemic women; pregnancy unfavourably affected by maternal iron excess. Hum Reprod (2000) 15:1843–8.10.1093/humrep/15.8.1843

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 249

  RaymanMPBarlisJEvansRWRedmanCWKingLJ. Abnormal iron parameters in the pregnancy syndrome preeclampsia. Am J Obstet Gynecol (2002) 187:412–8.10.1067/mob.2002.123895

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 250

  SerdarZGürEDevelioğluO. Serum iron and copper status and oxidative stress in severe and mild preeclampsia. Cell Biochem Funct (2006) 24:209–15.10.1002/cbf.1235

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 251

  SmithTGRobbinsPA. Iron, pre-eclampsia and hypoxia-inducible factor. BJOG (2007) 114:1581–2.10.1111/j.1471-0528.2007.01490.x

  • CrossRef
  • Google Scholar

• 252

  BhatlaNKaulNLalNKriplaniAAgarwalNSaxenaRet alComparison of effect of daily versus weekly iron supplementation during pregnancy on lipid peroxidation. J Obstet Gynaecol Res (2009) 35:438–45.10.1111/j.1447-0756.2008.00972.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 253

  SiddiquiIAJaleelAKadriHMSaeedWATamimiW. Iron status parameters in preeclamptic women. Arch Gynecol Obstet (2011) 284:587–91.10.1007/s00404-010-1728-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 254

  FatimaNIslamFNoorLDasSRZebaDZesminF. Serum ferritin in preeclampsia and eclampsia: a case control study. Faridpur Med Coll J (2013) 8:18–21.10.3329/fmcj.v8i1.16892

  • CrossRef
  • Google Scholar

• 255

  KandiSSudhakarTRamadeviCVenugopalBRajkumarRafiMet alPre eclampsia and iron status: a review. Am J Med Biol Res (2014) 2:121–3.10.12691/ajmbr-2-6-1

  • CrossRef
  • Google Scholar

• 256

  NegiRPandeDKarkiKKumarAKhannaRSKhannaHD. Association of oxidative DNA damage, protein oxidation and antioxidant function with oxidative stress induced cellular injury in pre-eclamptic/eclamptic mothers during fetal circulation. Chem Biol Interact (2014) 208:77–83.10.1016/j.cbi.2013.11.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 257

  BesterJSomaPKellDBPretoriusE. Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS). Oncotarget (2015) 6:35284–303.10.18632/oncotarget.6074

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 258

  PretoriusEMbotweSBesterJRobinsonCKellDB. Acute induction of anomalous blood clotting by highly substoichiometric levels of bacterial lipopolysaccharide (LPS). bioRxiv (2016) 053538.10.1101/053538

  • CrossRef
  • Google Scholar

• 259

  PretoriusEMbotweSBesterJRobinsonCJKellDB. Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide. J R Soc Interface (2016) 123:20160539.10.1098/rsif.2016.0539

  • CrossRef
  • Google Scholar

• 260

  LinIHMillerDSBerticsPJMurphyCJDe PabloJJAbbottNL. Endotoxin-induced structural transformations in liquid crystalline droplets. Science (2011) 332:1297–300.10.1126/science.1195639

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 261

  MillerDSAbbottNL. Influence of droplet size, pH and ionic strength on endotoxin-triggered ordering transitions in liquid crystalline droplets. Soft Matter (2013) 9:374–82.10.1039/C2SM26811F

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 262

  RahmanMMAbeSKRahmanMSKandaMNaritaSBilanoVet alMaternal anemia and risk of adverse birth and health outcomes in low- and middle-income countries: systematic review and meta-analysis. Am J Clin Nutr (2016) 103:495–504.10.3945/ajcn.115.107896

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 263

  HarrisCMKellDB. The estimation of microbial biomass. Biosensors (1985) 1:17–84.10.1016/0265-928X(85)85005-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 264

  KaprelyantsASKellDB. Do bacteria need to communicate with each other for growth?Trends Microbiol (1996) 4:237–42.10.1016/0966-842X(96)10035-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 265

  DomingueGJ. Electron dense cytoplasmic particles and chronic infection – a bacterial pleomorphy hypothesis. Endocytobiosis Cell Res (1995) 11:19–40.

  • Google Scholar

• 266

  DomingueGJSr. Cryptic bacterial infection in chronic prostatitis: diagnostic and therapeutic implications. Curr Opin Urol (1998) 8:45–9.10.1097/00042307-199801000-00009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 267

  MattmanL. Cell Wall Deficient Forms: Stealth Pathogens. 3rd ed. Boca Raton: CRC Press (2001).

  • Google Scholar

• 268

  DomingueGJ. Demystifying pleomorphic forms in persistence and expression of disease: are they bacteria, and is peptidoglycan the solution?Discov Med (2010) 10:234–46.

  • Pubmed Abstract
  • Google Scholar

• 269

  DaveyHMKellDB. Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analysis. Microbiol Rev (1996) 60:641–96.

  • Google Scholar

• 270

  KaprelyantsASKellDB. Rapid assessment of bacterial viability and vitality using rhodamine 123 and flow cytometry. J Appl Bacteriol (1992) 72:410–22.10.1111/j.1365-2672.1992.tb01854.x

  • CrossRef
  • Google Scholar

• 271

  GantVAWarnesGPhillipsISavidgeGF. The application of flow cytometry to the study of bacterial responses to antibiotics. J Med Microbiol (1993) 39:147–54.10.1099/00222615-39-2-147

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 272

  MasonDJShanmuganathanSMortimerFCGantVA. A fluorescent Gram stain for flow cytometry and epifluorescence microscopy. Appl Environ Microbiol (1998) 64:2681–5.

  • Pubmed Abstract
  • Google Scholar

• 273

  Nebe-Von-CaronGStephensPJHewittCJPowellJRBadleyRA. Analysis of bacterial function by multi-colour fluorescence flow cytometry and single cell sorting. J Microbiol Methods (2000) 42:97–114.10.1016/S0167-7012(00)00181-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 274

  ShapiroHMNebe-Von-CaronG. Multiparameter flow cytometry of bacteria. Methods Mol Biol (2004) 263:33–44.10.1385/1-59259-773-4:033

  • CrossRef
  • Google Scholar

• 275

  MüllerSNebe-Von-CaronG. Functional single-cell analyses: flow cytometry and cell sorting of microbial populations and communities. FEMS Microbiol Rev (2010) 34:554–87.10.1111/j.1574-6976.2010.00214.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 276

  DaveyHM. Life, death, and in-between: meanings and methods in microbiology. Appl Environ Microbiol (2011) 77:5571–6.10.1128/AEM.00744-11

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 277

  DaveyHMHexleyP. Red but not dead? Membranes of stressed Saccharomyces cerevisiae are permeable to propidium iodide. Environ Microbiol (2011) 13:163–71.10.1111/j.1462-2920.2010.02317.x

  • CrossRef
  • Google Scholar

• 278

  KellDBMarkxGHDaveyCLToddRW. Real-time monitoring of cellular biomass: methods and applications. Trends Anal Chem (1990) 9:190–4.10.1016/0165-9936(90)87042-K

  • CrossRef
  • Google Scholar

• 279

  KellDBSonnleitnerB. GMP – good modelling practice: an essential component of good manufacturing practice. Trends Biotechnol (1995) 13:481–92.10.1016/S0167-7799(00)89006-X

  • CrossRef
  • Google Scholar

• 280

  Firstenberg-EdenREdenG. Impedance Microbiology. Letchworth: Research Studies Press (1984).

  • Google Scholar

• 281

  HarrisCMToddRWBungardSJLovittRWMorrisJGKellDB. The dielectric permittivity of microbial suspensions at radio frequencies: a novel method for the estimation of microbial biomass. Enzyme Microbiol Technol (1987) 9:181–6.10.1016/0141-0229(87)90075-5

  • CrossRef
  • Google Scholar

• 282

  KellDBDaveyCL. Conductimetric and impedimetric devices. In: CassAEG, editor. Biosensors: A Practical Approach. Oxford: IRL Press (1990). p. 125–54.

  • Google Scholar

• 283

  WoeseCRFoxGE. Phylogenetic structure of the prokaryotic domain: the primary kingdoms. Proc Natl Acad Sci U S A (1977) 74:5088–90.10.1073/pnas.74.11.5088

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 284

  PettiCA. Detection and identification of microorganisms by gene amplification and sequencing. Clin Infect Dis (2007) 44:1108–14.10.1086/512818

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 285

  KloucheMSchröderU. Rapid methods for diagnosis of bloodstream infections. Clin Chem Lab Med (2008) 46:888–908.10.1515/CCLM.2008.157

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 286

  WooPCYLauSKPTengJLLTseHYuenKY. Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories. Clin Microbiol Infect (2008) 14:908–34.10.1111/j.1469-0691.2008.02070.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 287

  CherkaouiAEmonetSCeroniDCandolfiBHibbsJFrancoisPet alDevelopment and validation of a modified broad-range 16S rDNA PCR for diagnostic purposes in clinical microbiology. J Microbiol Methods (2009) 79:227–31.10.1016/j.mimet.2009.09.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 288

  CaporasoJGLauberCLWaltersWABerg-LyonsDLozuponeCATurnbaughPJet alGlobal patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci U S A (2011) 108(Suppl 1):4516–22.10.1073/pnas.1000080107

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 289

  KramskiMGaegutaAJLichtfussGFRajasuriarRCroweSMFrenchMAet alNovel sensitive real-time PCR for quantification of bacterial 16S rRNA genes in plasma of HIV-infected patients as a marker for microbial translocation. J Clin Microbiol (2011) 49:3691–3.10.1128/JCM.01018-11

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 290

  KämpferP. Systematics of prokaryotes: the state of the art. Antonie Van Leeuwenhoek (2012) 101:3–11.10.1007/s10482-011-9660-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 291

  OhlinABäckmanAEwaldUSchollinJBjörkqvistM. Diagnosis of neonatal sepsis by broad-range 16S real-time polymerase chain reaction. Neonatology (2012) 101:241–6.10.1159/000334655

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 292

  LangilleMGIZaneveldJCaporasoJGMcDonaldDKnightsDReyesJAet alPredictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol (2013) 31:814–21.10.1038/nbt.2676

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 293

  Mizrahi-ManODavenportERGiladY. Taxonomic classification of bacterial 16S rRNA genes using short sequencing reads: evaluation of effective study designs. PLoS One (2013) 8:e53608.10.1371/journal.pone.0053608

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 294

  Valencia-SheltonFLoeffelholzM. Nonculture techniques for the detection of bacteremia and fungemia. Future Microbiol (2014) 9:543–59.10.2217/fmb.14.8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 295

  YarzaPYilmazPPruesseEGlöcknerFOLudwigWSchleiferKHet alUniting the classification of cultured and uncultured bacteria and archaea using 16S rRNA gene sequences. Nat Rev Microbiol (2014) 12:635–45.10.1038/nrmicro3330

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 296

  ZumlaAAl-TawfiqJAEnneVIKiddMDrostenCBreuerJet alRapid point of care diagnostic tests for viral and bacterial respiratory tract infections – needs, advances, and future prospects. Lancet Infect Dis (2014) 14:1123–35.10.1016/S1473-3099(14)70827-8

  • CrossRef
  • Google Scholar

• 297

  D’AmoreRIjazUZSchirmerMKennyJGGregoryRDarbyACet alA comprehensive benchmarking study of protocols and sequencing platforms for 16S rRNA community profiling. BMC Genomics (2016) 17:55.10.1186/s12864-015-2194-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 298

  VersalovicJCarrollKCFunkeGJorgensenJHLandryMLWarnockDW. Manual of Clinical Microbiology. 10th ed. Washington: American Society of Microbiology (2011).

  • Google Scholar

• 299

  NikkariSMcLaughlinIJBiWDodgeDERelmanDA. Does blood of healthy subjects contain bacterial ribosomal DNA?J Clin Microbiol (2001) 39:1956–9.10.1128/JCM.39.5.1956-1959.2001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 300

  McLaughlinRWValiHLauPCPalfreeRGEDe CiccioASiroisMet alAre there naturally occurring pleomorphic bacteria in the blood of healthy humans?J Clin Microbiol (2002) 40:4771–5.10.1128/JCM.40.12.4771-4775.2002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 301

  MoriyamaKAndoCTashiroKKuharaSOkamuraSNakanoSet alPolymerase chain reaction detection of bacterial 16S rRNA gene in human blood. Microbiol Immunol (2008) 52:375–82.10.1111/j.1348-0421.2008.00048.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 302

  AmarJSerinoMLangeCChaboCIacovoniJMondotSet alInvolvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia (2011) 54:3055–61.10.1007/s00125-011-2329-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 303

  GaibaniPMaricontiMBuaGBonoraSSasseraDLandiniMPet alDevelopment of a broad-range 23S rDNA real-time PCR assay for the detection and quantification of pathogenic bacteria in human whole blood and plasma specimens. Biomed Res Int (2013) 2013:264651.10.1155/2013/264651

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 304

  DinakaranVRathinavelAPushpanathanMSivakumarRGunasekaranPRajendhranJ. Elevated levels of circulating DNA in cardiovascular disease patients: metagenomic profiling of microbiome in the circulation. PLoS One (2014) 9:e105221.10.1371/journal.pone.0105221

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 305

  SatoJKanazawaAIkedaFYoshiharaTGotoHAbeHet alGut dysbiosis and detection of “live gut bacteria” in blood of Japanese patients with type 2 diabetes. Diabetes Care (2014) 37:2343–50.10.2337/dc13-2817

  • CrossRef
  • Google Scholar

• 306

  DamgaardCMagnussenKEnevoldCNilssonMTolker-NielsenTHolmstrupPet alViable bacteria associated with red blood cells and plasma in freshly drawn blood donations. PLoS One (2015) 10:e0120826.10.1371/journal.pone.0120826

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 307

  GyarmatiPKjellanderCAustCKalinMÖhrmalmLGiskeCG. Bacterial landscape of bloodstream infections in neutropenic patients via high throughput sequencing. PLoS One (2015) 10:e0135756.10.1371/journal.pone.0135756

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 308

  GyarmatiPKjellanderCAustCSongYÖhrmalmLGiskeCG. Metagenomic analysis of bloodstream infections in patients with acute leukemia and therapy-induced neutropenia. Sci Rep (2016) 6:23532.10.1038/srep23532

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 309

  PaïsséSValleCServantFCourtneyMBurcelinRAmarJet alComprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing. Transfusion (2016) 56:1138–47.10.1111/trf.13477

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 310

  DomingueGJSchlegelJU. Novel bacterial structures in human blood: cultural isolation. Infect Immun (1977) 15:621–7.

  • Pubmed Abstract
  • Google Scholar

• 311

  BelstrømDHolmstrupPDamgaardCBorchTSSkjødtMOBendtzenKet alThe atherogenic bacterium Porphyromonas gingivalis evades circulating phagocytes by adhering to erythrocytes. Infect Immun (2011) 79:1559–65.10.1128/IAI.01036-10

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 312

  BillingsF. Focal Infection. New York: Appleton (1915).

  • Google Scholar

• 313

  PriceWA. Dental Infections Oral and Systemic, Being a Contribution to the Pathology of Dental Infections, Focal Infections and the Degenerative Diseases, Parts I and II. Cleveland: Penton Press (1923).

  • Google Scholar

• 314

  MiklossyJKisARadenovicAMillerLForroLMartinsRet alBeta-amyloid deposition and Alzheimer’s type changes induced by Borrelia spirochetes. Neurobiol Aging (2006) 27:228–36.10.1016/j.neurobiolaging.2005.01.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 315

  MiklossyJ. Chronic inflammation and amyloidogenesis in Alzheimer’s disease – role of spirochetes. J Alzheimers Dis (2008) 13:381–91.

  • Pubmed Abstract
  • Google Scholar

• 316

  WoolardMDFrelingerJA. Outsmarting the host: bacteria modulating the immune response. Immunol Res (2008) 41:188–202.10.1007/s12026-008-8021-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 317

  NicolsonGLHaierJ. Role of chronic bacterial and viral infections in neurodegenerative, neurobehavioural, psychiatric, autoimmune and fatiguing illnesses: part 1. Br J Med Pract (2009) 2:20–8.

  • Google Scholar

• 318

  ProalADAlbertPJMarshallT. Autoimmune disease in the era of the metagenome. Autoimmun Rev (2009) 8:677–81.10.1016/j.autrev.2009.02.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 319

  NicolsonGLHaierJ. Role of chronic bacterial and viral infections in neurodegenerative, neurobehavioural, psychiatric, autoimmune and fatiguing illnesses: part 2. Br J Med Pract (2010) 3:301–10.

  • Google Scholar

• 320

  MiklossyJ. Alzheimer’s disease – a neurospirochetosis. Analysis of the evidence following Koch’s and Hill’s criteria. J Neuroinflammation (2011) 8:90.10.1186/1742-2094-8-90

  • CrossRef
  • Google Scholar

• 321

  ProalADAlbertPJBlaneyGPLindsethIABenediktssonCMarshallTG. Immunostimulation in the era of the metagenome. Cell Mol Immunol (2011) 8:213–25.10.1038/cmi.2010.77

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 322

  BrecherMEHaySN. Bacterial contamination of blood components. Clin Microbiol Rev (2005) 18:195–204.10.1128/CMR.18.1.195-204.2005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 323

  HalliwellBGutteridgeJMC. Free Radicals in Biology and Medicine. 4th ed. Oxford: Oxford University Press (2006).

  • Google Scholar

• 324

  KaeberleinTLewisKEpsteinSS. Isolating “uncultivable” microorganisms in pure culture in a simulated natural environment. Science (2002) 296:1127–9.10.1126/science.1070633

  • CrossRef
  • Google Scholar

• 325

  BollmannALewisKEpsteinSS. Incubation of environmental samples in a diffusion chamber increases the diversity of recovered isolates. Appl Environ Microbiol (2007) 73:6386–90.10.1128/AEM.01309-07

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 326

  D’OnofrioACrawfordJMStewartEJWittKGavrishEEpsteinSet alSiderophores from neighboring organisms promote the growth of uncultured bacteria. Chem Biol (2010) 17:254–64.10.1016/j.chembiol.2010.02.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 327

  LewisKEpsteinSD’OnofrioALingLL. Uncultured microorganisms as a source of secondary metabolites. J Antibiot (Tokyo) (2010) 63:468–76.10.1038/ja.2010.87

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 328

  LingLLSchneiderTPeoplesAJSpoeringALEngelsIConlonBPet alA new antibiotic kills pathogens without detectable resistance. Nature (2015) 517:455–9.10.1038/nature14098

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 329

  DeschnerJEickSDamanakiANokhbehsaimM. The role of adipokines in periodontal infection and healing. Mol Oral Microbiol (2014) 29:258–69.10.1111/omi.12070

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 330

  HerreraJAChaudhuriGLópez-JaramilloP. Is infection a major risk factor for preeclampsia?Med Hypotheses (2001) 57:393–7.10.1054/mehy.2001.1378

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 331

  López-JaramilloPCasasJPSerranoN. Preeclampsia: from epidemiological observations to molecular mechanisms. Braz J Med Biol Res (2001) 34:1227–35.10.1590/S0100-879X2001001000001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 332

  Von DadelszenPMageeLA. Could an infectious trigger explain the differential maternal response to the shared placental pathology of preeclampsia and normotensive intrauterine growth restriction?Acta Obstet Gynecol Scand (2002) 81:642–8.10.1034/j.1600-0412.2002.810710.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 333

  MarshallB. Helicobacter pylori: 20 years on. Clin Med (2002) 2:147–52.10.1007/s102380200021

  • CrossRef
  • Google Scholar

• 334

  SuzukiHMarshallBJHibiT. Overview: Helicobacter pylori and extragastric disease. Int J Hematol (2006) 84:291–300.10.1532/IJH97.06180

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 335

  PrelipceanCCMihaiCGogalniceanuPMitricaDDrugVLStanciuC. Extragastric manifestations of Helicobacter pylori infection. Rev Med Chir Soc Med Nat Iasi (2007) 111:575–83.

  • Pubmed Abstract
  • Google Scholar

• 336

  PellicanoRFranceschiFSaraccoGFagooneeSRoccarinaDGasbarriniA. Helicobacters and extragastric diseases. Helicobacter (2009) 14(Suppl 1):58–68.10.1111/j.1523-5378.2009.00699.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 337

  FiguraNFranceschiFSantucciABernardiniGGasbarriniGGasbarriniA. Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2010) 15(Suppl 1):60–8.10.1111/j.1523-5378.2010.00778.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 338

  BanićMFranceschiFBabićZGasbarriniA. Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2012) 17(Suppl 1):49–55.10.1111/j.1523-5378.2012.00983.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 339

  Roubaud BaudronCFranceschiFSallesNGasbarriniA. Extragastric diseases and Helicobacter pylori. Helicobacter (2013) 18(Suppl 1):44–51.10.1111/hel.12077

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 340

  FranceschiFTortoraAGasbarriniGGasbarriniA. Helicobacter pylori and extragastric diseases. Helicobacter (2014) 19(Suppl 1):52–8.10.1111/hel.12159

  • CrossRef
  • Google Scholar

• 341

  FranceschiFZuccalaGRoccarinaDGasbarriniA. Clinical effects of Helicobacter pylori outside the stomach. Nat Rev Gastroenterol Hepatol (2014) 11:234–42.10.1038/nrgastro.2013.243

  • CrossRef
  • Google Scholar

• 342

  TestermanTLMorrisJ. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol (2014) 20:12781–808.10.3748/wjg.v20.i36.12781

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 343

  PonzettoACardaropoliSPiccoliERolfoAGenneroLKanducDet alPre-eclampsia is associated with Helicobacter pylori seropositivity in Italy. J Hypertens (2006) 24:2445–9.10.1097/HJH.0b013e3280109e8c

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 344

  FranceschiFDi SimoneND’IppolitoSCastellaniRDi NicuoloFGasbarriniGet alAntibodies anti-CagA cross-react with trophoblast cells: a risk factor for pre-eclampsia?Helicobacter (2012) 17:426–34.10.1111/j.1523-5378.2012.00966.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 345

  ShimodaAUedaKNishiumiSMurata-KamiyaNMukaiSASawadaSet alExosomes as nanocarriers for systemic delivery of the Helicobacter pylori virulence factor CagA. Sci Rep (2016) 6:18346.10.1038/srep18346

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 346

  RaghupathyR. Cytokines as key players in the pathophysiology of preeclampsia. Med Princ Pract (2013) 22:8–19.10.1159/000354200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 347

  WurdingerTGatsonNNBalajLKaurBBreakefieldXOPegtelDM. Extracellular vesicles and their convergence with viral pathways. Adv Virol (2012) 2012:767694.10.1155/2012/767694

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 348

  van DongenHMMasoumiNWitwerKWPegtelDM. Extracellular vesicles exploit viral entry routes for cargo delivery. Microbiol Mol Biol Rev (2016) 80:369–86.10.1128/MMBR.00063-15

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 349

  XieFHuYMageeLAMoneyDMPatrickDMBrunhamRMet alChlamydia pneumoniae infection in preeclampsia. Hypertens Pregnancy (2010) 29:468–77.10.3109/10641950903242642

  • CrossRef
  • Google Scholar

• 350

  HeineRPNessRBRobertsJM. Seroprevalence of antibodies to Chlamydia pneumoniae in women with preeclampsia. Obstet Gynecol (2003) 101:221–6.10.1016/S0029-7844(02)02591-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 351

  El-ShourbagyMAAEl-RefaieTASayedKKAWahbaKAHEl-DinASSFathyMM. Impact of seroconversion and antichlamydial treatment on the rate of pre-eclampsia among Egyptian primigravidae. Int J Gynaecol Obstet (2011) 113:137–40.10.1016/j.ijgo.2010.11.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 352

  HaggertyCLKlebanoffMAPanumIUldumSABassDCOlsenJet alPrenatal Chlamydia trachomatis infection increases the risk of preeclampsia. Pregnancy Hypertens (2013) 3:151–4.10.1016/j.preghy.2013.03.002

  • CrossRef
  • Google Scholar

• 353

  HaggertyCLPanumIUldumSABassDCOlsenJDarvilleTet alChlamydia trachomatis infection may increase the risk of preeclampsia. Pregnancy Hypertens (2013) 3:28–33.10.1016/j.preghy.2012.09.002

  • CrossRef
  • Google Scholar

• 354

  XieFHuYMageeLAMoneyDMPatrickDMKrajdenMet alAn association between cytomegalovirus infection and pre-eclampsia: a case-control study and data synthesis. Acta Obstet Gynecol Scand (2010) 89:1162–7.10.3109/00016349.2010.499449

  • CrossRef
  • Google Scholar

• 355

  XieFVon DadelszenPNadeauJ. CMV infection, TLR-2 and -4 expression, and cytokine profiles in early-onset preeclampsia with HELLP syndrome. Am J Reprod Immunol (2014) 71:379–86.10.1111/aji.12199

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 356

  PanarelliMSattarN. Pre-eclampsia associated with Helicobacter pylori seropositivity. J Hypertens (2006) 24:2353–4.10.1097/HJH.0b013e3280113638

  • CrossRef
  • Google Scholar

• 357

  MosbahANabielY. Helicobacter pylori, Chlamydiae pneumoniae and trachomatis as probable etiological agents of preeclampsia. J Matern Fetal Neonatal Med (2016) 29:1607–12.10.3109/14767058.2015.1056146

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 358

  TersigniCFranceschiFTodrosTCardaropoliSScambiaGDi SimoneN. Insights into the role of Helicobacter pylori infection in preeclampsia: from the bench to the bedside. Front Immunol (2014) 5:484.10.3389/fimmu.2014.00484

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 359

  ÜstünYEngin-ÜstünYOzkaplanEOtluBSait TekerekoğluM. Association of Helicobacter pylori infection with systemic inflammation in preeclampsia. J Matern Fetal Neonatal Med (2010) 23:311–4.10.3109/14767050903121456

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 360

  AksoyHOzkanAAktasFBorekciB. Helicobacter pylori seropositivity and its relationship with serum malondialdehyde and lipid profile in preeclampsia. J Clin Lab Anal (2009) 23:219–22.10.1002/jcla.20330

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 361

  CardaropoliSRolfoATodrosT. Helicobacter pylori and pregnancy-related disorders. World J Gastroenterol (2014) 20:654–64.10.3748/wjg.v20.i3.654

  • CrossRef
  • Google Scholar

• 362

  PuglieseABeltramoTTodrosTCardaropoliSPonzettoA. Interleukin-18 and gestosis: correlation with Helicobacter pylori seropositivity. Cell Biochem Funct (2008) 26:817–9.10.1002/cbf.1503

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 363

  CardaropoliSGiuffridaDPiazzeseATodrosT. Helicobacter pylori seropositivity and pregnancy-related diseases: a prospective cohort study. J Reprod Immunol (2015) 109:41–7.10.1016/j.jri.2015.02.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 364

  CardaropoliSRolfoAPiazzeseAPonzettoATodrosT. Helicobacter pylori’s virulence and infection persistence define pre-eclampsia complicated by fetal growth retardation. World J Gastroenterol (2011) 17:5156–65.10.3748/wjg.v17.i47.5156

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 365

  McDonnoldMDunnHHesterAPachecoLDHankinsGDSaadeGRet alHigh risk human papillomavirus at entry to prenatal care and risk of preeclampsia. Am J Obstet Gynecol (2014) 210(138):138.e1–5.10.1016/j.ajog.2013.09.040

  • CrossRef
  • Google Scholar

• 366

  HillJADevoeLDBryansCIJr. Frequency of asymptomatic bacteriuria in preeclampsia. Obstet Gynecol (1986) 67:529–32.

  • Pubmed Abstract
  • Google Scholar

• 367

  HsuCDWitterFR. Urogenital infection in preeclampsia. Int J Gynaecol Obstet (1995) 49:271–5.10.1016/0020-7292(95)02373-K

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 368

  MittendorfRLainKYWilliamsMAWalkerCK. Preeclampsia. A nested, case-control study of risk factors and their interactions. J Reprod Med (1996) 41:491–6.

  • Pubmed Abstract
  • Google Scholar

• 369

  EasterSRCantonwineDEZeraCALimKHParrySIMcelrathTF. Urinary tract infection during pregnancy, angiogenic factor profiles, and risk of preeclampsia. Am J Obstet Gynecol (2016) 214:387.e1–7.10.1016/j.ajog.2015.09.101

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 370

  Mazor-DrayELevyASchlaefferFSheinerE. Maternal urinary tract infection: is it independently associated with adverse pregnancy outcome?J Matern Fetal Neonatal Med (2009) 22:124–8.10.1080/14767050802488246

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 371

  MinassianCThomasSLWilliamsDJCampbellOSmeethL. Acute maternal infection and risk of pre-eclampsia: a population-based case-control study. PLoS One (2013) 8:e73047.10.1371/journal.pone.0073047

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 372

  RezavandNVeisiFZanganeMAminiRAlmasiA. Association between asymptomatic bacteriuria and pre-eclampsia. Glob J Health Sci (2016) 8:235–9.10.5539/gjhs.v8n7p235

  • CrossRef
  • Google Scholar

• 373

  KarmonASheinerE. The relationship between urinary tract infection during pregnancy and preeclampsia: causal, confounded or spurious?Arch Gynecol Obstet (2008) 277:479–81.10.1007/s00404-008-0643-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 374

  VillarJCarroliGWojdylaDAbalosEGiordanoDBa’aqeelHet alPreeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?Am J Obstet Gynecol (2006) 194:921–31.10.1016/j.ajog.2005.10.813

  • CrossRef
  • Google Scholar

• 375

  BánhidyFÁcsNPuhóEHCzeizelAE. Pregnancy complications and birth outcomes of pregnant women with urinary tract infections and related drug treatments. Scand J Infect Dis (2007) 39:390–7.10.1080/00365540601087566

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 376

  López-JaramilloPHerreraJAArenas-MantillaMJaureguiIEMendozaMA. Subclinical infection as a cause of inflammation in preeclampsia. Am J Ther (2008) 15:373–6.10.1097/MJT.0b013e318164c149

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 377

  IdeMPapapanouPN. Epidemiology of association between maternal periodontal disease and adverse pregnancy outcomes – systematic review. J Periodontol (2013) 84:S181–94.10.1902/jop.2013.134009

  • CrossRef
  • Google Scholar

• 378

  DunlopALMulleJGFerrantiEPEdwardsSDunnABCorwinEJ. Maternal microbiome and pregnancy outcomes that impact infant health: a review. Adv Neonatal Care (2015) 15:377–85.10.1097/ANC.0000000000000218

  • CrossRef
  • Google Scholar

• 379

  HlimiT. Association of anemia, pre-eclampsia and eclampsia with seasonality: a realist systematic review. Health Place (2015) 31:180–92.10.1016/j.healthplace.2014.12.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 380

  BrabinBJJohnsonPM. Placental malaria and pre-eclampsia through the looking glass backwards?J Reprod Immunol (2005) 65:1–15.10.1016/j.jri.2004.09.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 381

  AnyaSE. Seasonal variation in the risk and causes of maternal death in the Gambia: malaria appears to be an important factor. Am J Trop Med Hyg (2004) 70:510–3.

  • Pubmed Abstract
  • Google Scholar

• 382

  SarteletHRogierCMilko-SarteletIAngelGMichelG. Malaria associated pre-eclampsia in Senegal. Lancet (1996) 347:1121.10.1016/S0140-6736(96)90321-9

  • CrossRef
  • Google Scholar

• 383

  RomeroRMazorMWuYKSirtoriMOyarzunEMitchellMDet alInfection in the pathogenesis of preterm labor. Semin Perinatol (1988) 12:262–79.

  • Google Scholar

• 384

  TothMWitkinSSLedgerWThalerH. The role of infection in the etiology of preterm birth. Obstet Gynecol (1988) 71:723–6.

  • Pubmed Abstract
  • Google Scholar

• 385

  CassellGHWaitesKBWatsonHLCrouseDTHarasawaR. Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newborns. Clin Microbiol Rev (1993) 6:69–87.10.1128/CMR.6.1.69

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 386

  McGregorJAFrenchJIJonesWMilliganKMckinneyPJPattersonEet alBacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol (1994) 170:1048–59; discussion 1059–60.10.1016/S0002-9378(94)70098-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 387

  GoldenbergRLHauthJCAndrewsWW. Intrauterine infection and preterm delivery. N Engl J Med (2000) 342:1500–7.10.1056/NEJM200005183422007

  • CrossRef
  • Google Scholar

• 388

  GonçalvesLFChaiworapongsaTRomeroR. Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev (2002) 8:3–13.10.1002/mrdd.10008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 389

  GerberSVialYHohlfeldPWitkinSS. Detection of Ureaplasma urealyticum in second-trimester amniotic fluid by polymerase chain reaction correlates with subsequent preterm labor and delivery. J Infect Dis (2003) 187:518–21.10.1086/368205

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 390

  GardellaCRileyDEHittiJAgnewKKriegerJNEschenbachD. Identification and sequencing of bacterial rDNAs in culture-negative amniotic fluid from women in premature labor. Am J Perinatol (2004) 21:319–23.10.1055/s-2004-831884

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 391

  EspinozaJErezORomeroR. Preconceptional antibiotic treatment to prevent preterm birth in women with a previous preterm delivery. Am J Obstet Gynecol (2006) 194:630–7.10.1016/j.ajog.2005.11.050

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 392

  GoldenbergRLCulhaneJFIamsJDRomeroR. Epidemiology and causes of preterm birth. Lancet (2008) 371:75–84.10.1016/S0140-6736(08)60074-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 393

  CheckJH. A practical approach to the prevention of miscarriage. Part 4 – role of infection. Clin Exp Obstet Gynecol (2010) 37:252–5.

  • Pubmed Abstract
  • Google Scholar

• 394

  BastekJAGómezLMElovitzMA. The role of inflammation and infection in preterm birth. Clin Perinatol (2011) 38:385–406.10.1016/j.clp.2011.06.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 395

  JohnsonHLGhanemKGZenilmanJMErbeldingEJ. Sexually transmitted infections and adverse pregnancy outcomes among women attending inner city public sexually transmitted diseases clinics. Sex Transm Dis (2011) 38:167–71.10.1097/OLQ.0b013e3181f2e85f

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 396

  RoursGIJGDuijtsLMollHAArendsLRDe GrootRJaddoeVWet alChlamydia trachomatis infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. Eur J Epidemiol (2011) 26:493–502.10.1007/s10654-011-9586-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 397

  JeffersonKK. The bacterial etiology of preterm birth. Adv Appl Microbiol (2012) 80:1–22.10.1016/B978-0-12-394381-1.00001-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 398

  LeeSYRLeungCW. Histological chorioamnionitis – implication for bacterial colonization, laboratory markers of infection, and early onset sepsis in very-low-birth-weight neonates. J Matern Fetal Neonatal Med (2012) 25:364–8.10.3109/14767058.2011.579208

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 399

  SubramaniamAAbramoviciAAndrewsWWTitaAT. Antimicrobials for preterm birth prevention: an overview. Infect Dis Obstet Gynecol (2012) 2012:157159.10.1155/2012/157159

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 400

  AagaardKMaJAntonyKMGanuRPetrosinoJVersalovicJ. The placenta harbors a unique microbiome. Sci Transl Med (2014) 6:237ra265.10.1126/scitranslmed.3008599

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 401

  JoergensenJSKjaer WeileLKLamontRF. The early use of appropriate prophylactic antibiotics in susceptible women for the prevention of preterm birth of infectious etiology. Expert Opin Pharmacother (2014) 15:2173–91.10.1517/14656566.2014.950225

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 402

  Allen-DanielsMJSerranoMGPflugnerLPFettweisJMPrestosaMAKopardeVNet alIdentification of a gene in Mycoplasma hominis associated with preterm birth and microbial burden in intraamniotic infection. Am J Obstet Gynecol (2015) 212:779.e1–13.10.1016/j.ajog.2015.01.032

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 403

  de Andrade RamosBKanninenTTSistiGWitkinSS. Microorganisms in the female genital tract during pregnancy: tolerance versus pathogenesis. Am J Reprod Immunol (2015) 73:383–9.10.1111/aji.12326

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 404

  KacerovskyMVrbackyFKutovaRPliskovaLAndrysCMusilovaIet alCervical microbiota in women with preterm prelabor rupture of membranes. PLoS One (2015) 10:e0126884.10.1371/journal.pone.0126884

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 405

  LamontRF. Advances in the prevention of infection-related preterm birth. Front Immunol (2015) 6:566.10.3389/fimmu.2015.00566

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 406

  UenoTNiimiHYonedaNYonedaSMoriMTabataHet alEukaryote-made thermostable DNA polymerase enables rapid PCR-based detection of mycoplasma, ureaplasma and other bacteria in the amniotic fluid of preterm labor cases. PLoS One (2015) 10:e0129032.10.1371/journal.pone.0129032

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 407

  FreyHAKlebanoffMA. The epidemiology, etiology, and costs of preterm birth. Semin Fetal Neonatal Med (2016) 21:68–73.10.1016/j.siny.2015.12.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 408

  NadeauHCGSubramaniamAAndrewsWW. Infection and preterm birth. Semin Fetal Neonatal Med (2016) 21:100–5.10.1016/j.siny.2015.12.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 409

  VinturacheAEGyamfi-BannermanCHwangJMysorekarIUJacobssonBPreterm Birth International Collaborative (Prebic). Maternal microbiome – a pathway to preterm birth. Semin Fetal Neonatal Med (2016) 21:94–9.10.1016/j.siny.2016.02.004

  • CrossRef
  • Google Scholar

• 410

  YonedaSShiozakiAYonedaNItoMShimaTFukudaKet alAntibiotic therapy increases the risk of preterm birth in preterm labor without intra-amniotic microbes, but may prolong the gestation period in preterm labor with microbes, evaluated by rapid and high-sensitive PCR system. Am J Reprod Immunol (2016) 75:440–50.10.1111/aji.12484

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 411

  OliverRSLamontRF. Infection and antibiotics in the aetiology, prediction and prevention of preterm birth. J Obstet Gynaecol (2013) 33:768–75.10.3109/01443615.2013.842963

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 412

  KacerovskyMLencoJMusilovaITamborVLamontRTorloniMRet alProteomic biomarkers for spontaneous preterm birth: a systematic review of the literature. Reprod Sci (2014) 21:283–95.10.1177/1933719113503415

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 413

  McClureEMGoldenbergRL. Infection and stillbirth. Semin Fetal Neonatal Med (2009) 14:182–9.10.1016/j.siny.2009.02.003

  • CrossRef
  • Google Scholar

• 414

  MenezesEVYakoobMYSoomroTHawsRADarmstadtGLBhuttaZA. Reducing stillbirths: prevention and management of medical disorders and infections during pregnancy. BMC Pregnancy Childbirth (2009) 9(Suppl 1):S4.10.1186/1471-2393-9-S1-S4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 415

  NigroGMazzoccoMMattiaEDi RenzoGCCartaGAnceschiMM. Role of the infections in recurrent spontaneous abortion. J Matern Fetal Neonatal Med (2011) 24:983–9.10.3109/14767058.2010.547963

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 416

  GiakoumelouSWheelhouseNCuschieriKEntricanGHowieSEMHorneAW. The role of infection in miscarriage. Hum Reprod Update (2015) 22:116–33.10.1093/humupd/dmv041

  • CrossRef
  • Google Scholar

• 417

  TothALesserMLBrooks-TothCWFeinerC. Outcome of subsequent pregnancies following antibiotic therapy after primary or multiple spontaneous abortions. Surg Gynecol Obstet (1986) 163:243–50.

  • Google Scholar

• 418

  LauderAPRocheAMSherrill-MixSBaileyALaughlinALBittingerKet alComparison of placenta samples with contamination controls does not provide evidence for a distinct placenta microbiota. Microbiome (2016) 4:29.10.1186/s40168-016-0172-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 419

  OnderdonkABDelaneyMLDuboisAMAllredENLevitonAExtremely Low Gestational Age Newborns Study Investigators. Detection of bacteria in placental tissues obtained from extremely low gestational age neonates. Am J Obstet Gynecol (2008) 198(110):e111–7.10.1016/j.ajog.2007.05.044

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 420

  SatokariRGronroosTLaitinenKSalminenSIsolauriE. Bifidobacterium and Lactobacillus DNA in the human placenta. Lett Appl Microbiol (2009) 48:8–12.10.1111/j.1472-765X.2008.02475.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 421

  StoutMJConlonBLandeauMLeeIBowerCZhaoQet alIdentification of intracellular bacteria in the basal plate of the human placenta in term and preterm gestations. Am J Obstet Gynecol (2013) 208(226):e221–7.10.1016/j.ajog.2013.01.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 422

  CaoBMysorekarIU. Intracellular bacteria in placental basal plate localize to extravillous trophoblasts. Placenta (2014) 35:139–42.10.1016/j.placenta.2013.12.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 423

  CaoBStoutMJLeeIMysorekarIU. Placental microbiome and its role in preterm birth. Neoreviews (2014) 15:e537–45.10.1542/neo.15-12-e537

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 424

  DoyleRMAlberDGJonesHEHarrisKFitzgeraldFPeeblesDet alTerm and preterm labour are associated with distinct microbial community structures in placental membranes which are independent of mode of delivery. Placenta (2014) 35:1099–101.10.1016/j.placenta.2014.10.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 425

  MysorekarIUCaoB. Microbiome in parturition and preterm birth. Semin Reprod Med (2014) 32:50–5.10.1055/s-0033-1361830

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 426

  AbrahamssonTRWuRYJenmalmMC. Gut microbiota and allergy: the importance of the pregnancy period. Pediatr Res (2015) 77:214–9.10.1038/pr.2014.165

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 427

  AntonyKMMaJMitchellKBRacusinDAVersalovicJAagaardK. The preterm placental microbiome varies in association with excess maternal gestational weight gain. Am J Obstet Gynecol (2015) 212: 653.e651–616.10.1016/j.ajog.2014.12.041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 428

  GarmiGOkopnikMKenessYZafranNBerkowitzESalimR. Correlation between clinical, placental histology and microbiological findings in spontaneous preterm births. Fetal Diagn Ther (2015) 40:141–9.10.1159/000441518

  • CrossRef
  • Google Scholar

• 429

  ZhengJXiaoXZhangQMaoLYuMXuJ. The placental microbiome varies in association with low birth weight in full-term neonates. Nutrients (2015) 7:6924–37.10.3390/nu7085315

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 430

  ColladoMCRautavaSAakkoJIsolauriESalminenS. Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid. Sci Rep (2016) 6:23129.10.1038/srep23129

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 431

  KupermanAAKorenO. Antibiotic use during pregnancy: how bad is it?BMC Med (2016) 14:91.10.1186/s12916-016-0636-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 432

  PrinceALMaJKannanPSAlvarezMGisslenTHarrisRAet alThe placental microbiome is altered among subjects with spontaneous preterm birth with and without chorioamnionitis. Am J Obstet Gynecol (2016) 214:627.e1–16.10.1016/j.ajog.2016.01.193

  • CrossRef
  • Google Scholar

• 433

  VinikerDA. Hypothesis on the role of sub-clinical bacteria of the endometrium (bacteria endometrialis) in gynaecological and obstetric enigmas. Hum Reprod Update (1999) 5:373–85.10.1093/humupd/5.4.373

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 434

  SvareJASchmidtHHansenBBLoseG. Bacterial vaginosis in a cohort of Danish pregnant women: prevalence and relationship with preterm delivery, low birthweight and perinatal infections. BJOG (2006) 113:1419–25.10.1111/j.1471-0528.2006.01087.x

  • CrossRef
  • Google Scholar

• 435

  SheldonIMBromfieldJJ. Innate immunity in the human endometrium and ovary. Am J Reprod Immunol (2011) 66(Suppl 1):63–71.10.1111/j.1600-0897.2011.01034.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 436

  AagaardKRiehleKMaJSegataNMistrettaTACoarfaCet alA metagenomic approach to characterization of the vaginal microbiome signature in pregnancy. PLoS One (2012) 7:e36466.10.1371/journal.pone.0036466

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 437

  Walther-AntónioMRJeraldoPBerg MillerMEYeomanCJNelsonKEWilsonBAet alPregnancy’s stronghold on the vaginal microbiome. PLoS One (2014) 9:e98514.10.1371/journal.pone.0098514

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 438

  HuangYEWangYHeYJiYWangLPShengHFet alHomogeneity of the vaginal microbiome at the cervix, posterior fornix, and vaginal canal in pregnant Chinese women. Microb Ecol (2015) 69:407–14.10.1007/s00248-014-0487-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 439

  WitkinSS. The vaginal microbiome, vaginal anti-microbial defence mechanisms and the clinical challenge of reducing infection-related preterm birth. BJOG (2015):213–8.10.1111/1471-0528.13115

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 440

  NelsonDBRockwellLCPrioleauMDGoetzlL. The role of the bacterial microbiota on reproductive and pregnancy health. Anaerobe (2016) 42:67–73.10.1016/j.anaerobe.2016.09.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 441

  PayneMSBayatibojakhiS. Exploring preterm birth as a polymicrobial disease: an overview of the uterine microbiome. Front Immunol (2014) 5:595.10.3389/fimmu.2014.00595

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 442

  VerstraelenHVilchez-VargasRDesimpelFJaureguiRVankeirsbilckNWeyersSet alCharacterisation of the human uterine microbiome in non-pregnant women through deep sequencing of the V1-2 region of the 16S rRNA gene. PeerJ (2016) 4:e1602.10.7717/peerj.1602

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 443

  DongYSt ClairPJRamzyIKagan-HalletKSGibbsRS. A microbiologic and clinical study of placental inflammation at term. Obstet Gynecol (1987) 70:175–82.

  • Pubmed Abstract
  • Google Scholar

• 444

  BearfieldCDavenportESSivapathasundaramVAllakerRP. Possible association between amniotic fluid micro-organism infection and microflora in the mouth. BJOG (2002) 109:527–33.10.1111/j.1471-0528.2002.01349.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 445

  CombsCAGravettMGariteTJHickokDELapidusJPorrecoRet alAmniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. Am J Obstet Gynecol (2014) 210:125.e1–15.10.1016/j.ajog.2013.11.032

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 446

  WassenaarTMPanigrahiP. Is a foetus developing in a sterile environment?Lett Appl Microbiol (2014) 59:572–9.10.1111/lam.12334

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 447

  CombsCAGariteTJLapidusJALapointeJPGravettMRaelJet alDetection of microbial invasion of the amniotic cavity by analysis of cervicovaginal proteins in women with preterm labor and intact membranes. Am J Obstet Gynecol (2015) 212:482.e481–e412.10.1016/j.ajog.2015.02.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 448

  KolevaPTKimJSScottJAKozyrskyjAL. Microbial programming of health and disease starts during fetal life. Birth Defects Res C Embryo Today (2015) 105:265–77.10.1002/bdrc.21117

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 449

  PelzerESAllanJACunninghamKMengersenKAllanJMLaunchburyTet alMicrobial colonization of follicular fluid: alterations in cytokine expression and adverse assisted reproduction technology outcomes. Hum Reprod (2011) 26:1799–812.10.1093/humrep/der108

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 450

  PelzerESAllanJAWaterhouseMARossTBeagleyKWKnoxCL. Microorganisms within human follicular fluid: effects on IVF. PLoS One (2013) 8:e59062.10.1371/journal.pone.0059062

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 451

  BarakSOettinger-BarakOMachteiEESprecherHOhelG. Evidence of periopathogenic microorganisms in placentas of women with preeclampsia. J Periodontol (2007) 78:670–6.10.1902/jop.2007.060362

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 452

  McDonaghSMaidjiEMaWChangHTFisherSPereiraL. Viral and bacterial pathogens at the maternal-fetal interface. J Infect Dis (2004) 190:826–34.10.1086/422330

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 453

  AmarasekaraRJayasekaraRWSenanayakeHDissanayakeVH. Microbiome of the placenta in pre-eclampsia supports the role of bacteria in the multifactorial cause of pre-eclampsia. J Obstet Gynaecol Res (2015) 41:662–9.10.1111/jog.12619

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 454

  MuehlenbachsAMutabingwaTKEdmondsSFriedMDuffyPE. Hypertension and maternal-fetal conflict during placental malaria. PLoS Med (2006) 3:e446.10.1371/journal.pmed.0030446

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 455

  DuffyPE. Plasmodium in the placenta: parasites, parity, protection, prevention and possibly preeclampsia. Parasitology (2007) 134:1877–81.10.1017/S0031182007000170

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 456

  VanterpoolSFBeenJVHoubenMLNikkelsPGDe KrijgerRRZimmermannLJet alPorphyromonas gingivalis within placental villous mesenchyme and umbilical cord stroma is associated with adverse pregnancy outcome. PLoS One (2016) 11:e0146157.10.1371/journal.pone.0146157

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 457

  ChaparroABlanlotCRamirezVSanzAQuinteroAInostrozaCet alPorphyromonas gingivalis, Treponema denticola and toll-like receptor 2 are associated with hypertensive disorders in placental tissue: a case-control study. J Periodontal Res (2013) 48:802–9.10.1111/jre.12074

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 458

  EbringerARashidTWilsonC. Rheumatoid arthritis, proteus, anti-CCP antibodies and Karl Popper. Autoimmun Rev (2010) 9:216–23.10.1016/j.autrev.2009.10.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 459

  EbringerA. Rheumatoid Arthritis and Proteus. London: Springer (2012).

  • Google Scholar

• 460

  EbringerARashidT. Rheumatoid arthritis is caused by a Proteus urinary tract infection. APMIS (2014) 122:363–8.10.1111/apm.12154

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 461

  VatanenTKosticADD’HennezelESiljanderHFranzosaEAYassourMet alVariation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell (2016) 165:842–53.10.1016/j.cell.2016.04.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 462

  FerrierLMazelinLCenacNDesreumauxPJaninAEmilieDet alStress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice. Gastroenterology (2003) 125:795–804.10.1016/S0016-5085(03)01057-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 463

  HondaKLittmanDR. The microbiome in infectious disease and inflammation. Annu Rev Immunol (2012) 30:759–95.10.1146/annurev-immunol-020711-074937

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 464

  KlattNRFunderburgNTBrenchleyJM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol (2013) 21:6–13.10.1016/j.tim.2012.09.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 465

  AmarJBurcelinRRuidavetsJBCaniPDFauvelJAlessiMCet alEnergy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr (2008) 87:1219–23.

  • Pubmed Abstract
  • Google Scholar

• 466

  LasseniusMIPietiläinenKHKaartinenKPussinenPJSyrjänenJForsblomCet alBacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care (2011) 34:1809–15.10.2337/dc10-2197

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 467

  VorsCPineauGDraiJMeugnierEPesentiSLavilleMet alPostprandial endotoxemia linked with chylomicrons and lipopolysaccharides handling in obese versus lean men: a lipid dose-effect trial. J Clin Endocrinol Metab (2015) 100:3427–35.10.1210/JC.2015-2518

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 468

  SawchuckDJWittmannBK. Pre-eclampsia renamed and reframed: intra-abdominal hypertension in pregnancy. Med Hypotheses (2014) 83:619–32.10.1016/j.mehy.2014.08.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 469

  PerezPFDoreJLeclercMLevenezFBenyacoubJSerrantPet alBacterial imprinting of the neonatal immune system: lessons from maternal cells?Pediatrics (2007) 119:e724–32.10.1542/peds.2006-1649

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 470

  GensollenTIyerSSKasperDLBlumbergRS. How colonization by microbiota in early life shapes the immune system. Science (2016) 352:539–44.10.1126/science.aad9378

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 471

  NewnhamJPNewnhamIABallCMWrightMPennellCESwainJet alTreatment of periodontal disease during pregnancy: a randomized controlled trial. Obstet Gynecol (2009) 114:1239–48.10.1097/AOG.0b013e3181c15b40

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 472

  HuangXWangJLiuJHuaLZhangDHuTet alMaternal periodontal disease and risk of preeclampsia: a meta-analysis. J Huazhong Univ Sci Technolog Med Sci (2014) 34:729–35.10.1007/s11596-014-1343-8

  • CrossRef
  • Google Scholar

• 473

  GilbertGLGarlandSMFairleyKFMcdowallDM. Bacteriuria due to ureaplasmas and other fastidious organisms during pregnancy: prevalence and significance. Pediatr Infect Dis (1986) 5:S239–43.10.1097/00006454-198611010-00007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 474

  HaJEJunJKKoHJPaikDIBaeKH. Association between periodontitis and preeclampsia in never-smokers: a prospective study. J Clin Periodontol (2014) 41:869–74.10.1111/jcpe.12281

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 475

  SgolastraFPetrucciASeverinoMGattoRMonacoA. Relationship between periodontitis and pre-eclampsia: a meta-analysis. PLoS One (2013) 8:e71387.10.1371/journal.pone.0071387

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 476

  BoggessKAEdelsteinBL. Oral health in women during preconception and pregnancy: implications for birth outcomes and infant oral health. Matern Child Health J (2006) 10:S169–74.10.1007/s10995-006-0095-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 477

  BoggessKABerggrenEKKoskenojaVUrlaubDLorenzC. Severe preeclampsia and maternal self-report of oral health, hygiene, and dental care. J Periodontol (2013) 84:143–51.10.1902/jop.2012.120079

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 478

  ArmitageGC. Bi-directional relationship between pregnancy and periodontal disease. Periodontol 2000 (2013) 61:160–76.10.1111/j.1600-0757.2011.00396.x

  • CrossRef
  • Google Scholar

• 479

  Moura da SilvaGCoutinhoSBPiscoyaMDBVXimenesRAAJamelliSR. Periodontitis as a risk factor for preeclampsia. J Periodontol (2012) 83:1388–96.10.1902/jop.2012.110256

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 480

  JahromiBNAdibiRAdibiSSalarianL. Periodontal disease as a risk factor for preeclampsia. Womens Health Bull (2014) 1:e18908.10.17795/whb-18908

  • CrossRef
  • Google Scholar

• 481

  LachatMFSolnikALNanaADCitronTL. Periodontal disease in pregnancy: review of the evidence and prevention strategies. J Perinat Neonatal Nurs (2011) 25:312–9.10.1097/JPN.0b013e31821072e4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 482

  PolitanoGTPassiniRNomuraMLVellosoLMorariJCoutoE. Correlation between periodontal disease, inflammatory alterations and pre-eclampsia. J Periodontal Res (2011) 46:505–11.10.1111/j.1600-0765.2011.01368.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 483

  NabetCLelongNColombierMLSixouMMussetAMGoffinetFet alMaternal periodontitis and the causes of preterm birth: the case-control Epipap study. J Clin Periodontol (2010) 37:37–45.10.1111/j.1600-051X.2009.01503.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 484

  MadianosPNBobetsisYAOffenbacherS. Adverse pregnancy outcomes (APOs) and periodontal disease: pathogenic mechanisms. J Periodontol (2013) 84:S170–80.10.1902/jop.2013.1340015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 485

  BobetsisYABarrosSPOffenbacherS. Exploring the relationship between periodontal disease and pregnancy complications. J Am Dent Assoc (2006) 137(Suppl):7S–13S.10.14219/jada.archive.2006.0403

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 486

  HerreraJAParraBHerreraEBoteroJEArceRMContrerasAet alPeriodontal disease severity is related to high levels of C-reactive protein in pre-eclampsia. J Hypertens (2007) 25:1459–64.10.1097/HJH.0b013e3281139ea9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 487

  RumaMBoggessKMossKJaredHMurthaABeckJet alMaternal periodontal disease, systemic inflammation, and risk for preeclampsia. Am J Obstet Gynecol (2008) 198:389.e1–5.10.1016/j.ajog.2007.12.002

  • CrossRef
  • Google Scholar

• 488

  PralhadSThomasBKushtagiP. Periodontal disease and pregnancy hypertension: a clinical correlation. J Periodontol (2013) 84:1118–25.10.1902/jop.2012.120264

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 489

  ZiMYLongoPLBueno-SilvaBMayerMP. Mechanisms involved in the association between periodontitis and complications in pregnancy. Front Public Health (2014) 2:290.10.3389/fpubh.2014.00290

  • CrossRef
  • Google Scholar

• 490

  SwatiPThomasBVahabSAKapaettuSKushtagiP. Simultaneous detection of periodontal pathogens in subgingival plaque and placenta of women with hypertension in pregnancy. Arch Gynecol Obstet (2012) 285:613–9.10.1007/s00404-011-2012-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 491

  ShubASwainJRNewnhamJP. Periodontal disease and adverse pregnancy outcomes. J Matern Fetal Neonatal Med (2006) 19:521–8.10.1080/14767050600797749

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 492

  XiongXBuekensPFraserWDBeckJOffenbacherS. Periodontal disease and adverse pregnancy outcomes: a systematic review. BJOG (2006) 113:135–43.10.1111/j.1471-0528.2005.00827.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 493

  HaJEOhKJYangHJJunJKJinBHPaikDIet alOral health behaviors, periodontal disease, and pathogens in preeclampsia: a case-control study in Korea. J Periodontol (2011) 82:1685–92.10.1902/jop.2011.110035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 494

  Komine-AizawaSHirohataNAizawaSAbikoYHayakawaS. Porphyromonas gingivalis lipopolysaccharide inhibits trophoblast invasion in the presence of nicotine. Placenta (2015) 36:27–33.10.1016/j.placenta.2014.10.015

  • CrossRef
  • Google Scholar

• 495

  ContrerasAHerreraJASotoJEArceRMJaramilloABoteroJE. Periodontitis is associated with preeclampsia in pregnant women. J Periodontol (2006) 77:182–8.10.1902/jop.2006.050020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 496

  Oettinger-BarakOBarakSOhelGOettingerMKreutzerHPeledMet alSevere pregnancy complication (preeclampsia) is associated with greater periodontal destruction. J Periodontol (2005) 76:134–7.10.1902/jop.2005.76.1.134

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 497

  FoxmanB. Recurring urinary tract infection: incidence and risk factors. Am J Public Health (1990) 80:331–3.10.2105/AJPH.80.3.331

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 498

  FoxmanB. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med (2002) 113(Suppl 1A):5S–13S.10.1016/S0002-9343(02)01054-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 499

  MarrsCFZhangLFoxmanB. Escherichia coli mediated urinary tract infections: are there distinct uropathogenic E. coli (UPEC) pathotypes?FEMS Microbiol Lett (2005) 252:183–90.10.1016/j.femsle.2005.08.028

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 500

  HannanTJMysorekarIUHungCSIsaacson-SchmidMLHultgrenSJ. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog (2010) 6:e1001042.10.1371/journal.ppat.1001042

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 501

  HunstadDAJusticeSS. Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli. Annu Rev Microbiol (2010) 64:203–21.10.1146/annurev.micro.112408.134258

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 502

  EjrnaesK. Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli. Dan Med Bull (2011) 58:B4187.

  • Pubmed Abstract
  • Google Scholar

• 503

  HannanTJTotsikaMMansfieldKJMooreKHSchembriMAHultgrenSJ. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev (2012) 36:616–48.10.1111/j.1574-6976.2012.00339.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 504

  FoxmanB. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am (2014) 28:1–13.10.1016/j.idc.2013.09.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 505

  JusticeSSHungCTheriotJAFletcherDAAndersonGGFooterMJet alDifferentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci U S A (2004) 101:1333–8.10.1073/pnas.0308125100

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 506

  BowerJMEtoDSMulveyMA. Covert operations of uropathogenic Escherichia coli within the urinary tract. Traffic (2005) 6:18–31.10.1111/j.1600-0854.2004.00251.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 507

  RosenDAHootonTMStammWEHumphreyPAHultgrenSJ. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med (2007) 4:e329.10.1371/journal.pmed.0040329

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 508

  DhakalBKKulesusRRMulveyMA. Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli. Eur J Clin Invest (2008) 38(Suppl 2):2–11.10.1111/j.1365-2362.2008.01986.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 509

  SchwartzDJChenSLHultgrenSJSeedPC. Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection. Infect Immun (2011) 79:4250–9.10.1128/IAI.05339-11

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 510

  BraunerAJacobsonSHKuhnI. Urinary Escherichia coli causing recurrent infections – a prospective follow-up of biochemical phenotypes. Clin Nephrol (1992) 38:318–23.

  • Google Scholar

• 511

  RussoTAStapletonAWenderothSHootonTMStammWE. Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women. J Infect Dis (1995) 172:440–5.10.1093/infdis/172.2.440

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 512

  IkäheimoRSiitonenAHeiskanenTKärkkäinenUKuosmanenPLipponenPet alRecurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis (1996) 22:91–9.10.1093/clinids/22.1.91

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 513

  RosenDAPinknerJSJonesJMWalkerJNCleggSHultgrenSJ. Utilization of an intracellular bacterial community pathway in Klebsiella pneumoniae urinary tract infection and the effects of FimK on type 1 pilus expression. Infect Immun (2008) 76:3337–45.10.1128/IAI.00090-08

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 514

  LuoYMaYZhaoQWangLGuoLYeLet alSimilarity and divergence of phylogenies, antimicrobial susceptibilities, and virulence factor profiles of Escherichia coli isolates causing recurrent urinary tract infections that persist or result from reinfection. J Clin Microbiol (2012) 50:4002–7.10.1128/JCM.02086-12

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 515

  ÖzlüTAlçelikAÇalışkanBDönmezME. Preeclampsia: is it because of the asymptomatic, unrecognized renal scars caused by urinary tract infections in childhood that become symptomatic with pregnancy?Med Hypotheses (2012) 79:653–5.10.1016/j.mehy.2012.08.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 516

  Kincaid-SmithPBullenM. Bacteriuria in pregnancy. Lancet (1965) 1:395–9.10.1016/S0140-6736(65)90001-2

  • CrossRef
  • Google Scholar

• 517

  LohKSivalingamN. Urinary tract infections in pregnancy. Malays Fam Physician (2007) 2:54–7.

  • Pubmed Abstract
  • Google Scholar

• 518

  MacejkoAMSchaefferAJ. Asymptomatic bacteriuria and symptomatic urinary tract infections during pregnancy. Urol Clin North Am (2007) 34:35–42.10.1016/j.ucl.2006.10.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 519

  SchnarrJSmaillF. Asymptomatic bacteriuria and symptomatic urinary tract infections in pregnancy. Eur J Clin Invest (2008) 38(Suppl 2):50–7.10.1111/j.1365-2362.2008.02009.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 520

  ImadePEIzekorPEEghafonaNOEnabuleleOIOphoriE. Asymptomatic bacteriuria among pregnant women. N Am J Med Sci (2010) 2:263–6.10.4297/najms.2010.2263

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 521

  GilbertNMO’BrienVPHultgrenSMaconesGLewisWGLewisAL. Urinary tract infection as a preventable cause of pregnancy complications: opportunities, challenges, and a global call to action. Glob Adv Health Med (2013) 2:59–69.10.7453/gahmj.2013.061

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 522

  GlaserAPSchaefferAJ. Urinary tract infection and bacteriuria in pregnancy. Urol Clin North Am (2015) 42:547–60.10.1016/j.ucl.2015.05.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 523

  GermainSJSacksGPSoorannaSRSargentILRedmanCWG. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol (2007) 178:5949–56.10.4049/jimmunol.178.9.5949

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 524

  RedmanCWGSargentIL. Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta (2008) 29(Suppl A):S73–7.10.1016/j.placenta.2007.11.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 525

  HahnSRusterholzCHösliILapaireO. Cell-free nucleic acids as potential markers for preeclampsia. Placenta (2011) 32(Suppl):S17–20.10.1016/j.placenta.2010.06.018

  • CrossRef
  • Google Scholar

• 526

  RusterholzCMesserliMHoesliIHahnS. Placental microparticles, DNA, and RNA in preeclampsia. Hypertens Pregnancy (2011) 30:364–75.10.3109/10641951003599571

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 527

  RedmanCWGTannettaDSDragovicRAGardinerCSouthcombeJHCollettGPet alReview: does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta (2012) 33(Suppl):S48–54.10.1016/j.placenta.2011.12.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 528

  GoulopoulouSDavidgeST. Molecular mechanisms of maternal vascular dysfunction in preeclampsia. Trends Mol Med (2015) 21:88–97.10.1016/j.molmed.2014.11.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 529

  NiccolaiEEmmiGSquatritoDSilvestriEEmmiLAmedeiAet alMicroparticles: bridging the gap between autoimmunity and thrombosis. Semin Thromb Hemost (2015) 41:413–22.10.1055/s-0035-1549850

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 530

  SouzaACPYuenPSTStarRA. Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI. Kidney Int (2015) 87:1100–8.10.1038/ki.2015.26

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 531

  MitchellMDPeirisHNKobayashiMKohYQDuncombeGIllanesSEet alPlacental exosomes in normal and complicated pregnancy. Am J Obstet Gynecol (2015) 213:S173–81.10.1016/j.ajog.2015.07.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 532

  de JongeLBosHJVan LangenIMDe Jong-Van Den BergLTWBakkerMK. Antibiotics prescribed before, during and after pregnancy in the Netherlands: a drug utilization study. Pharmacoepidemiol Drug Saf (2014) 23:60–8.10.1002/pds.3492

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 533

  BookstaverPBBlandCMGriffinBStoverKREilandLSMcLaughlinM. A review of antibiotic use in pregnancy. Pharmacotherapy (2015) 35:1052–62.10.1002/phar.1649

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 534

  PalmstenKHernández-DíazSChambersCDMogunHLaiSGilmerTPet alThe most commonly dispensed prescription medications among pregnant women enrolled in the U.S. Medicaid program. Obstet Gynecol (2015) 126:465–73.10.1097/AOG.0000000000000982

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 535

  MawsonAR. Effects of antiretroviral therapy on occurrence of pre-eclampsia. Lancet (2003) 361:347–8.10.1016/S0140-6736(03)12359-8

  • CrossRef
  • Google Scholar

• 536

  SuyAMartínezECollOLoncaMPalacioMDe LazzariEet alIncreased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS (2006) 20:59–66.10.1097/01.aids.0000198090.70325.bd

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 537

  WimalasunderaRCLarbalestierNSmithJHDe RuiterAMcGTSAHughesADet alPre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet (2002) 360:1152–4.10.1016/S0140-6736(02)11195-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 538

  HallDR. Is pre-eclampsia less common in patients with HIV/AIDS?J Reprod Immunol (2007) 76:75–7.10.1016/j.jri.2007.04.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 539

  AdamsJWWattsDHPhelpsBR. A systematic review of the effect of HIV infection and antiretroviral therapy on the risk of pre-eclampsia. Int J Gynaecol Obstet (2016) 133:17–21.10.1016/j.ijgo.2015.08.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 540

  TodrosTVerdiglionePOggèGPaladiniDVerganiPCardaropoliS. Low incidence of hypertensive disorders of pregnancy in women treated with spiramycin for Toxoplasma infection. Br J Clin Pharmacol (2006) 61:336–40.10.1111/j.1365-2125.2005.02572.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 541

  Alvarado-EsquivelCVázquez-AlanízFSandoval-CarrilloAASalas-PachecoJMHernández-TinocoJSanchez-AnguianoLFet alLack of association between Toxoplasma gondii infection and hypertensive disorders in pregnancy: a case-control study in a Northern Mexican population. Parasit Vectors (2014) 7:167.10.1186/1756-3305-7-167

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 542

  HallDGebhardtSTheronGGrovéD. Pre-eclampsia and gestational hypertension are less common in HIV infected women. Pregnancy Hypertens (2014) 4:91–6.10.1016/j.preghy.2013.11.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 543

  McCarthyFPKingdomJCKennyLCWalshSK. Animal models of preeclampsia; uses and limitations. Placenta (2011) 32:413–9.10.1016/j.placenta.2011.03.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 544

  AubuchonMSchulzLCSchustDJ. Preeclampsia: animal models for a human cure. Proc Natl Acad Sci U S A (2011) 108:1197–8.10.1073/pnas.1018164108

  • CrossRef
  • Google Scholar

• 545

  KumasawaKIkawaMKidoyaHHasuwaHSaito-FujitaTMoriokaYet alPravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A (2011) 108:1451–5.10.1073/pnas.1011293108

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 546

  FaasMMSchuilingGABallerJFVisscherCABakkerWW. A new animal model for human preeclampsia: ultra-low-dose endotoxin infusion in pregnant rats. Am J Obstet Gynecol (1994) 171:158–64.10.1016/0002-9378(94)90463-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 547

  FaasMMSchuilingGALintonEASargentILRedmanCWG. Activation of peripheral leukocytes in rat pregnancy and experimental preeclampsia. Am J Obstet Gynecol (2000) 182:351–7.10.1016/S0002-9378(00)70223-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 548

  SakawiYTarpeyMChenYFCalhounDAConnorMGChestnutDHet alEvaluation of low-dose endotoxin administration during pregnancy as a model of preeclampsia. Anesthesiology (2000) 93:1446–55.10.1097/00000542-200012000-00017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 549

  LinFZengPXuZYYeDYYuXFWangNet alTreatment of lipoxin A₄ and its analogue on low-dose endotoxin induced preeclampsia in rat and possible mechanisms. Reprod Toxicol (2012) 34:677–85.10.1016/j.reprotox.2012.09.009

  • CrossRef
  • Google Scholar

• 550

  CotechiniTKomisarenkoMSperouAMacDonald-GoodfellowSAdamsMAGrahamCH. Inflammation in rat pregnancy inhibits spiral artery remodeling leading to fetal growth restriction and features of preeclampsia. J Exp Med (2014) 211:165–79.10.1084/jem.20130295

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 551

  XuePPZhengMMGongPLinCMZhouJJLiYJet alSingle administration of ultra-low-dose lipopolysaccharide in rat early pregnancy induces TLR4 activation in the placenta contributing to preeclampsia. PLoS One (2015) 10:e0124001.10.1371/journal.pone.0124001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 552

  KalkunteSBoijRNorrisWFriedmanJLaiZKurtisJet alSera from preeclampsia patients elicit symptoms of human disease in mice and provide a basis for an in vitro predictive assay. Am J Pathol (2010) 177:2387–98.10.2353/ajpath.2010.100475

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 553

  NymarkMPussinenPJTuomainenAMForsblomCGroopPHLehtoMet alSerum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes. Diabetes Care (2009) 32:1689–93.10.2337/dc09-0467

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 554

  Al-AttasOSAl-DaghriNMAl-RubeaanKDa SilvaNFSabicoSLKumarSet alChanges in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc Diabetol (2009) 8:20.10.1186/1475-2840-8-20

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 555

  HawkesworthSMooreSEFulfordAJCBarclayGRDarboeAAMarkHet alEvidence for metabolic endotoxemia in obese and diabetic Gambian women. Nutr Diabetes (2013) 3:e83.10.1038/nutd.2013.24

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 556

  ZamanGSZamanF. Relationship between postprandial endotoxemia in nonobese postmenopausal women and diabetic nonobese postmenopausal women. J Nat Sci Biol Med (2015) 6:89–93.10.4103/0976-9668.149098

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 557

  RusterholzCHahnSHolzgreveW. Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia. Semin Immunopathol (2007) 29:151–62.10.1007/s00281-007-0071-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 558

  XieFTurveySEWilliamsMAMorGVon DadelszenP. Toll-like receptor signaling and pre-eclampsia. Am J Reprod Immunol (2010) 63:7–16.10.1111/j.1600-0897.2009.00745.x

  • CrossRef
  • Google Scholar

• 559

  AntonLBrownAGParrySElovitzMA. Lipopolysaccharide induces cytokine production and decreases extravillous trophoblast invasion through a mitogen-activated protein kinase-mediated pathway: possible mechanisms of first trimester placental dysfunction. Hum Reprod (2012) 27:61–72.10.1093/humrep/der362

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 560

  AhnHParkJGilman-SachsAKwak-KimJ. Immunologic characteristics of preeclampsia, a comprehensive review. Am J Reprod Immunol (2011) 65:377–94.10.1111/j.1600-0897.2010.00913.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 561

  PinedaAVerdin-TeránSLCamachoAMoreno-FierrosL. Expression of toll-like receptor TLR-2, TLR-3, TLR-4 and TLR-9 is increased in placentas from patients with preeclampsia. Arch Med Res (2011) 42:382–91.10.1016/j.arcmed.2011.08.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 562

  ChatterjeePWeaverLEDoerschKMKoprivaSEChiassonVLAllenSJet alPlacental toll-like receptor 3 and toll-like receptor 7/8 activation contributes to preeclampsia in humans and mice. PLoS One (2012) 7:e41884.10.1371/journal.pone.0041884

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 563

  GalloPMRapsinskiGJWilsonRPOppongGOSriramUGoulianMet alAmyloid-DNA composites of bacterial biofilms stimulate autoimmunity. Immunity (2015) 42:1171–84.10.1016/j.immuni.2015.06.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 564

  RapsinskiGJWynosky-DolfiMAOppongGOTursiSAWilsonRPBrodskyIEet alToll-like receptor 2 and NLRP3 cooperate to recognize a functional bacterial amyloid, curli. Infect Immun (2015) 83:693–701.10.1128/IAI.02370-14

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 565

  SpauldingCNDodsonKWChapmanMRHultgrenSJ. Fueling the fire with fibers: bacterial amyloids promote inflammatory disorders. Cell Host Microbe (2015) 18:1–2.10.1016/j.chom.2015.06.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 566

  WucherpfennigKW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest (2001) 108:1097–104.10.1172/JCI14235

  • CrossRef
  • Google Scholar

• 567

  WucherpfennigKW. Structural basis of molecular mimicry. J Autoimmun (2001) 16:293–302.10.1006/jaut.2000.0499

  • CrossRef
  • Google Scholar

• 568

  KohmAPFullerKGMillerSD. Mimicking the way to autoimmunity: an evolving theory of sequence and structural homology. Trends Microbiol (2003) 11:101–5.10.1016/S0966-842X(03)00006-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 569

  MorrisJABroughtonSJWesselsQ. Microbes, molecular mimicry and molecules of mood and motivation. Med Hypotheses (2016) 87:40–3.10.1016/j.mehy.2015.12.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 570

  JainDKaurKJGoelMSalunkeDM. Structural basis of functional mimicry between carbohydrate and peptide ligands of con A. Biochem Biophys Res Commun (2000) 272:843–9.10.1006/bbrc.2000.2871

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 571

  GoelMKrishnanLKaurSKaurKJSalunkeDM. Plasticity within the antigen-combining site may manifest as molecular mimicry in the humoral immune response. J Immunol (2004) 173:7358–67.10.4049/jimmunol.173.12.7358

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 572

  UhANicholsonRCGonzalezGVSimmonsCFGombartASmithRet alLipopolysaccharide stimulation of trophoblasts induces corticotropin-releasing hormone expression through MyD88. Am J Obstet Gynecol (2008) 199(317):e311–6.10.1016/j.ajog.2008.06.091

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 573

  ChenQViallCKangYLiuBStonePChamleyL. Anti-phospholipid antibodies increase non-apoptotic trophoblast shedding: a contribution to the pathogenesis of pre-eclampsia in affected women?Placenta (2009) 30:767–73.10.1016/j.placenta.2009.06.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 574

  ChenQGuoFHensby-BennettSStonePChamleyL. Antiphospholipid antibodies prolong the activation of endothelial cells induced by necrotic trophoblastic debris: implications for the pathogenesis of preeclampsia. Placenta (2012) 33:810–5.10.1016/j.placenta.2012.07.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 575

  PanthamPRosarioRChenQPrintCGChamleyLW. Transcriptomic analysis of placenta affected by antiphospholipid antibodies: following the TRAIL of trophoblast death. J Reprod Immunol (2012) 94:151–4.10.1016/j.jri.2012.03.487

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 576

  TongMViallCAChamleyLW. Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment. Hum Reprod Update (2015) 21:97–118.10.1093/humupd/dmu049

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 577

  DechendRHomuthVWallukatGKreuzerJParkJKTheuerJet alAT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation (2000) 101:2382–7.10.1161/01.CIR.101.20.2382

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 578

  RobertsJM. Angiotensin-1 receptor autoantibodies: a role in the pathogenesis of preeclampsia?Circulation (2000) 101:2335–7.10.1161/01.CIR.101.20.2335

  • CrossRef
  • Google Scholar

• 579

  WallukatGNeichelDNissenEHomuthVLuftFC. Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia. Can J Physiol Pharmacol (2003) 81:79–83.10.1139/y02-160

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 580

  DechendRMullerDNWallukatGHomuthVKrauseMDudenhausenJet alAT1 receptor agonistic antibodies, hypertension, and preeclampsia. Semin Nephrol (2004) 24:571–9.10.1016/j.semnephrol.2004.07.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 581

  DechendRHomuthVWallukatGMullerDNKrauseMDudenhausenJet alAgonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia. J Soc Gynecol Investig (2006) 13:79–86.10.1016/j.jsgi.2005.11.006

  • CrossRef
  • Google Scholar

• 582

  HubelCAWallukatGWolfMHerseFRajakumarARobertsJMet alAgonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension (2007) 49:612–7.10.1161/01.HYP.0000256565.20983.d4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 583

  DechendRLuftFC. Are we getting closer to a nobel prize for unraveling preeclampsia?Curr Cardiol Rep (2008) 10:440–7.10.1007/s11886-008-0070-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 584

  HerseFStaffACHeringLMüllerDNLuftFCDechendR. AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia. J Mol Med (Berl) (2008) 86:697–703.10.1007/s00109-008-0332-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 585

  ZhouCCZhangYIraniRAZhangHMiTPopekEJet alAngiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med (2008) 14:855–62.10.1038/nm.1856

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 586

  LorquetSPequeuxCMunautCFoidartJM. Aetiology and physiopathology of preeclampsia and related forms. Acta Clin Belg (2010) 65:237–41.10.1179/acb.2010.051

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 587

  ParrishMRMurphySRRutlandSWallaceKWenzelKWallukatGet alThe effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens (2010) 23:911–6.10.1038/ajh.2010.70

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 588

  CarbillonL. AT1-receptor autoantibody: a true causal factor of pre-eclampsia or only a marker of poor placentation?Am J Hypertens (2011) 24:375; author reply 376.10.1038/ajh.2010.249

  • CrossRef
  • Google Scholar

• 589

  HerseFLaMarcaB. Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension. Am J Reprod Immunol (2013) 69:413–8.10.1111/aji.12072

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 590

  SiddiquiAHIraniRAZhangWWangWBlackwellSCKellemsREet alAngiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1 induction contributes to impaired adrenal vasculature and decreased aldosterone production in preeclampsia. Hypertension (2013) 61:472–9.10.1161/HYPERTENSIONAHA.111.00157

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 591

  PietarinenIKivinenSYlostaloPMakitaloRLaaksoL. Smooth muscle antibodies in pre-eclampsia of pregnancy. Gynecol Obstet Invest (1982) 13:142–9.10.1159/000299502

  • CrossRef
  • Google Scholar

• 592

  AlanenA. Serum IgE and smooth muscle antibodies in pre-eclampsia. Acta Obstet Gynecol Scand (1984) 63:581–2.10.3109/00016348409155540

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 593

  FliserDBuchholzKHallerHOlmesartanEUTOPravastatin InIAtherosclerosisI. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation (2004) 110:1103–7.10.1161/01.CIR.0000140265.21608.8E

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 594

  DagenaisNJJamaliF. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy (2005) 25:1213–29.10.1592/phco.2005.25.9.1213

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 595

  PlattenMYoussefSHurEMHoPPHanMHLanzTVet alBlocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A (2009) 106:14948–53.10.1073/pnas.0903958106

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 596

  MaGLiYZhangJLiuHHouDZhuLet alAssociation between the presence of autoantibodies against adrenoreceptors and severe pre-eclampsia: a pilot study. PLoS One (2013) 8:e57983.10.1371/journal.pone.0057983

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 597

  LiYMaGZhangZYueYYuanYWangYet alAssociation of autoantibodies against the M2-muscarinic receptor with perinatal outcomes in women with severe preeclampsia. J Transl Med (2013) 11:285.10.1186/1479-5876-11-285

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 598

  CorneliusDCLamarcaB. TH17- and IL-17-mediated autoantibodies and placental oxidative stress play a role in the pathophysiology of pre-eclampsia. Minerva Ginecol (2014) 66:243–9.

  • Pubmed Abstract
  • Google Scholar

• 599

  Darmochwał-KolarzDKludka-SternikMTabarkiewiczJKolarzBRolinskiJLeszczynska-GorzelakBet alThe predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia. J Reprod Immunol (2012) 93:75–81.10.1016/j.jri.2012.01.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 600

  WenzelKRajakumarAHaaseHGeusensNHubnerNSchulzHet alAngiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension (2011) 58:77–84.10.1161/HYPERTENSIONAHA.111.171348

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 601

  StepanHWallukatGSchultheissHPFaberRWaltherT. Is parvovirus B19 the cause for autoimmunity against the angiotensin II type receptor?J Reprod Immunol (2007) 73:130–4.10.1016/j.jri.2006.08.084

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 602

  IraniRAZhangYZhouCCBlackwellSCHicksMJRaminSMet alAutoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling. Hypertension (2010) 55:1246–53.10.1161/HYPERTENSIONAHA.110.150540

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 603

  IraniRAXiaY. Renin angiotensin signaling in normal pregnancy and preeclampsia. Semin Nephrol (2011) 31:47–58.10.1016/j.semnephrol.2010.10.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 604

  MistryHDKurlakLOBroughton PipkinF. The placental renin-angiotensin system and oxidative stress in pre-eclampsia. Placenta (2013) 34:182–6.10.1016/j.placenta.2012.11.027

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 605

  VerdonkKVisserWVan Den MeirackerAHDanserAH. The renin-angiotensin-aldosterone system in pre-eclampsia: the delicate balance between good and bad. Clin Sci (Lond) (2014) 126:537–44.10.1042/CS20130455

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 606

  DiveuCMcgeachyMJCuaDJ. Cytokines that regulate autoimmunity. Curr Opin Immunol (2008) 20:663–8.10.1016/j.coi.2008.09.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 607

  DongC. Regulation and pro-inflammatory function of interleukin-17 family cytokines. Immunol Rev (2008) 226:80–6.10.1111/j.1600-065X.2008.00709.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 608

  MiossecPKornTKuchrooVK. Interleukin-17 and type 17 helper T cells. N Engl J Med (2009) 361:888–98.10.1056/NEJMra0707449

  • CrossRef
  • Google Scholar

• 609

  MiossecPKollsJK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov (2012) 11:763–76.10.1038/nrd3794

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 610

  BenedettiGMiossecP. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur J Immunol (2014) 44:339–47.10.1002/eji.201344184

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 611

  AujlaSJDubinPJKollsJK. Th17 cells and mucosal host defense. Semin Immunol (2007) 19:377–82.10.1016/j.smim.2007.10.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 612

  IvanovIIZhouLLittmanDR. Transcriptional regulation of Th17 cell differentiation. Semin Immunol (2007) 19:409–17.10.1016/j.smim.2007.10.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 613

  StockingerBVeldhoenMMartinB. Th17 T cells: linking innate and adaptive immunity. Semin Immunol (2007) 19:353–61.10.1016/j.smim.2007.10.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 614

  AnnunziatoFCosmiLLiottaFMaggiERomagnaniS. The phenotype of human T_h17 cells and their precursors, the cytokines that mediate their differentiation and the role of T_h17 cells in inflammation. Int Immunol (2008) 20:1361–8.10.1093/intimm/dxn106

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 615

  OuyangWKollsJKZhengY. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity (2008) 28:454–67.10.1016/j.immuni.2008.03.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 616

  CurtisMMWaySS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology (2009) 126:177–85.10.1111/j.1365-2567.2008.03017.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 617

  EyerichKPenninoDScarponiCFoersterSNasorriFBehrendtHet alIL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol (2009) 123:59–66.e4.10.1016/j.jaci.2008.10.031

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 618

  KhaderSAGaffenSLKollsJK. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol (2009) 2:403–11.10.1038/mi.2009.100

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 619

  CypowyjSPicardCMarodiLCasanovaJLPuelA. Immunity to infection in IL-17-deficient mice and humans. Eur J Immunol (2012) 42:2246–54.10.1002/eji.201242605

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 620

  RubinoSJGeddesKGirardinSE. Innate IL-17 and IL-22 responses to enteric bacterial pathogens. Trends Immunol (2012) 33:112–8.10.1016/j.it.2012.01.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 621

  WeberAZimmermannCKieseierBCHartungHPHofstetterHH. Bacteria and their cell wall components uniformly co-activate interleukin-17-producing thymocytes. Clin Exp Immunol (2014) 178:504–15.10.1111/cei.12414

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 622

  BeringerANoackMMiossecP. IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med (2016) 22:230–41.10.1016/j.molmed.2016.01.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 623

  KumarPMoninLCastilloPElsegeinyWHorneWEddensTet alIntestinal interleukin-17 receptor signaling mediates reciprocal control of the gut microbiota and autoimmune inflammation. Immunity (2016) 44:659–71.10.1016/j.immuni.2016.02.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 624

  SaitoSNakashimaAItoMShimaT. Clinical implication of recent advances in our understanding of IL-17 and reproductive immunology. Expert Rev Clin Immunol (2011) 7:649–57.10.1586/eci.11.49

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 625

  FuBTianZWeiH. TH17 cells in human recurrent pregnancy loss and pre-eclampsia. Cell Mol Immunol (2014) 11:564–70.10.1038/cmi.2014.54

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 626

  OzkanZSSimsekMIlhanFDeveciDGodekmerdanASapmazE. Plasma IL-17, IL-35, interferon-gamma, SOCS3 and TGF-beta levels in pregnant women with preeclampsia, and their relation with severity of disease. J Matern Fetal Neonatal Med (2014) 27:1513–7.10.3109/14767058.2013.861415

  • CrossRef
  • Google Scholar

• 627

  Santner-NananBPeekMJKhanamRRichartsLZhuEFazekas De St GrothBet alSystemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J Immunol (2009) 183:7023–30.10.4049/jimmunol.0901154

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 628

  JianjunZYaliHZhiqunWMingmingZXiaZ. Imbalance of T-cell transcription factors contributes to the Th1 type immunity predominant in pre-eclampsia. Am J Reprod Immunol (2010) 63:38–45.10.1111/j.1600-0897.2009.00763.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 629

  SaitoS. Th17 cells and regulatory T cells: new light on pathophysiology of preeclampsia. Immunol Cell Biol (2010) 88:615–7.10.1038/icb.2010.68

  • CrossRef
  • Google Scholar

• 630

  ToldiGRigóJStenczerBVásárhelyiBMolvarecA. Increased prevalence of IL-17-producing peripheral blood lymphocytes in pre-eclampsia. Am J Reprod Immunol (2011) 66:223–9.10.1111/j.1600-0897.2011.00987.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 631

  CorneliusDCHoggJPScottJWallaceKHerseFMoseleyJet alAdministration of interleukin-17 soluble receptor C suppresses TH17 cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy. Hypertension (2013) 62:1068–73.10.1161/HYPERTENSIONAHA.113.01514

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 632

  Laresgoiti-ServitjeE. A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol (2013) 94:247–57.10.1189/jlb.1112603

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 633

  Perez-SepulvedaATorresMJKhouryMIllanesSE. Innate immune system and preeclampsia. Front Immunol (2014) 5:244.10.3389/fimmu.2014.00244

  • CrossRef
  • Google Scholar

• 634

  CaoWWangXChenTZhuHXuWZhaoSet alThe expression of notch/notch ligand, IL-35, IL-17, and Th17/Treg in preeclampsia. Dis Markers (2015) 2015:316182.10.1155/2015/316182

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 635

  MolvarecACzegleISzijártóJRigóJ. Increased circulating interleukin-17 levels in preeclampsia. J Reprod Immunol (2015) 112:53–7.10.1016/j.jri.2015.05.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 636

  WangHGuoMLiuFWangJZhouZJiJet alRole of IL-17 variants in preeclampsia in Chinese Han women. PLoS One (2015) 10:e0140118.10.1371/journal.pone.0140118

  • CrossRef
  • Google Scholar

• 637

  Vargas-RojasMISolleiro-VillavicencioHSoto-VegaE. Th1, Th2, Th17 and Treg levels in umbilical cord blood in preeclampsia. J Matern Fetal Neonatal Med (2016) 29:1642–5.10.3109/14767058.2015.1057811

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 638

  Darmochwał-KolarzDOleszczukJ. The critical role of Th17 cells, T_reg cells and co-stimulatory molecules in the development of pre-eclampsia. Dev Period Med (2014) 18:141–7.

  • Pubmed Abstract
  • Google Scholar

• 639

  SuntharalingamGPerryMRWardSBrettSJCastello-CortesABrunnerMDet alCytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 355:1018–28.10.1056/NEJMoa063842

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 640

  WangHMaS. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med (2008) 26:711–5.10.1016/j.ajem.2007.10.031

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 641

  TscherneDMGarcía-SastreA. Virulence determinants of pandemic influenza viruses. J Clin Invest (2011) 121:6–13.10.1172/JCI44947

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 642

  D’EliaRVHarrisonKOystonPCLukaszewskiRAClarkGC. Targeting the “cytokine storm” for therapeutic benefit. Clin Vaccine Immunol (2013) 20:319–27.10.1128/CVI.00636-12

  • CrossRef
  • Google Scholar

• 643

  SingerMDeutschmanCSSeymourCWShankar-HariMAnnaneDBauerMet alThe third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA (2016) 315:801–10.10.1001/jama.2016.0287

  • CrossRef
  • Google Scholar

• 644

  RanieriVMThompsonBTBariePSDhainautJFDouglasISFinferSet alDrotrecogin alfa (activated) in adults with septic shock. N Engl J Med (2012) 366:2055–64.10.1056/NEJMoa1202290

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 645

  LaiPSMatteauAIddrissAHawesJCRanieriVThompsonBT. An updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock. Minerva Anestesiol (2013) 79:33–43.

  • Pubmed Abstract
  • Google Scholar

• 646

  VulcanoMMeissRPIsturizMA. Deferoxamine reduces tissue injury and lethality in LPS-treated mice. Int J Immunopharmacol (2000) 22:635–44.10.1016/S0192-0561(00)00026-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 647

  MessarisEAntonakisPTMemosNChatzigianniELeandrosEKonstadoulakisMM. Deferoxamine administration in septic animals: improved survival and altered apoptotic gene expression. Int Immunopharmacol (2004) 4:455–9.10.1016/j.intimp.2004.01.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 648

  IslamSJaroschSZhouJDel Carmen ParquetCToguriJTColpPet alAnti-inflammatory and anti-bacterial effects of iron chelation in experimental sepsis. J Surg Res (2016) 200:266–73.10.1016/j.jss.2015.07.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 649

  DoronMWMakhloufRAKatzVLLawsonEEStilesAD. Increased incidence of sepsis at birth in neutropenic infants of mothers with preeclampsia. J Pediatr (1994) 125:452–8.10.1016/S0022-3476(05)83294-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 650

  KocherlakotaPLa GammaEF. Preliminary report: rhG-CSF may reduce the incidence of neonatal sepsis in prolonged preeclampsia-associated neutropenia. Pediatrics (1998) 102:1107–11.10.1542/peds.102.5.1107

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 651

  BhaumikSGhoshSHaldarKKMitraPKMannaB. Risk of early onset neonatal septicemia in babies born to mothers with pre-eclampsia. Indian Pediatr (2000) 37:775–9.

  • Pubmed Abstract
  • Google Scholar

• 652

  ProcianoyRSSilveiraRCMussi-PinhataMMRugoloLMSSLeoneCRLopesJMDet alSepsis and neutropenia in very low birth weight infants delivered of mothers with preeclampsia. J Pediatr (2010) 157:434–U118.10.1016/j.jpeds.2010.02.066

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 653

  NamdevSBhatVAdhisivamBZachariahB. Oxidative stress and antioxidant status among neonates born to mothers with pre-eclampsia and their early outcome. J Matern Fetal Neonatal Med (2014) 27:1481–4.10.3109/14767058.2013.860521

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 654

  KennyLCDunnWBEllisDIMyersJBakerPNThe Gopec Consortiumet alNovel biomarkers for pre-eclampsia detected using metabolomics and machine learning. Metabolomics (2005) 1:227–34.10.1007/s11306-005-0003-1

  • CrossRef
  • Google Scholar

• 655

  KennyLCBroadhurstDBrownMDunnWBRedmanCWGKellDBet alDetection and identification of novel metabolomic biomarkers in preeclampsia. Reprod Sci (2008) 15:591–7.10.1177/1933719108316908

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 656

  OdiboAOGoetzingerKROdiboLCahillAGMaconesGANelsonDMet alFirst-trimester prediction of preeclampsia using metabolomic biomarkers: a discovery phase study. Prenat Diagn (2011) 31:990–4.10.1002/pd.2822

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 657

  Bahado-SinghROAkolekarRMandalRDongEXiaJKrugerMet alMetabolomics and first-trimester prediction of early-onset preeclampsia. J Matern Fetal Neonatal Med (2012) 25:1840–7.10.3109/14767058.2012.680254

  • CrossRef
  • Google Scholar

• 658

  DunnWBBrownMWortonSADaviesKJonesRLKellDBet alThe metabolome of human placental tissue: investigation of first trimester tissue and changes related to preeclampsia in late pregnancy. Metabolomics (2012) 8:579–97.10.1007/s11306-011-0348-6

  • CrossRef
  • Google Scholar

• 659

  WoodhamPCO’ConnellTGrimesJHaeriSEichelbergerKBakerAet alMetabolomics to predict severe preeclampsia in early pregnancy. Am J Obstet Gynecol (2012) 206:S348–348.10.1016/j.ajog.2011.10.809

  • CrossRef
  • Google Scholar

• 660

  KucSKosterMPHPenningsJLAHankemeierTBergerRHarmsACet alMetabolomics profiling for identification of novel potential markers in early prediction of preeclampsia. PLoS One (2014) 9:e98540.10.1371/journal.pone.0098540

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 661

  KosterMPHVreekenRJHarmsACDaneADKucSSchielenPCJIet alFirst-trimester serum acylcarnitine levels to predict preeclampsia: a metabolomics approach. Dis Markers (2015) 2015:857108.10.1155/2015/857108

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 662

  MyersJEHartSArmstrongSMiresGJBeynonRGaskellSJet alEvidence for multiple circulating factors in preeclampsia. Am J Obstet Gynecol (2007) 196(266):e261–6.10.1016/j.ajog.2006.10.875

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 663

  KollaVJenöPMoesSLapaireOHoesliIHahnS. Quantitative proteomic (iTRAQ) analysis of 1st trimester maternal plasma samples in pregnancies at risk for preeclampsia. J Biomed Biotechnol (2012) 2012:305964.10.1155/2012/305964

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 664

  MyersJEKennyLCMccowanLMChanEHDekkerGAPostonLet alAngiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG (2013) 120:1215–23.10.1111/1471-0528.12195

  • CrossRef
  • Google Scholar

• 665

  MyersJETuyttenRThomasGLaroyWKasKVanpouckeGet alIntegrated proteomics pipeline yields novel biomarkers for predicting preeclampsia. Hypertension (2013) 61:1281–8.10.1161/HYPERTENSIONAHA.113.01168

  • CrossRef
  • Google Scholar

• 666

  PolsaniSPhippsEJimB. Emerging new biomarkers of preeclampsia. Adv Chronic Kidney Dis (2013) 20:271–9.10.1053/j.ackd.2013.01.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 667

  HahnSLapaireOThanNG. Biomarker development for presymptomatic molecular diagnosis of preeclampsia: feasible, useful or even unnecessary?Expert Rev Mol Diagn (2015) 15:617–29.10.1586/14737159.2015.1025757

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 668

  KhanGHGalazisNDochevaNLayfieldRAtiomoW. Overlap of proteomics biomarkers between women with pre-eclampsia and PCOS: a systematic review and biomarker database integration. Hum Reprod (2015) 30:133–48.10.1093/humrep/deu268

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 669

  PaulusPJenneweinCZacharowskiK. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?Biomarkers (2011) 16(Suppl 1):S11–21.10.3109/1354750X.2011.587893

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 670

  NeteaMGJoostenLABLatzEMillsKHGNatoliGStunnenbergHGet alTrained immunity: a program of innate immune memory in health and disease. Science (2016) 352:aaf1098.10.1126/science.aaf1098

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 671

  SavvidouMDLeesCCParraMHingoraniADNicolaidesKH. Levels of C-reactive protein in pregnant women who subsequently develop pre-eclampsia. BJOG (2002) 109:297–301.10.1111/j.1471-0528.2002.01130.x

  • CrossRef
  • Google Scholar

• 672

  KashanianMAghbaliFMahaliN. Evaluation of the diagnostic value of the first-trimester maternal serum high-sensitivity C-reactive protein level for prediction of pre-eclampsia. J Obstet Gynaecol Res (2013) 39:1549–54.10.1111/jog.12105

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 673

  SaitoSShiozakiANakashimaASakaiMSasakiY. The role of the immune system in preeclampsia. Mol Aspects Med (2007) 28:192–209.10.1016/j.mam.2007.02.006

  • CrossRef
  • Google Scholar

• 674

  RinehartBKTerroneDALagoo-DeenadayalanSBarberWHHaleEAMartinJNJret alExpression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol (1999) 181:915–20.10.1016/S0002-9378(99)70325-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 675

  SerinÝSÖzçelikBBapbuðMKýlýçHOkurDErezR. Predictive value of tumor necrosis factor alpha (TNF-alpha) in preeclampsia. Eur J Obstet Gynecol Reprod Biol (2002):143–5.10.1016/S0301-2115(01)00484-5

  • CrossRef
  • Google Scholar

• 676

  TodrosTBontempoSPiccoliEIettaFRomagnoliRBiolcatiMet alIncreased levels of macrophage migration inhibitory factor (MIF) in preeclampsia. Eur J Obstet Gynecol Reprod Biol (2005) 123:162–6.10.1016/j.ejogrb.2005.03.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 677

  MehrSDoyleLW. Cytokines as markers of bacterial sepsis in newborn infants: a review. Pediatr Infect Dis J (2000) 19:879–87.10.1097/00006454-200009000-00014

  • CrossRef
  • Google Scholar

• 678

  RogerTGlauserMPCalandraT. Macrophage migration inhibitory factor (MIF) modulates innate immune responses induced by endotoxin and Gram-negative bacteria. J Endotoxin Res (2001) 7:456–60.10.1179/096805101101533089

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 679

  TakalaANupponenIKylanpää-BäckMLRepoH. Markers of inflammation in sepsis. Ann Med (2002) 34:614–23.10.1080/078538902321117841

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 680

  BriassoulisGGalaniA. Prognostic markers of pediatric meningococcal sepsis. Expert Rev Anti Infect Ther (2014) 12:1017–20.10.1586/14787210.2014.945431

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 681

  SuHChangSSHanCMWuKYLiMCHuangCYet alInflammatory markers in cord blood or maternal serum for early detection of neonatal sepsis-a systemic review and meta-analysis. J Perinatol (2014) 34:268–74.10.1038/jp.2013.186

  • CrossRef
  • Google Scholar

• 682

  KellDBKnowlesJD. The role of modeling in systems biology. In: SzallasiZStellingJPeriwalV, editors. System Modeling in Cellular Biology: From Concepts to Nuts and Bolts. Cambridge: MIT Press (2006). p. 3–18.

  • Google Scholar

• 683

  PalssonBØ. Systems Biology: Properties of Reconstructed Networks. Cambridge: Cambridge University Press (2006).

  • Google Scholar

• 684

  PalssonBØ. Systems Biology: Constraint-Based Reconstruction and Analysis. Cambridge: Cambridge University Press (2015).

  • Google Scholar

• 685

  HuckaMFinneyASauroHMBolouriHDoyleJCKitanoHet alThe systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics (2003) 19:524–31.10.1093/bioinformatics/btg015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 686

  FunahashiAMatsuokaYJourakuAMorohashiMKikuchiNKitanoH. CellDesigner 3.5: a versatile modeling tool for biochemical networks. Proc IEEE (2008) 96:1254–65.10.1109/JPROC.2008.925458

  • CrossRef
  • Google Scholar

• 687

  HoopsSSahleSGaugesRLeeCPahleJSimusNet alCOPASI: a complex pathway simulator. Bioinformatics (2006) 22:3067–74.10.1093/bioinformatics/btl485

  • CrossRef
  • Google Scholar

• 688

  SmootMEOnoKRuscheinskiJWangPLIdekerT. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics (2011) 27:431–2.10.1093/bioinformatics/btq675

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 689

  MadazliRKuseyriogluBUzunHUludagSOcakV. Prediction of preeclampsia with maternal mid-trimester placental growth factor, activin A, fibronectin and uterine artery Doppler velocimetry. Int J Gynaecol Obstet (2005) 89:251–7.10.1016/j.ijgo.2005.02.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 690

  DieschCHHolzgreveWHahnSZhongXY. Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia. Prenat Diagn (2006) 26:1267–70.10.1002/pd.1606

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 691

  ReddyASuriSSargentILRedmanCWMuttukrishnaS. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. PLoS One (2009) 4:e4453.10.1371/journal.pone.0004453

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 692

  PhillipsDJJonesKLScheerlinckJYHedgerMPDe KretserDM. Evidence for activin A and follistatin involvement in the systemic inflammatory response. Mol Cell Endocrinol (2001) 180:155–62.10.1016/S0303-7207(01)00516-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 693

  HodgesRSalvadorLD’AntonaDGeorgiouHMWallaceEM. Activin A as a marker of intrauterine infection in women with preterm prelabour rupture of membranes. J Perinatol (2010) 30:22–6.10.1038/jp.2009.109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 694

  RosenbergVABuhimschiIADulayATAbdel-RazeqSSOliverEADuzyjCMet alModulation of amniotic fluid activin-A and inhibin-A in women with preterm premature rupture of the membranes and infection-induced preterm birth. Am J Reprod Immunol (2012) 67:122–31.10.1111/j.1600-0897.2011.01074.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 695

  PetrakouEFotopoulosSAnagnostakouMAnatolitouFSamitasKSemitekolouMet alActivin-A exerts a crucial anti-inflammatory role in neonatal infections. Pediatr Res (2013) 74:675–81.10.1038/pr.2013.159

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 696

  ShuCLiuZCuiLWeiCWangSTangJJet alProtein profiling of preeclampsia placental tissues. PLoS One (2014) 9:e112890.10.1371/journal.pone.0112890

  • CrossRef
  • Google Scholar

• 697

  LugliAForsterYHaasPNocitoABucherCBissigHet alCalretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum Pathol (2003) 34:994–1000.10.1053/S0046-8177(03)00339-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 698

  RizzoACarratelliCRDe FilippisABevilacquaNTufanoMABuomminoE. Transforming activities of Chlamydia pneumoniae in human mesothelial cells. Int Microbiol (2014) 17:185–93.10.2436/20.1501.01.221

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 699

  XuQLZhuMJinYWangNXuHXQuanLMet alThe predictive value of the first-trimester maternal serum chemerin level for pre-eclampsia. Peptides (2014) 62:150–4.10.1016/j.peptides.2014.10.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 700

  StepanHPhilippARothIKralischSJankASchaarschmidtWet alSerum levels of the adipokine chemerin are increased in preeclampsia during and 6 months after pregnancy. Regul Pept (2011) 168:69–72.10.1016/j.regpep.2011.03.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 701

  AL-RefaiAA. Evaluation of serum levels of the adipokines chemerin and resistin in preeclampsia. Life Sci J (2012) 9:5143–51.

  • Google Scholar

• 702

  DuanDMNiuJMLeiQLinXHChenX. Serum levels of the adipokine chemerin in preeclampsia. J Perinat Med (2012) 40:121–7.10.1515/Jpm.2011.127

  • CrossRef
  • Google Scholar

• 703

  WangLQYangTLDingYLZhongYYuLPengM. Chemerin plays a protective role by regulating human umbilical vein endothelial cell-induced nitric oxide signaling in preeclampsia. Endocrine (2015) 48:299–308.10.1007/s12020-014-0286-y

  • CrossRef
  • Google Scholar

• 704

  BroadhurstDKellDB. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics (2006) 2:171–96.10.1007/s11306-006-0037-z

  • CrossRef
  • Google Scholar

• 705

  KuklaMZwirska-KorczalaKGabrielAWalugaMWarakomskaISzczygielBet alChemerin, vaspin and insulin resistance in chronic hepatitis C. J Viral Hepat (2010) 17:661–7.10.1111/j.1365-2893.2009.01224.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 706

  KuklaMMazurWBuldakRJŻwirska-KorczalaK. Potential role of leptin, adiponectin and three novel adipokines-visfatin, chemerin and vaspin-in chronic hepatitis. Mol Med (2011) 17:1397–410.10.2119/molmed.2010.00105

  • CrossRef
  • Google Scholar

• 707

  KuligPKantykaTZabelBABanasMChyraAStefanskaAet alRegulation of chemerin chemoattractant and antibacterial activity by human cysteine cathepsins. J Immunol (2011) 187:1403–10.10.4049/jimmunol.1002352

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 708

  BanasMZabiegloKKasettyGKapinska-MrowieckaMBorowczykJDrukalaJet alChemerin is an antimicrobial agent in human epidermis. PLoS One (2013) 8:e58709.10.1371/journal.pone.0058709

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 709

  ZabelBAKwitniewskiMBanasMZabiegloKMurzynKCichyJ. Chemerin regulation and role in host defense. Am J Clin Exp Immunol (2014) 3:1–19.

  • Pubmed Abstract
  • Google Scholar

• 710

  BanasMZegarAKwitniewskiMZabiegloKMarczynskaJKapinska-MrowieckaMet alThe expression and regulation of chemerin in the epidermis. PLoS One (2015) 10:e0117830.10.1371/journal.pone.0117830

  • CrossRef
  • Google Scholar

• 711

  HornPMetzingUBSteidlRRomeikeBRauchfußFSponholzCet alChemerin in peritoneal sepsis and its associations with glucose metabolism and prognosis: a translational cross-sectional study. Crit Care (2016) 20:39.10.1186/s13054-016-12090-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 712

  CorneliusDC. Copeptin: a new biomarker that is specific for preeclampsia?Hypertension (2014) 64:1189–91.10.1161/HYPERTENSIONAHA.114.04255

  • CrossRef
  • Google Scholar

• 713

  BirdirCJanssenKStanescuADEnekweAKasimir-BauerSGellhausAet alMaternal serum copeptin, MR-proANP and procalcitonin levels at 11-13 weeks gestation in the prediction of preeclampsia. Arch Gynecol Obstet (2015) 292:1033–42.10.1007/s00404-015-3745-7

  • CrossRef
  • Google Scholar

• 714

  JochbergerSMorgenthalerNGMayrVDLucknerGWenzelVUlmerHet alCopeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab (2006) 91:4381–6.10.1210/jc.2005-2830

  • CrossRef
  • Google Scholar

• 715

  MorgenthalerNGStruckJJochbergerSDünserMW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab (2008) 19:43–9.10.1016/j.tem.2007.11.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 716

  KatanMChrist-CrainM. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly (2010) 140:w13101.10.4414/smw.2010.13101

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 717

  NickelCHBingisserRMorgenthalerNG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med (2012) 10:7.10.1186/1741-7015-10-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 718

  DobšaLEdozienKC. Copeptin and its potential role in diagnosis and prognosis of various diseases. Biochem Med (Zagreb) (2013) 23:172–90.10.11613/BM.2013.021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 719

  OdermattJBolligerRHersbergerLOttigerMChrist-CrainMBrielMet alCopeptin predicts 10-year all-cause mortality in community patients: a 10-year prospective cohort study. Clin Chem Lab Med (2016) 54:1681–90.10.1515/cclm-2016-0151

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 720

  JochbergerSLucknerGMayrVDWenzelVMorgenthalerNGFrieseneckerBEet alCourse of vasopressin and copeptin plasma concentrations in a patient with severe septic shock. Anaesth Intensive Care (2006) 34:498–500.

  • Pubmed Abstract
  • Google Scholar

• 721

  MüllerBMorgenthalerNStolzDSchuetzPMullerCBingisserRet alCirculating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest (2007) 37:145–52.10.1111/j.1365-2362.2007.01762.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 722

  JochbergerSDörlerJLucknerGMayrVDWenzelVUlmerHet alThe vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med (2009) 37:476–82.10.1097/CCM.0b013e3181957532

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 723

  KrügerSEwigSKundeJHanschmannAMarreRSuttorpNet alC-terminal provasopressin (copeptin) in patients with community-acquired pneumonia – influence of antibiotic pre-treatment: results from the German competence network CAPNETZ. J Antimicrob Chemother (2009) 64:159–62.10.1093/jac/dkp148

  • CrossRef
  • Google Scholar

• 724

  LimperMGoeijenbierMWagenaarJFGasemMHIsbandrioBKundeJet alCopeptin as a predictor of disease severity and survival in leptospirosis. J Infect (2010) 61:92–4.10.1016/j.jinf.2010.03.029

  • CrossRef
  • Google Scholar

• 725

  FluriFMorgenthalerNGMuellerBChrist-CrainMKatanM. Copeptin, procalcitonin and routine inflammatory markers-predictors of infection after stroke. PLoS One (2012) 7:e48309.10.1371/journal.pone.0048309

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 726

  KolditzMHalankMSchulte-HubbertBBergmannSAlbrechtSHöffkenG. Copeptin predicts clinical deterioration and persistent instability in community-acquired pneumonia. Respir Med (2012) 106:1320–8.10.1016/j.rmed.2012.06.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 727

  DuJMSangGJiangCMHeXJHanY. Relationship between plasma copeptin levels and complications of community-acquired pneumonia in preschool children. Peptides (2013) 45:61–5.10.1016/j.peptides.2013.04.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 728

  Masajtis-ZagajewskaAKurnatowskaIWajdlichMNowickiM. Utility of copeptin and standard inflammatory markers in the diagnostics of upper and lower urinary tract infections. BMC Urol (2015) 15:67.10.1186/s12894-015-0061-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 729

  WrotekAJackowskaTPawlikK. Sodium and copeptin levels in children with community acquired pneumonia. Adv Exp Med Biol (2015) 835:31–6.10.1007/5584_2014_41

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 730

  StrevensHWide-SwenssonDGrubbAHansenAHornTIngemarssonIet alSerum cystatin C reflects glomerular endotheliosis in normal, hypertensive and pre-eclamptic pregnancies. BJOG (2003) 110:825–30.10.1111/j.1471-0528.2003.02051.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 731

  YangXWangHWangZDongM. Alteration and significance of serum cardiac troponin I and cystatin C in preeclampsia. Clin Chim Acta (2006) 374:168–9.10.1016/j.cca.2006.07.006

  • CrossRef
  • Google Scholar

• 732

  KristensenKWide-SwenssonDSchmidtCBlirup-JensenSLindströmVStrevensHet alCystatin C, beta-2-microglobulin and beta-trace protein in pre-eclampsia. Acta Obstet Gynecol Scand (2007) 86:921–6.10.1080/00016340701318133

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 733

  GuoHXWangCHLiZQGongSPZhouZQLengLZet alThe application of serum cystatin C in estimating the renal function in women with preeclampsia. Reprod Sci (2012) 19:712–7.10.1177/1933719111431001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 734

  Novakov MikicACabarkapaVNikolicAMaricDBrkicSMiticGet alCystatin C in pre-eclampsia. J Matern Fetal Neonatal Med (2012) 25:961–5.10.3109/14767058.2011.601366

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 735

  XiaoJNiuJYeXYuQGuY. Combined biomarkers evaluation for diagnosing kidney injury in preeclampsia. Hypertens Pregnancy (2013) 32:439–49.10.3109/10641955.2013.827203

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 736

  YalcinSUlasTErenMAAydoganHCamuzcuogluAKucukAet alRelationship between oxidative stress parameters and cystatin C levels in patients with severe preeclampsia. Medicina (Kaunas) (2013) 49:118–23.

  • Pubmed Abstract
  • Google Scholar

• 737

  OddenMCScherzerRBacchettiPSzczechLASidneySGrunfeldCet alCystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med (2007) 167:2213–9.10.1001/archinte.167.20.2213

  • CrossRef
  • Google Scholar

• 738

  RandersEKornerupKErlandsenEJHaslingCDanielsenH. Cystatin C levels in sera of patients with acute infectious diseases with high C-reactive protein levels. Scand J Clin Lab Invest (2001) 61:333–5.10.1080/00365510118007

  • CrossRef
  • Google Scholar

• 739

  GuptaSKKitchDTierneyCMelbourneKHaBMccomseyGAet alMarkers of renal disease and function are associated with systemic inflammation in HIV infection. HIV Med (2015) 16:591–8.10.1111/hiv.12268

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 740

  WalkerJBNesheimME. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem (1999) 274:5201–12.10.1074/jbc.274.8.5201

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 741

  BellartJGilabertRAnglèsAPieraVMirallesRMMonasterioJet alTissue factor levels and high ratio of fibrinopeptide A:d-dimer as a measure of endothelial procoagulant disorder in pre-eclampsia. Br J Obstet Gynaecol (1999) 106:594–7.10.1111/j.1471-0528.1999.tb08330.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 742

  GulecUKOzgunenFTGuzelABBuyukkurtSSeydaogluGUrunsakIFet alAn analysis of C-reactive protein, procalcitonin, and d-dimer in pre-eclamptic patients. Am J Reprod Immunol (2012) 68:331–7.10.1111/j.1600-0897.2012.01171.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 743

  PinheiroMDBJunqueiraDRGCoelhoFFFreitasLGCarvalhoMGGomesKBet ald-dimer in preeclampsia: systematic review and meta-analysis. Clin Chim Acta (2012) 414:166–70.10.1016/j.cca.2012.08.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 744

  BozkurtMYumruAESahinLSalmanS. Troponin I and d-dimer levels in preeclampsia and eclampsia: prospective study. Clin Exp Obstet Gynecol (2015) 42:26–31.

  • Pubmed Abstract
  • Google Scholar

• 745

  RahmanRBegumKKhondkerLMajumderNINaharKSultanaRet alRole of d-dimer in determining coagulability status in pre-eclamptic and normotensive pregnant women. Mymensingh Med J (2015) 24:115–20.

  • Pubmed Abstract
  • Google Scholar

• 746

  Di CastelnuovoADe CurtisACostanzoSPersichilloMOlivieriMZitoFet alAssociation of d-dimer levels with all-cause mortality in a healthy adult population: findings from the MOLI-SANI study. Haematologica (2013) 98:1476–80.10.3324/haematol.2012.083410

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 747

  JenningsIWoodsTALKitchenDPKitchenSWalkerID. Laboratory d-dimer measurement: improved agreement between methods through calibration. Thromb Haemost (2007) 98:1127–35.10.1160/TH07-05-0377

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 748

  KhalafallahAAMorseMAl-BarzanAMAdamsMDennisABatesGet ald-dimer levels at different stages of pregnancy in Australian women: a single centre study using two different immunoturbidimetric assays. Thromb Res (2012) 130:e171–7.10.1016/j.thromres.2012.05.022

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 749

  RodeloJRDe La RosaGValenciaMLOspinaSArangoCMGómezCIet ald-dimer is a significant prognostic factor in patients with suspected infection and sepsis. Am J Emerg Med (2012) 30:1991–9.10.1016/j.ajem.2012.04.033

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 750

  KhalafallahAJarvisCMorseMAlbarzanAMStewartPBatesGet alEvaluation of the innovance d-dimer assay for the diagnosis of disseminated intravascular coagulopathy in different clinical settings. Clin Appl Thromb Hemost (2014) 20:91–7.10.1177/1076029612454936

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 751

  HentschkeMRLucasLSMistryHDPinheiro Da CostaBEPoli-De-FigueiredoCE. Endocan-1 concentrations in maternal and fetal plasma and placentae in pre-eclampsia in the third trimester of pregnancy. Cytokine (2015) 74:152–6.10.1016/j.cyto.2015.04.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 752

  CakmakMYilmazHBağlarEDarcinTInanOAktasAet alSerum levels of endocan correlate with the presence and severity of pre-eclampsia. Clin Exp Hypertens (2016) 38:137–42.10.3109/10641963.2015.1060993

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 753

  MosevollKALindåsRWendelboØBruserudØReikvamH. Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis. Springerplus (2014) 3:571.10.1186/2193-1801-3-571

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 754

  YukselMATutenAOnculMAcikgozASTemel YukselIToprakMSet alSerum endocan concentration in women with pre-eclampsia. Arch Gynecol Obstet (2015) 292:69–73.10.1007/s00404-014-3605-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 755

  BaltaSMikhailidisDPDemirkolSOzturkCCelikTIyisoyA. Endocan: a novel inflammatory indicator in cardiovascular disease?Atherosclerosis (2015) 243:339–43.10.1016/j.atherosclerosis.2015.09.030

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 756

  PawlakKMysliwiecMPawlakD. Endocan – the new endothelial activation marker independently associated with soluble endothelial adhesion molecules in uraemic patients with cardiovascular disease. Clin Biochem (2015) 48:425–30.10.1016/j.clinbiochem.2015.01.006

  • CrossRef
  • Google Scholar

• 757

  FilepJG. Endocan or endothelial cell-specific molecule-1: a novel prognostic marker of sepsis?Crit Care Med (2006) 34:574–5.10.1097/01.CCM.0000199054.13823.A7

  • CrossRef
  • Google Scholar

• 758

  ScherpereelADepontieuFGrigoriuBCavestriBTsicopoulosAGentinaTet alEndocan, a new endothelial marker in human sepsis. Crit Care Med (2006) 34:532–7.10.1097/01.CCM.0000198525.82124.74

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 759

  MihajlovicDMLendakDFBrkicSVDraskovicBGMiticGPNovakov MikicASet alEndocan is useful biomarker of survival and severity in sepsis. Microvasc Res (2014) 93:92–7.10.1016/j.mvr.2014.04.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 760

  PaulyDHamedSBehnesMLepiorzDLangSAkinIet alEndothelial cell-specific molecule-1/endocan: diagnostic and prognostic value in patients suffering from severe sepsis and septic shock. J Crit Care (2016) 31:68–75.10.1016/j.jcrc.2015.09.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 761

  ShovlinCLHughesJMBScottJSeidmanCESeidmanJG. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet (1997) 61:68–79.10.1086/513906

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 762

  ShovlinCL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev (2010) 24:203–19.10.1016/j.blre.2010.07.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 763

  GregoryALXuGSotovVLetarteM. Review: the enigmatic role of endoglin in the placenta. Placenta (2014) 35(Suppl):S93–9.10.1016/j.placenta.2013.10.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 764

  BellMJRobertsJMFoundsSAJeyabalanATerhorstLConleyYP. Variation in endoglin pathway genes is associated with preeclampsia: a case-control candidate gene association study. BMC Pregnancy Childbirth (2013) 13:82.10.1186/1471-2393-13-82

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 765

  LuftFC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant (2006) 21:3052–4.10.1093/ndt/gfl439

  • CrossRef
  • Google Scholar

• 766

  VenkateshaSToporsianMLamCHanaiJMammotoTKimYMet alSoluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 12:642–9.10.1038/nm1429

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 767

  GovenderNMoodleyJGathiramPNaickerT. Soluble fms-like tyrosine kinase-1 in HIV infected pre-eclamptic South African Black women. Placenta (2014) 35:618–24.10.1016/j.placenta.2014.04.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 768

  PrattADa Silva CostaFBorgAJKalionisBKeoghRMurthiP. Placenta-derived angiogenic proteins and their contribution to the pathogenesis of preeclampsia. Angiogenesis (2015) 18:115–23.10.1007/s10456-014-9452-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 769

  KleinrouwelerCEWiegerinckMMJRis-StalpersCBossuytPMMvan der PostJAMVon DadelszenPet alAccuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG (2012) 119:778–87.10.1111/j.1471-0528.2012.03311.x

  • CrossRef
  • Google Scholar

• 770

  MuenznerPRohdeMKneitzSHauckCR. CEACAM engagement by human pathogens enhances cell adhesion and counteracts bacteria-induced detachment of epithelial cells. J Cell Biol (2005) 170:825–36.10.1083/jcb.200412151

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 771

  ClementeMNúñezOLorenteRRincónDMatillaASalcedoMet alIncreased intrahepatic and circulating levels of endoglin, a TGF-beta 1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis. J Viral Hepat (2006) 13:625–32.10.1111/j.1365-2893.2006.00733.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 772

  SilverKLConroyALLekeRGLekeRJGwanmesiaPMolyneuxMEet alCirculating soluble endoglin levels in pregnant women in Cameroon and Malawi – associations with placental malaria and fetal growth restriction. PLoS One (2011) 6:e24985.10.1371/journal.pone.0024985

  • CrossRef
  • Google Scholar

• 773

  SasmitoSDUlfiatiAWardanaANugraheniFPradiptasariNFZulaifaZet alEndoglin expression and the level of tgf-β are increased in the placental tissue and correlated with low fetal weight in malaria infected mice. J Trop Life Sci (2015) 5:1–7.10.11594/jtls.05.01.01

  • CrossRef
  • Google Scholar

• 774

  JansenPMummeTRandauTGraviusSHermanns-SachwehB. Endoglin (CD105) expression differentiates between aseptic loosening and periprosthetic joint infection after total joint arthroplasty. Springerplus (2014) 3:561.10.1186/2193-1801-3-561

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 775

  ValerioLG. Mammalian iron metabolism. Toxicol Mech Methods (2007) 17:497–517.10.1080/15376510701556690

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 776

  AndrewsNC. Forging a field: the golden age of iron biology. Blood (2008) 112:219–30.10.1182/blood-2007-12-077388

  • CrossRef
  • Google Scholar

• 777

  HowerVMendesPTortiFMLaubenbacherRAkmanSShulaevVet alA general map of iron metabolism and tissue-specific subnetworks. Mol Biosyst (2009) 5:422–43.10.1039/b816714c

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 778

  ChifmanJKnissANeupanePWilliamsILeungBDengZet alThe core control system of intracellular iron homeostasis: a mathematical model. J Theor Biol (2012) 300:91–9.10.1016/j.jtbi.2012.01.024

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 779

  MitchellSMendesP. A computational model of liver iron metabolism. PLoS Comput Biol (2013) 9:e1003299.10.1371/journal.pcbi.1003299

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 780

  OliveiraFRochaSFernandesR. Iron metabolism: from health to disease. J Clin Lab Anal (2014) 28:210–8.10.1002/jcla.21668

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 781

  KellDBPretoriusE. Interpreting raised serum ferritin levels. BMJ (2015) 351.10.1136/bmj.h3692

  • CrossRef
  • Google Scholar

• 782

  NielsenPGüntherUDürkenMFischerRDüllmannJ. Serum ferritin iron in iron overload and liver damage: correlation to body iron stores and diagnostic relevance. J Lab Clin Med (2000) 135:413–8.10.1067/mlc.2000.106456

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 783

  WatanabeKYamashitaYOhgawaraKSekiguchiMSatakeNOrinoKet alIron content of rat serum ferritin. J Vet Med Sci (2001) 63:587–9.10.1292/Jvms.63.587

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 784

  YamanishiHIyamaSYamaguchiYKanakuraYIwataniY. Relation between iron content of serum ferritin and clinical status factors extracted by factor analysis in patients with hyperferritinemia. Clin Biochem (2002) 35:523–9.10.1016/S0009-9120(02)00380-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 785

  KonzTAñôn AlvarezEMontes-BayonMSanz-MedelA. Antibody labeling and elemental mass spectrometry (inductively coupled plasma-mass spectrometry) using isotope dilution for highly sensitive ferritin determination and iron-ferritin ratio measurements. Anal Chem (2013) 85:8334–40.10.1021/ac401692k

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 786

  EntmanSSRichardsonLDKillamAP. Altered ferrokinetics in toxemia of pregnancy – a possible indicator of decreased red cell survival. Clin Exp Hypertens B (1983) 2:171–8.10.3109/10641958309023469

  • CrossRef
  • Google Scholar

• 787

  HubelCABodnarLMManyAHargerGNessRBRobertsJM. Nonglycosylated ferritin predominates in the circulation of women with preeclampsia but not intrauterine growth restriction. Clin Chem (2004) 50:948–51.10.1373/clinchem.2003.030932

  • CrossRef
  • Google Scholar

• 788

  VisserAvan de VyverA. Severe hyperferritinemia in Mycobacteria tuberculosis infection. Clin Infect Dis (2011) 52:273–4.10.1093/cid/ciq126

  • CrossRef
  • Google Scholar

• 789

  IshidaJHJohansenKL. Iron and infection in hemodialysis patients. Semin Dial (2014) 27:26–36.10.1111/sdi.12168

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 790

  EstellerM. Non-coding RNAs in human disease. Nat Rev Genet (2011) 12:861–74.10.1038/nrg3074

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 791

  KozomaraAGriffiths-JonesS. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res (2014) 42:D68–73.10.1093/nar/gkt1181

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 792

  GoulartLFBettellaFSønderbyIESchorkAJThompsonWKMattingsdalMet almicroRNAs enrichment in GWAS of complex human phenotypes. BMC Genomics (2015) 16:304.10.1186/s12864-015-1513-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 793

  LondinELoherPTelonisAGQuannKClarkPJingYet alAnalysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci U S A (2015) 112:E1106–15.10.1073/pnas.1420955112

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 794

  LuoSSIshibashiOIshikawaGIshikawaTKatayamaAMishimaTet alHuman villous trophoblasts express and secrete placenta-specific microRNAs into maternal circulation via exosomes. Biol Reprod (2009) 81:717–29.10.1095/biolreprod.108.075481

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 795

  OuyangYMouilletJFCoyneCBSadovskyY. Review: placenta-specific microRNAs in exosomes – good things come in nano-packages. Placenta (2014) 35(Suppl):S69–73.10.1016/j.placenta.2013.11.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 796

  RecordM. Intercellular communication by exosomes in placenta: a possible role in cell fusion?Placenta (2014) 35:297–302.10.1016/j.placenta.2014.02.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 797

  MiuraKMiuraSYamasakiKHigashijimaAKinoshitaAYoshiuraKet alIdentification of pregnancy-associated microRNAs in maternal plasma. Clin Chem (2010) 56:1767–71.10.1373/clinchem.2010.147660

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 798

  Morales-PrietoDMMarkertUR. microRNAs in pregnancy. J Reprod Immunol (2011) 88:106–11.10.1016/j.jri.2011.01.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 799

  MouilletJFOuyangYCoyneCBSadovskyY. microRNAs in placental health and disease. Am J Obstet Gynecol (2015) 213:S163–72.10.1016/j.ajog.2015.05.057

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 800

  JairajpuriDSAlmawiWY. microRNA expression pattern in pre-eclampsia (review). Mol Med Rep (2016) 13:2351–8.10.3892/mmr.2016.4846

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 801

  KotlabovaKDouchaJHromadnikovaI. Placental-specific microRNA in maternal circulation –identification of appropriate pregnancy-associated microRNAs with diagnostic potential. J Reprod Immunol (2011) 89:185–91.10.1016/j.jri.2011.02.006

  • CrossRef
  • Google Scholar

• 802

  ZhaoZMoleyKHGronowskiAM. Diagnostic potential for miRNAs as biomarkers for pregnancy-specific diseases. Clin Biochem (2013) 46:953–60.10.1016/j.clinbiochem.2013.01.026

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 803

  TsochandaridisMNascaLTogaCLevy-MozziconacciA. Circulating microRNAs as clinical biomarkers in the predictions of pregnancy complications. Biomed Res Int (2015) 2015:294954.10.1155/2015/294954

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 804

  ZhuXMHanTSargentILYinGWYaoYQ. Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. Am J Obstet Gynecol (2009) 200:661.e661–7.10.1016/j.ajog.2008.12.045

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 805

  WangDSongWNaQ. The emerging roles of placenta-specific microRNAs in regulating trophoblast proliferation during the first trimester. Aust N Z J Obstet Gynaecol (2012) 52:565–70.10.1111/j.1479-828X.2012.01481.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 806

  ChenDBWangW. Human placental microRNAs and preeclampsia. Biol Reprod (2013) 88:130.10.1095/biolreprod.113.107805

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 807

  DongFZhangYXiaFYangYXiongSJinLet alGenome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients. Reproduction (2014) 148:33–41.10.1530/REP-14-0095

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 808

  HromadnikovaIKotlabovaKHympanovaLDouchaJKroftaL. First trimester screening of circulating C19MC microRNAs can predict subsequent onset of gestational hypertension. PLoS One (2014) 9:e113735.10.1371/journal.pone.0113735

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 809

  AntonLOlarerin-GeorgeAOHogeneschJBElovitzMA. Placental expression of miR-517a/b and miR-517c contributes to trophoblast dysfunction and preeclampsia. PLoS One (2015) 10:e0122707.10.1371/journal.pone.0122707

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 810

  YangSLiHGeQGuoLChenF. Deregulated microRNA species in the plasma and placenta of patients with preeclampsia. Mol Med Rep (2015) 12:527–34.10.3892/mmr.2015.3414

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 811

  UraBFeriottoGMonastaLBilelSZweyerMCeleghiniC. Potential role of circulating microRNAs as early markers of preeclampsia. Taiwan J Obstet Gynecol (2014) 53:232–4.10.1016/j.tjog.2014.03.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 812

  Bortolin-CavailléMLDanceMWeberMCavailléJ. C19MC microRNAs are processed from introns of large Pol-II, non-protein-coding transcripts. Nucleic Acids Res (2009) 37:3464–73.10.1093/nar/gkp205

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 813

  Morales-PrietoDMOspina-PrietoSChaiwangyenWSchoenlebenMMarkertUR. Pregnancy-associated miRNA-clusters. J Reprod Immunol (2013) 97:51–61.10.1016/j.jri.2012.11.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 814

  Delorme-AxfordEDonkerRBMouilletJFChuTBayerAOuyangYet alHuman placental trophoblasts confer viral resistance to recipient cells. Proc Natl Acad Sci U S A (2013) 110:12048–53.10.1073/pnas.1304718110

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 815

  BayerADelorme-AxfordESleigherCFreyTKTrobaughDWKlimstraWBet alHuman trophoblasts confer resistance to viruses implicated in perinatal infection. Am J Obstet Gynecol (2015) 212(71):e71–8.10.1016/j.ajog.2014.07.060

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 816

  Olarerin-GeorgeAOAntonLHwangYCElovitzMAHogeneschJB. A functional genomics screen for microRNA regulators of NF-kappaB signaling. BMC Biol (2013) 11:19.10.1186/1741-7007-11-19

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 817

  SongGYSongWWHanYWangDNaQ. Characterization of the role of microRNA-517a expression in low birth weight infants. J Dev Orig Health Dis (2013) 4:522–6.10.1017/S204017441300024X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 818

  MouilletJFOuyangYBayerACoyneCBSadovskyY. The role of trophoblastic microRNAs in placental viral infection. Int J Dev Biol (2014) 58:281–9.10.1387/ijdb.130349ys

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 819

  MoroLBardajiAMaceteEBarriosDMorales-PrietoDMEspanaCet alPlacental microparticles and microRNAs in pregnant women with Plasmodium falciparum or HIV infection. PLoS One (2016) 11:e0146361.10.1371/journal.pone.0146361

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 820

  KhatunSKanayamaNBelayetHMBhuiyanABJahanSBegumAet alIncreased concentrations of plasma neuropeptide Y in patients with eclampsia and preeclampsia. Am J Obstet Gynecol (2000) 182:896–900.10.1016/S0002-9378(00)70342-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 821

  HauserGJDayaoEKZukowska-GrojecZ. Effect of neuropeptide Y on endotoxin-induced suppression of the response to various agonists in conscious rats. Life Sci (1995) 57:235–44.10.1016/0024-3205(95)00266-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 822

  KuncováJSýkoraRChvojkaJŠvíglerováJŠtenglMKroužeckýAet alPlasma and tissue levels of neuropeptide y in experimental septic shock: relation to hemodynamics, inflammation, oxidative stress, and hemofiltration. Artif Organs (2011) 35:625–33.10.1111/j.1525-1594.2010.01154.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 823

  GoetzDHHolmesMABorregaardNBluhmMERaymondKNStrongRK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell (2002) 10:1033–43.10.1016/S1097-2765(02)00708-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 824

  BachmanMALenioSSchmidtLOylerJEWeiserJN. Interaction of lipocalin 2, transferrin, and siderophores determines the replicative niche of Klebsiella pneumoniae during pneumonia. mBio (2012) 3:e224–211.10.1128/mBio.00224-11

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 825

  FloTHSmithKDSatoSRodriguezDJHolmesMAStrongRKet alLipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature (2004) 432:917–21.10.1038/nature03104

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 826

  ChakrabortySKaurSGuhaSBatraSK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta (2012) 1826:129–69.10.1016/j.bbcan.2012.03.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 827

  Cemgil ArikanDOzkayaMAdaliEKilincMCoskunAOzerAet alPlasma lipocalin-2 levels in pregnant women with pre-eclampsia, and their relation with severity of disease. J Matern Fetal Neonatal Med (2010) 24:291–6.10.3109/14767058.2010.487138

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 828

  D’AnnaRBavieraGGiordanoDTodarelloGCorradoFBuemiM. Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia. Acta Obstet Gynecol Scand (2008) 87:1370–3.10.1080/00016340802464463

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 829

  D’AnnaRBavieraGGiordanoDRussoSDugoNSantamariaAet alFirst trimester serum PAPP-A and NGAL in the prediction of late-onset pre-eclampsia. Prenat Diagn (2009) 29:1066–8.10.1002/pd.2339

  • CrossRef
  • Google Scholar

• 830

  D’AnnaRBavieraGGiordanoDTodarelloGRussoSRecuperoSet alNeutrophil gelatinase-associated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand (2010) 89:275–8.10.3109/00016340903443676

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 831

  StepanHPhilippAReicheMKlostermannKSchreySReisenbuchlerCet alSerum levels of the adipokine lipocalin-2 are increased in preeclampsia. J Endocrinol Invest (2010) 33:629–32.10.3275/6884

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 832

  KimSMParkJSNorwitzERJungHJKimBJParkCWet alCirculating levels of neutrophil gelatinase-associated lipocalin (NGAL) correlate with the presence and severity of preeclampsia. Reprod Sci (2013) 20:1083–9.10.1177/1933719113477480

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 833

  ScazzochioEMunmanyMGarciaLMelerECrispiFGratacosEet alPrognostic role of maternal neutrophil gelatinase-associated lipocalin in women with severe early-onset preeclampsia. Fetal Diagn Ther (2013) 35:127–32.10.1159/000356499

  • CrossRef
  • Google Scholar

• 834

  KarampasGEleftheriadesMPanoulisKRizouMHaliassosAHassiakosDet alMaternal serum levels of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in pregnancies with preeclampsia and those with a small for gestational age neonate. A longitudinal study. Prenat Diagn (2014) 34:726–33.10.1002/pd.4337

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 835

  SachanRPatelMGauravAGangwarRSachanP. Correlation of serum neutrophil gelatinase associated lipocalin with disease severity in hypertensive disorders of pregnancy. Adv Biomed Res (2014) 3:223.10.4103/2277-9175.145690

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 836

  SimonazziGCapelliICurtiAComaiGRizzoNLa MannaG. Serum and urinary neutrophil gelatinase-associated lipocalin monitoring in normal pregnancy versus pregnancies complicated by pre-eclampsia. In Vivo (2015) 29:117–21.

  • Pubmed Abstract
  • Google Scholar

• 837

  KarampasGAEleftheriadesMIPanoulisKCRizouMDHaliassosADMetallinouDKet alPrediction of pre-eclampsia combining NGAL and other biochemical markers with Doppler in the first and/or second trimester of pregnancy. A pilot study. Eur J Obstet Gynecol Reprod Biol (2016) 205:153–7.10.1016/j.ejogrb.2016.08.034

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 838

  MishraJDentCTarabishiRMitsnefesMMMaQKellyCet alNeutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet (2005) 365:1231–8.10.1016/S0140-6736(05)74811-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 839

  SoniSSCruzDBobekIChionhCYNalessoFLentiniPet alNGAL: a biomarker of acute kidney injury and other systemic conditions. Int Urol Nephrol (2010) 42:141–50.10.1007/s11255-009-9608-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 840

  ClericoAGalliCFortunatoARoncoC. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med (2012) 50:1505–17.10.1515/cclm-2011-0814

  • CrossRef
  • Google Scholar

• 841

  PatelMSachanRGangwarRSachanPNatuS. Correlation of serum neutrophil gelatinase-associated lipocalin with acute kidney injury in hypertensive disorders of pregnancy. Int J Nephrol Renovasc Dis (2013) 6:181–6.10.2147/IJNRD.S45523

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 842

  AydoğduMGürselGSancakBYeniSSariGTaşyürekSet alThe use of plasma and urine neutrophil gelatinase associated lipocalin (NGAL) and cystatin C in early diagnosis of septic acute kidney injury in critically ill patients. Dis Markers (2013) 34:237–46.10.3233/DMA-130966

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 843

  MårtenssonJBellMXuSBottaiMRavnBVengePet alAssociation of plasma neutrophil gelatinase-associated lipocalin (NGAL) with sepsis and acute kidney dysfunction. Biomarkers (2013) 18:349–56.10.3109/1354750X.2013.787460

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 844

  OttoGPBuschMSossdorfMClausRA. Impact of sepsis-associated cytokine storm on plasma NGAL during acute kidney injury in a model of polymicrobial sepsis. Crit Care (2013) 17:419.10.1186/cc12540

  • CrossRef
  • Google Scholar

• 845

  ZughaierSMTangprichaVLeongTStecenkoAAMccartyNA. Peripheral monocytes derived from patients with cystic fibrosis and healthy donors secrete NGAL in response to Pseudomonas aeruginosa infection. J Investig Med (2013) 61:1018–25.10.231/JIM.0b013e31829cbd14

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 846

  MacDonaldSPJStoneSFNeilCLVan EedenPEFatovichDMArendtsGet alSustained elevation of resistin, NGAL and IL-8 are associated with severe sepsis/septic shock in the emergency department. PLoS One (2014) 9:e110678.10.1371/journal.pone.0110678

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 847

  SmertkaMWroblewskaJSuchojadAMajcherczykMJadamus-NiebrojDOwsianka-PodlesnyTet alSerum and urinary NGAL in septic newborns. Biomed Res Int (2014) 2014:717318.10.1155/2014/717318

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 848

  HjortrupPBHaaseNTreschowFMøllerMHPernerA. Predictive value of NGAL for use of renal replacement therapy in patients with severe sepsis. Acta Anaesthesiol Scand (2015) 59:25–34.10.1111/aas.12427

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 849

  NgaHSMedeirosPMenezesPBridiRBalbiAPonceD. Sepsis and AKI in clinical emergency room patients: the role of urinary NGAL. Biomed Res Int (2015) 2015:413751.10.1155/2015/413751

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 850

  SuchojadATarkoASmertkaMMajcherczykMBrzozowskaAWroblewskaJet alFactors limiting usefulness of serum and urinary NGAL as a marker of acute kidney injury in preterm newborns. Ren Fail (2015) 37:439–45.10.3109/0886022X.2014.996109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 851

  KandaJMoriKKawabataHKuwabaraTMoriKPImamakiHet alAn AKI biomarker lipocalin 2 in the blood derives from the kidney in renal injury but from neutrophils in normal and infected conditions. Clin Exp Nephrol (2014) 19:99–106.10.1007/s10157-014-0952-7

  • CrossRef
  • Google Scholar

• 852

  MårtenssonJBellomoR. The rise and fall of NGAL in acute kidney injury. Blood Purif (2014) 37:304–10.10.1159/000364937

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 853

  SrisawatNPraditpornsilpaKPatarakulKTechapornrungMDaraswangTSukmarkTet alNeutrophil gelatinase associated lipocalin (NGAL) in leptospirosis acute kidney injury: a multicenter study in Thailand. PLoS One (2015) 10:e0143367.10.1371/journal.pone.0143367

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 854

  LeelahavanichkulASomparnPIssara-AmphornJEiam-OngSAvihingsanonYHirankarnNet alSerum neutrophil gelatinase associated lipocalin (NGAL) outperforms serum creatinine in detecting sepsis-induced acute kidney injury, experiments on bilateral nephrectomy and bilateral ureter obstruction mouse models. Shock (2016) 45:570–6.10.1097/SHK.0000000000000530

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 855

  DewerchinMCarmelietP. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med (2012) 2:a011056.10.1101/cshperspect.a011056

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 856

  De VivoABavieraGGiordanoDTodarelloGCorradoFD’AnnaR. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand (2008) 87:837–42.10.1080/00016340802253759

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 857

  KaufmannIRusterholzCHosliIHahnSLapaireO. Can detection of late-onset PE at triage by sflt-1 or PlGF be improved by the use of additional biomarkers?Prenat Diagn (2012) 32:1288–94.10.1002/pd.3995

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 858

  Gómez-ArriagaPIHerraizILópez-JiménezEAGómez-MontesEDenkBGalindoA. Uterine artery Doppler and sFlt-1/PlGF ratio: usefulness in diagnosis of pre-eclampsia. Ultrasound Obstet Gynecol (2013) 41:530–7.10.1002/uog.12400

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 859

  OhkuchiAHirashimaCTakahashiKSuzukiHMatsubaraSSuzukiM. Onset threshold of the plasma levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation. Hypertens Res (2013) 36:1073–80.10.1038/hr.2013.95

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 860

  HirashimaCOhkuchiATakahashiKSuzukiHMatsubaraSSuzukiM. A novel three-step approach for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation. Hypertens Res (2014) 37:519–25.10.1038/hr.2014.31

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 861

  LaiJGarcia-Tizon LarrocaSPeevaGPoonLCWrightDNicolaidesKH. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks’ gestation. Fetal Diagn Ther (2014) 35:240–8.10.1159/000359968

  • CrossRef
  • Google Scholar

• 862

  MasouraSKalogiannidisIMakedouKTheodoridisTKoiouKGerouSet alBiomarkers of endothelial dysfunction in preeclampsia and neonatal morbidity: a case-control study. Eur J Obstet Gynecol Reprod Biol (2014) 175:119–23.10.1016/j.ejogrb.2014.01.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 863

  OhkuchiAHirashimaCTakahashiKShirasunaKSuzukiHArigaHet alA trio of risk factors for the onset of preeclampsia in the second and early third trimesters. Pregnancy Hypertens (2014) 4:224–30.10.1016/j.preghy.2014.04.024

  • CrossRef
  • Google Scholar

• 864

  DrögeLHerraìzIZeislerHSchlembachDStepanHKüsselLet alMaternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies. Ultrasound Obstet Gynecol (2015) 45:286–93.10.1002/uog.14760

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 865

  RolfoAAttiniRTavassoliENeveFVNigraMCicilanoMet alIs it possible to differentiate chronic kidney disease and preeclampsia by means of new and old biomarkers? A prospective study. Dis Markers (2015) 2015:127083.10.1155/2015/127083

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 866

  StepanHHerraizISchlembachDVerlohrenSBrenneckeSChantraineFet alImplementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol (2015) 45:241–6.10.1002/uog.14799

  • CrossRef
  • Google Scholar

• 867

  KhalilAMaizNGarcia-MandujanoRPencoJMNicolaidesKH. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia. Ultrasound Obstet Gynecol (2016) 47:324–31.10.1002/uog.15750

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 868

  KimMYBuyonJPGuerraMMRanaSZhangDLaskinCAet alAngiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol (2016) 214: 108.e101–e114.10.1016/j.ajog.2015.09.066

  • CrossRef
  • Google Scholar

• 869

  ZeislerHLlurbaEChantraineFVatishMStaffACSennstromMet alPredictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med (2016) 374:13–22.10.1056/NEJMoa1414838

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 870

  LevineRJThadhaniRQianCLamCLimKHYuKFet alUrinary placental growth factor and risk of preeclampsia. JAMA (2005) 293:77–85.10.1001/jama.293.1.77

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 871

  OdiboAOPatelKRSpitalnikAOdiboLHuettnerP. Placental pathology, first-trimester biomarkers and adverse pregnancy outcomes. J Perinatol (2014) 34:186–91.10.1038/Jp.2013.176

  • CrossRef
  • Google Scholar

• 872

  BramhamKSeedPTLightstoneLNelson-PiercyCGillCWebsterPet alDiagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease. Kidney Int (2016) 89:874–85.10.1016/j.kint.2015.10.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 873

  DuckworthSGriffinMSeedPTNorthRMyersJMackillopLet alDiagnostic biomarkers in women with suspected preeclampsia in a prospective multicenter study. Obstet Gynecol (2016) 128:245–52.10.1097/AOG.0000000000001508

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 874

  YanoKLiawPCMullingtonJMShihSCOkadaHBodyakNet alVascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 203:1447–58.10.1084/jem.20060375

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 875

  YanoKOkadaYBeldiGShihSCBodyakNOkadaHet alElevated levels of placental growth factor represent an adaptive host response in sepsis. J Exp Med (2008) 205:2623–31.10.1084/jem.20080398

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 876

  FoidartJMSchaapsJPChantraineFMunautCLorquetS. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia – a step forward but not the definitive answer. J Reprod Immunol (2009) 82:106–11.10.1016/j.jri.2009.09.001

  • CrossRef
  • Google Scholar

• 877

  FuruyaMKurasawaKNagahamaKKawachiKNozawaATakahashiTet alDisrupted balance of angiogenic and antiangiogenic signalings in preeclampsia. J Pregnancy (2011) 2011:123717.10.1155/2011/123717

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 878

  De OliveiraLSassNBouteTMoronAF. sFlt-1 and PlGF levels in a patient with mirror syndrome related to cytomegalovirus infection. Eur J Obstet Gynecol Reprod Biol (2011) 158:366–7.10.1016/j.ejogrb.2011.04.049

  • CrossRef
  • Google Scholar

• 879

  BentonSJHuYXieFKupferKLeeSWMageeLAet alCan placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction?Am J Obstet Gynecol (2012) 206(163):e161–7.10.1016/j.ajog.2011.09.019

  • CrossRef
  • Google Scholar

• 880

  AcharyaA. Promising biomarkers for superimposed pre-eclampsia in pregnant women with established hypertension and chronic kidney disease. Kidney Int (2016) 89:743–6.10.1016/j.kint.2016.01.008

  • CrossRef
  • Google Scholar

• 881

  MontagnanaMLippiGAlbieroAScevarolliSSalvagnoGLFranchiMet alProcalcitonin values in preeclamptic women are related to severity of disease. Clin Chem Lab Med (2008) 46:1050–1.10.1515/CCLM.2008.199

  • CrossRef
  • Google Scholar

• 882

  CanMSancarEHarmaMGuvenBMunganGAcikgozS. Inflammatory markers in preeclamptic patients. Clin Chem Lab Med (2011) 49:1469–72.10.1515/CCLM.2011.232

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 883

  SimonLGauvinFAmreDKSaint-LouisPLacroixJ. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis (2004) 39:206–17.10.1086/421997

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 884

  UcarBYildizBAksitMAYararCColakOAkbayYet alSerum amyloid A, procalcitonin, tumor necrosis factor-alpha, and interleukin-1beta levels in neonatal late-onset sepsis. Mediators Inflamm (2008) 2008:737141.10.1155/2008/737141

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 885

  RiedelSMelendezJHAnATRosenbaumJEZenilmanJM. Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. Am J Clin Pathol (2011) 135:182–9.10.1309/AJCP1MFYINQLECV2

  • CrossRef
  • Google Scholar

• 886

  RiedelS. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis (2012) 73:221–7.10.1016/j.diagmicrobio.2012.05.002

  • CrossRef
  • Google Scholar

• 887

  SchuetzPMullerBChrist-CrainMStolzDTammMBouadmaLet alProcalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev (2012) 9:CD007498.10.1002/14651858.CD007498.pub2

  • CrossRef
  • Google Scholar

• 888

  UllaMPizzolatoELucchiariMLoiaconoMSoardoFFornoDet alDiagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care (2013) 17:R168.10.1186/cc12847

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 889

  Henriquez-CamachoCLosaJ. Biomarkers for sepsis. Biomed Res Int (2014) 2014:547818.10.1155/2014/547818

  • CrossRef
  • Google Scholar

• 890

  TianGPanSYMaGLiaoWSuQGGuBCet alSerum levels of procalcitonin as a biomarker for differentiating between sepsis and systemic inflammatory response syndrome in the neurological intensive care unit. J  Clin Neurosci (2014) 21:1153–8.10.1016/j.jocn.2013.09.021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 891

  WestwoodMRamaekersBWhitingPTominiFJooreMArmstrongNet alProcalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess (2015) 19:v–xxv, 1–236.10.3310/hta19960

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 892

  Engin-ÜstünYÜstünYKarabulutABÖzkaplanEMeydanliMMKafkaslıA. Serum amyloid A levels are increased in pre-eclampsia. Gynecol Obstet Invest (2007) 64:117–20.10.1159/000100329

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 893

  KristensenKWide-SwenssonDLindströmVSchmidtCGrubbAStrevensH. Serum amyloid A protein and C-reactive protein in normal pregnancy and preeclampsia. Gynecol Obstet Invest (2009) 67:275–80.10.1159/000214081

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 894

  MalleEDe BeerFC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest (1996) 26:427–35.10.1046/j.1365-2362.1996.159291.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 895

  PizziniCMussapMPlebaniMFanosV. C-reactive protein and serum amyloid A protein in neonatal infections. Scand J Infect Dis (2000) 32:229–35.10.1080/00365540050165848

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 896

  SipeJD. Serum amyloid A: from fibril to function. Current status. Amyloid (2000) 7:10–2.10.3109/13506120009146815

  • CrossRef
  • Google Scholar

• 897

  Urieli-ShovalSLinkeRPMatznerY. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol (2000) 7:64–9.10.1097/00062752-200001000-00012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 898

  FalseyARWalshEEFrancisCWLooneyRJKolassaJEHallWJet alResponse of C-reactive protein and serum amyloid A to influenza A infection in older adults. J Infect Dis (2001) 183:995–9.10.1086/319275

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 899

  ArnonSLitmanovitzIRegevRHBauerSShainkin-KestenbaumRDolfinT. Serum amyloid A: an early and accurate marker of neonatal early-onset sepsis. J Perinatol (2007) 27:297–302.10.1038/sj.jp.7211682

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 900

  BozinovskiSHutchinsonAThompsonMMacGregorLBlackJGiannakisEet alSerum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 177:269–78.10.1164/rccm.200705-678OC

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 901

  CicarelliDDVieiraJEBensenorFE. Comparison of C-reactive protein and serum amyloid a protein in septic shock patients. Mediators Inflamm (2008) 2008:631414.10.1155/2008/631414

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 902

  EbertECNagarM. Gastrointestinal manifestations of amyloidosis. Am J  Gastroenterol (2008) 103:776–87.10.1111/j.1572-0241.2007.01669.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 903

  LannergårdALarssonAFrimanGEwaldU. Human serum amyloid A (SAA) and high sensitive C-reactive protein (hsCRP) in preterm newborn infants with nosocomial infections. Acta Paediatr (2008) 97:1061–5.10.1111/j.1651-2227.2008.00814.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 904

  ÇetinkayaMÖzkanHKöksalNÇelebiSHacımustafaoğluM. Comparison of serum amyloid A concentrations with those of C-reactive protein and procalcitonin in diagnosis and follow-up of neonatal sepsis in premature infants. J Perinatol (2009) 29:225–31.10.1038/jp.2008.207

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 905

  LannergårdAVibergACarsOKarlssonMOSandströmMLarssonA. The time course of body temperature, serum amyloid A protein, C-reactive protein and interleukin-6 in patients with bacterial infection during the initial 3 days of antibiotic therapy. Scand J Infect Dis (2009) 41:663–71.10.1080/00365540903127417

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 906

  YuanHHuangJLvBYanWHuGWangJet alDiagnosis value of the serum amyloid A test in neonatal sepsis: a meta-analysis. Biomed Res Int (2013) 2013:520294.10.1155/2013/520294

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 907

  DerebeMGZlatkovCMGattuSRuhnKAVaishnavaSDiehlGEet alSerum amyloid A is a retinol binding protein that transports retinol during bacterial infection. Elife (2014) 3:e03206.10.7554/eLife.03206

  • CrossRef
  • Google Scholar

• 908

  BuhimschiIANayeriUAZhaoGShookLLPensalfiniAFunaiEFet alProtein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Sci Transl Med (2014) 6:245ra292.10.1126/scitranslmed.3008808

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 909

  LittleCSHammondCJMacintyreABalinBJAppeltDM. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging (2004) 25:419–29.10.1016/S0197-4580(03)00127-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 910

  WozniakMAItzhakiRFShipleySJDobsonCB. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci Lett (2007) 429:95–100.10.1016/j.neulet.2007.09.077

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 911

  VeasCJAguileraVCMunozIJGallardoVIMiguelPLGonzalezMAet alFetal endothelium dysfunction is associated with circulating maternal levels of sE-selectin, sVCAM1, and sFlt-1 during pre-eclampsia. J Matern Fetal Neonatal Med (2011) 24:1371–7.10.3109/14767058.2011.556204

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 912

  WhiteheadCLPalmerKRNilssonUGaoYSaglamBLappasMet alPlacental expression of a novel primate-specific splice variant of sFlt-1 is upregulated in pregnancies complicated by severe early onset pre-eclampsia. BJOG (2011):1268–71.10.1111/j.1471-0528.2011.02962.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 913

  HigginsLERey De CastroNAddoNWareingMGreenwoodSLJonesRLet alPlacental features of late-onset adverse pregnancy outcome. PLoS One (2015) 10:e0129117.10.1371/journal.pone.0129117

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 914

  HodTCerdeiraASKarumanchiSA. Molecular mechanisms of preeclampsia. Cold Spring Harb Perspect Med (2015) 5:a023473.10.1101/cshperspect.a023473

  • CrossRef
  • Google Scholar

• 915

  ThadhaniRKisnerTHagmannHBossungVNoackSSchaarschmidtWet alPilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 124:940–50.10.1161/CIRCULATIONAHA.111.034793

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 916

  LiFHagamanJRKimHSMaedaNJennetteJCFaberJEet aleNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype. J Am Soc Nephrol (2012) 23:652–60.10.1681/ASN.2011040369

  • CrossRef
  • Google Scholar

• 917

  CarneyEF. Hypertension: sFlt-1 removal seems to be beneficial in women with pre-eclampsia. Nat Rev Nephrol (2015) 11:690.10.1038/nrneph.2015.168

  • CrossRef
  • Google Scholar

• 918

  ThadhaniRHagmannHSchaarschmidtWRothBCingoezTKarumanchiSAet alRemoval of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol (2016) 27:903–13.10.1681/ASN.2015020157

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 919

  ShapiroNIYanoKOkadaHFischerCHowellMSpokesKCet alA prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis. Shock (2008) 29:452–7.10.1097/SHK.0b013e31815072c1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 920

  SchuetzPJonesAEAirdWCShapiroNI. Endothelial cell activation in emergency department patients with sepsis-related and non-sepsis-related hypotension. Shock (2011) 36:104–8.10.1097/SHK.0b013e31821e4e04

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 921

  ShapiroNISchuetzPYanoKSorasakiMParikhSMJonesAEet alThe association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care (2010) 14:R182.10.1186/cc9290

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 922

  AlvesBEMontalvaoSAAranhaFJLorand-MetzeIDe SouzaCAAnnichino-BizzacchiJMet alTime-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: a prospective study. J Transl Med (2011) 9:23.10.1186/1479-5876-9-23

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 923

  XingKMurthySLilesWCSinghJM. Clinical utility of biomarkers of endothelial activation in sepsis – a systematic review. Crit Care (2012) 16:R7.10.1186/cc11145

  • CrossRef
  • Google Scholar

• 924

  HsuCDIriyeBJohnsonTRWitterFRHongSFChanDW. Elevated circulating thrombomodulin in severe preeclampsia. Am J Obstet Gynecol (1993) 169:148–9.10.1016/0002-9378(93)90151-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 925

  MinakamiHTakahashiTIzumiATamadaT. Increased levels of plasma thrombomodulin in preeclampsia. Gynecol Obstet Invest (1993) 36:208–10.10.1159/000292631

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 926

  BontisJVavilisDAgorastosTZournatziVKonstantinidisTTagouK. Maternal plasma level of thrombomodulin is increased in mild preeclampsia. Eur J Obstet Gynecol Reprod Biol (1995) 60:139–41.10.1016/0028-2243(95)02093-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 927

  HsuCDCopelJAHongSFChanDW. Thrombomodulin levels in preeclampsia, gestational hypertension, and chronic hypertension. Obstet Gynecol (1995) 86:897–9.10.1016/0029-7844(95)00326-M

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 928

  ShaarawyMDidyHE. Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia. Int J Gynaecol Obstet (1996) 55:135–9.10.1016/S0020-7292(96)02755-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 929

  BoffaMCValsecchiLFaustoAGozinDVigano’ D’AngeloSSafaOet alPredictive value of plasma thrombomodulin in preeclampsia and gestational hypertension. Thromb Haemost (1998) 79:1092–5.

  • Pubmed Abstract
  • Google Scholar

• 930

  KobayashiHSadakataHSuzukiKSheMYShibataSTeraoT. Thrombomodulin release from umbilical endothelial cells initiated by preeclampsia plasma-induced neutrophil activation. Obstet Gynecol (1998) 92:425–30.10.1016/S0029-7844(98)00217-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 931

  BrennerB. Haemostatic changes in pregnancy. Thromb Res (2004) 114:409–14.10.1016/j.thromres.2004.08.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 932

  BoscoCParraMBarjaPRodrigoRFernándezVSuarezMet alIncreased immunohistochemical expression of thrombomodulin at placental perivascular myofibroblast in severe preeclampsia (PE). Histol Histopathol (2005) 20:1045–55.

  • Pubmed Abstract
  • Google Scholar

• 933

  WiwanitkitV. Correlation between thrombomodulin and severe preeclampsia: a summary. Clin Appl Thromb Hemost (2008) 14:99–101.10.1177/1076029607303965

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 934

  TurnerRJBloemenkampKWMBruijnJABaeldeHJ. Loss of thrombomodulin in placental dysfunction in preeclampsia. Arterioscler Thromb Vasc Biol (2016) 36:728–35.10.1161/ATVBAHA.306780

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 935

  SaitoHMaruyamaIShimazakiSYamamotoYAikawaNOhnoRet alEfficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost (2007) 5:31–41.10.1111/j.1538-7836.2006.02267.x

  • CrossRef
  • Google Scholar

• 936

  LeviMvan der PollT. Thrombomodulin in sepsis. Minerva Anestesiol (2013) 79:294–8.

  • Pubmed Abstract
  • Google Scholar

• 937

  MimuroJTakahashiHKitajimaITsujiHEguchiYMatsushitaTet alImpact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res (2013) 131:436–43.10.1016/j.thromres.2013.03.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 938

  VincentJLRameshMKErnestDLarosaSPPachlJAikawaNet alA randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med (2013) 41:2069–79.10.1097/CCM.0b013e31828e9b03

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 939

  ShirahataAMimuroJTakahashiHKitajimaITsujiHEguchiYet alRecombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation. Eur J Pediatr (2014) 173:303–11.10.1007/s00431-013-2155-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 940

  LeviM. Recombinant soluble thrombomodulin: coagulation takes another chance to reduce sepsis mortality. J Thromb Haemost (2015) 13:505–7.10.1111/jth.12868

  • CrossRef
  • Google Scholar

• 941

  YamakawaKAiharaMOguraHYuharaHHamasakiTShimazuT. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost (2015) 13:508–19.10.1111/jth.12841

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 942

  YoshimuraJYamakawaKOguraHUmemuraYTakahashiHMorikawaMet alBenefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit Care (2015) 19:78.10.1186/s13054-015-0810-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 943

  HayakawaMYamakawaKSaitoSUchinoSKudoDIizukaYet alRecombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Thromb Haemost (2016) 115:1157–66.10.1160/TH15-12-0987

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 944

  KimYMRomeroROhSYKimCJKilburnBAArmantDRet alToll-like receptor 4: a potential link between “danger signals,” the innate immune system and preeclampsia?Am J Obstet Gynecol (2005) 193:921–7.10.1016/j.ajog.2005.06.053

  • CrossRef
  • Google Scholar

• 945

  BonneyEA. Preeclampsia: a view through the danger model. J Reprod Immunol (2007) 76:68–74.10.1016/j.jri.2007.03.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 946

  FasshauerMWaldeyerTSeegerJSchreySEbertTKratzschJet alSerum levels of the adipokine visfatin are increased in pre-eclampsia. Clin Endocrinol (Oxf) (2008) 69:69–73.10.1111/j.1365-2265.2007.03147.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 947

  AdaliEYildizhanRKolusariAKurdogluMBugdayciGSahinHGet alIncreased visfatin and leptin in pregnancies complicated by pre-eclampsia. J Matern Fetal Neonatal Med (2009) 22:873–9.10.1080/14767050902994622

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 948

  Mazaki-ToviSVaisbuchERomeroRKusanovicJPChaiworapongsaTKimSKet alMaternal and neonatal circulating visfatin concentrations in patients with pre-eclampsia and a small-for-gestational age neonate. J Matern Fetal Neonatal Med (2010) 23:1119–28.10.3109/14767050903572190

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 949

  HuWWangZWangHHuangHDongM. Serum visfatin levels in late pregnancy and pre-eclampsia. Acta Obstet Gynecol Scand (2008) 87:413–8.10.1080/00016340801976012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 950

  ZonneveldRMartinelliRShapiroNIKuijpersTWPlotzFBCarmanCV. Soluble adhesion molecules as markers for sepsis and the potential pathophysiological discrepancy in neonates, children and adults. Crit Care (2014) 18:204.10.1186/cc13733

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 951

  de PabloRMonserratJReyesEDíazDRodríguez-ZapataMDe La HeraAet alCirculating sICAM-1 and sE-selectin as biomarker of infection and prognosis in patients with systemic inflammatory response syndrome. Eur J Intern Med (2013) 24:132–8.10.1016/j.ejim.2012.10.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 952

  MussapMNotoAFravegaMFanosV. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med (2011) 24(Suppl 2):12–4.10.3109/14767058.2011.601923

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 953

  OkamuraYYokoiH. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta (2011) 412:2157–61.10.1016/j.cca.2011.07.024

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 954

  EndoSSuzukiYTakahashiGShozushimaTIshikuraHMuraiAet alUsefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother (2012) 18:891–7.10.1007/s10156-012-0435-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 955

  EndoSSuzukiYTakahashiGShozushimaTIshikuraHMuraiAet alPresepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: a multicenter prospective study. J Infect Chemother (2014) 20:30–4.10.1016/j.jiac.2013.07.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 956

  NakamuraYIshikuraHNishidaTKawanoYYugeRIchikiRet alUsefulness of presepsin in the diagnosis of sepsis in patients with or without acute kidney injury. BMC Anesthesiol (2014) 14:88.10.1186/1471-2253-14-88

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 957

  WuJHuLZhangGWuFHeT. Accuracy of presepsin in sepsis diagnosis: a systematic review and meta-analysis. PLoS One (2015) 10:e0133057.10.1371/journal.pone.0133057

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 958

  AliFTAliMAElnakeebMMBendaryHN. Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis. Clin Chim Acta (2016) 460:93–101.10.1016/j.cca.2016.06.030

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 959

  KloucheKCristolJPDevinJGillesVKusterNLarcherRet alDiagnostic and prognostic value of soluble CD14 subtype (presepsin) for sepsis and community-acquired pneumonia in ICU patients. Ann Intensive Care (2016) 6:59.10.1186/s13613-016-0160-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 960

  SongXSongYYuanYZhangPZhangX. Prognostic value of presepsin for outcomes and complications in enterocutaneous fistula complicated by abdominal sepsis. Int J Surg (2016) 33(Pt A):96–101.10.1016/j.ijsu.2016.07.070

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 961

  TakahashiGShibataSFukuiYOkamuraYInoueY. Diagnostic accuracy of procalcitonin and presepsin for infectious disease in patients with acute kidney injury. Diagn Microbiol Infect Dis (2016) 86:205–10.10.1016/j.diagmicrobio.2016.07.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 962

  KellDBWesterhoffHV. Metabolic control theory: its role in microbiology and biotechnology. FEMS Microbiol Rev (1986) 39:305–20.10.1111/j.1574-6968.1986.tb01863.x

  • CrossRef
  • Google Scholar

• 963

  KellDB. Forces, fluxes and the control of microbial growth and metabolism. The twelfth Fleming lecture. J Gen Microbiol (1987) 133:1651–65.

  • Google Scholar

• 964

  FellDA. Metabolic control analysis – a survey of its theoretical and experimental development. Biochem J (1992) 286:313–30.10.1042/bj2860313

  • CrossRef
  • Google Scholar

• 965

  HeinrichRSchusterS. The Regulation of Cellular Systems. New York: Chapman & Hall (1996).

  • Google Scholar

• 966

  KellDBOliverSG. The metabolome 18 years on: a concept comes of age. Metabolomics (2016) 12:148.10.1007/s11306-016-1108-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 967

  OliverSGWinsonMKKellDBBaganzF. Systematic functional analysis of the yeast genome. Trends Biotechnol (1998) 16:373–8.10.1016/S0167-7799(98)01214-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 968

  Cornish-BowdenACárdenasML. Silent genes given voice. Nature (2001) 409:571–2.10.1038/35054646

  • CrossRef
  • Google Scholar

• 969

  RaamsdonkLMTeusinkBBroadhurstDZhangNHayesAWalshMet alA functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol (2001) 19:45–50.10.1038/83496

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 970

  GoodacreRVaidyanathanSDunnWBHarriganGGKellDB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol (2004) 22:245–52.10.1016/j.tibtech.2004.03.007

  • CrossRef
  • Google Scholar

• 971

  KellDB. Metabolomics and systems biology: making sense of the soup. Curr Opin Microbiol (2004) 7:296–307.10.1016/j.mib.2004.04.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 972

  KitanoH. Biological robustness. Nat Rev Genet (2004) 5:826–37.10.1038/nrg1471

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 973

  KitanoHOdaKKimuraTMatsuokaYCseteMDoyleJet alMetabolic syndrome and robustness tradeoffs. Diabetes (2004) 53(Suppl 3):S6–15.10.2337/diabetes.53.suppl_3.S6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 974

  WilhelmTBehreJSchusterS. Analysis of structural robustness of metabolic networks. Syst Biol (Stevenage) (2004) 1:114–20.10.1049/sb:20045004

  • CrossRef
  • Google Scholar

• 975

  GrimbsSSelbigJBulikSHolzhutterHGSteuerR. The stability and robustness of metabolic states: identifying stabilizing sites in metabolic networks. Mol Syst Biol (2007) 3:146.10.1038/msb4100186

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 976

  KellDB. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening, and knowledge of transporters: where drug discovery went wrong and how to fix it. FEBS J (2013) 280:5957–80.10.1111/febs.12268

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 977

  Quinton-TullochMJBruggemanFJSnoepJLWesterhoffHV. Trade-off of dynamic fragility but not of robustness in metabolic pathways in silico. FEBS J (2013) 280:160–73.10.1111/febs.12057

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 978

  KellDBGoodacreR. Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. Drug Discov Today (2014) 19:171–82.10.1016/j.drudis.2013.07.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 979

  BegleyPFrancis-McintyreSDunnWBBroadhurstDIHalsallATsengAet alDevelopment and performance of a gas chromatography-time-of-flight mass spectrometry analysis for large-scale non-targeted metabolomic studies of human serum. Anal Chem (2009) 81:7038–46.10.1021/ac9011599

  • CrossRef
  • Google Scholar

• 980

  ZelenaEDunnWBBroadhurstDFrancis-McintyreSCarrollKMBegleyPet alDevelopment of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal Chem (2009) 81:1357–64.10.1021/ac8019366

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 981

  DunnWBBroadhurstDBegleyPZelenaEFrancis-McintyreSAndersonNet alProcedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc (2011) 6:1060–83.10.1038/nprot.2011.335

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 982

  DunnWBLinWBroadhurstDBegleyPBrownMZelenaEet alMolecular phenotyping of a UK population: defining the human serum metabolome. Metabolomics (2015) 11:9–26.10.1007/s11306-014-0707-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 983

  SwainstonNMendesPKellDB. An analysis of a ‘community-driven’ reconstruction of the human metabolic network. Metabolomics (2013) 9:757–64.10.1007/s11306-013-0564-3

  • CrossRef
  • Google Scholar

• 984

  ThieleISwainstonNFlemingRMTHoppeASahooSAurichMKet alA community-driven global reconstruction of human metabolism. Nat Biotechnol (2013) 31:419–25.10.1038/nbt.2488

  • CrossRef
  • Google Scholar

• 985

  SwainstonNSmallboneKHefziHDobsonPDBrewerJHanschoMet alRecon 2.2: from reconstruction to model of human metabolism. Metabolomics (2016) 12:109.10.1007/s11306-016-1051-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 986

  HerrgårdMJSwainstonNDobsonPDunnWBArgaKYArvasMet alA consensus yeast metabolic network obtained from a community approach to systems biology. Nat Biotechnol (2008) 26:1155–60.10.1038/nbt1492

  • CrossRef
  • Google Scholar

• 987

  BolteACVan GeijnHPDekkerGA. Pathophysiology of preeclampsia and the role of serotonin. Eur J Obstet Gynecol Reprod Biol (2001) 95:12–21.10.1016/S0301-2115(00)00367-5

  • CrossRef
  • Google Scholar

• 988

  KellDBKaprelyantsASGrafenA. On pheromones, social behaviour and the functions of secondary metabolism in bacteria. Trends Ecol Evol (1995) 10:126–9.10.1016/S0169-5347(00)89013-8

  • CrossRef
  • Google Scholar

• 989

  TakanoE. Gamma-butyrolactones: Streptomyces signalling molecules regulating antibiotic production and differentiation. Curr Opin Microbiol (2006) 9:287–94.10.1016/j.mib.2006.04.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 990

  HyppönenECavadinoAWilliamsDFraserAVereczkeyAFraserWDet alVitamin D and pre-eclampsia: original data, systematic review and meta-analysis. Ann Nutr Metab (2013) 63:331–40.10.1159/000358338

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 991

  TabeshMSalehi-AbargoueiATabeshMEsmaillzadehA. Maternal vitamin D status and risk of pre-eclampsia: a systematic review and meta-analysis. J Clin Endocrinol Metab (2013) 98:3165–73.10.1210/jc.2013-1257

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 992

  BakacakMSerinSErcanOKostuBAvciFKilincMet alComparison of vitamin D levels in cases with preeclampsia, eclampsia and healthy pregnant women. Int J Clin Exp Med (2015) 8:16280–6.

  • Pubmed Abstract
  • Google Scholar

• 993

  BarreraDDiazLNoyola-MartinezNHalhaliA. Vitamin D and inflammatory cytokines in healthy and preeclamptic pregnancies. Nutrients (2015) 7:6465–90.10.3390/nu7085293

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 994

  GargariBPTabriziFPFSadienBJafarabadiMAFarzadiL. Vitamin D status is related to oxidative stress but not high-sensitive C-reactive protein in women with pre-eclampsia. Gynecol Obstet Invest (2015) 81:308–14.10.1159/000441781

  • CrossRef
  • Google Scholar

• 995

  HarveyNCHolroydCNtaniGJavaidKCooperPMoonRet alVitamin D supplementation in pregnancy: a systematic review. Health Technol Assess (2014) 18:1–190.10.3310/hta18450

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 996

  KielyMEZhangJYKinsellaMKhashanASKennyLC. Vitamin D status is associated with utero-placental dysfunction in a large prospective pregnancy cohort with low 25(OH)D₃ and ubiquitous 3-epi-25(OH)D₃ and 25(OH)D₂. Am J Clin Nutr (2016) 102:354–61.10.3945/ajcn.116.130419

  • CrossRef
  • Google Scholar

• 997

  van WeertBVan Den BergDHrudeyEJOostvogelsAJJMDe MirandaEVrijkotteTGM. Is first trimester vitamin D status in nulliparous women associated with pregnancy related hypertensive disorders?Midwifery (2016) 34:–22.10.1016/j.midw.2015.12.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 998

  PalaciosCDe-RegilLMLombardoLKPeña-RosasJP. Vitamin D supplementation during pregnancy: updated meta-analysis on maternal outcomes. J Steroid Biochem Mol Biol (2016) 164:148–55.10.1016/j.jsbmb.2016.02.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 999

  Bahado-SinghROSyngelakiAAkolekarRMandalRBjondahlTCHanBet alValidation of metabolomic models for prediction of early-onset preeclampsia. Am J Obstet Gynecol (2015) 213:530.e1–10.10.1016/j.ajog.2015.06.044

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1000

  Melland-SmithMErminiLChauvinSCraig-BarnesHTagliaferroATodrosTet alDisruption of sphingolipid metabolism augments ceramide-induced autophagy in preeclampsia. Autophagy (2015) 11:653–69.10.1080/15548627.2015.1034414

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1001

  FunkeCSchneiderSABergDKellDB. Genetics and iron in the systems biology of Parkinson’s disease and some related disorders. Neurochem Int (2013) 62:637–52.10.1016/j.neuint.2012.11.015

  • CrossRef
  • Google Scholar

• 1002

  ManyondaITSlaterDMFenskeCHoleDChoyMYWilsonC. A role for noradrenaline in pre-eclampsia: towards a unifying hypothesis for the pathophysiology. Br J Obstet Gynaecol (1998) 105:641–8.10.1111/j.1471-0528.1998.tb10179.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1003

  Ferreira-de-AlmeidaJAAmentaFCardosoFPoloniaJJ. Association of circulating endothelium and noradrenaline with increased calcium-channel binding sites in the placental bed in pre-eclampsia. Br J Obstet Gynaecol (1998) 105:1104–12.10.1111/j.1471-0528.1998.tb09944.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1004

  LyteMErnstS. Catecholamine-induced growth of Gram-negative bacteria. Life Sci (1992) 50:203–12.10.1016/0024-3205(92)90273-R

  • CrossRef
  • Google Scholar

• 1005

  FreestonePPHaighRDWilliamsPHLyteM. Stimulation of bacterial growth by heat-stable, norepinephrine-induced autoinducers. FEMS Microbiol Lett (1999) 172:53–60.10.1111/j.1574-6968.1999.tb13449.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1006

  ReissbrodtRRienaeckerIRomanovaJMFreestonePPEHaighRDLyteMet alResuscitation of Salmonella enterica serovar typhimurium and enterohemorrhagic Escherichia coli from the viable but nonculturable state by heat-stable enterobacterial autoinducer. Appl Environ Microbiol (2002) 68:4788–94.10.1128/AEM.68.10.4788-4794.2002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1007

  LyteM. Microbial endocrinology and infectious disease in the 21st century. Trends Microbiol (2004) 12:14–20.10.1016/j.tim.2003.11.004

  • CrossRef
  • Google Scholar

• 1008

  LyteM. The effect of stress on microbial growth. Anim Health Res Rev (2014) 15:172–4.10.1017/S146625231400019X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1009

  FreestonePPLyteMNealCPMaggsAFHaighRDWilliamsPH. The mammalian neuroendocrine hormone norepinephrine supplies iron for bacterial growth in the presence of transferrin or lactoferrin. J Bacteriol (2000) 182:6091–8.10.1128/JB.182.21.6091-6098.2000

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1010

  FreestonePPEHaighRDWilliamsPHLyteM. Involvement of enterobactin in norepinephrine-mediated iron supply from transferrin to enterohaemorrhagic Escherichia coli. FEMS Microbiol Lett (2003) 222:39–43.10.1016/S0378-1097(03)00243-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1011

  O’DonnellPMAvilesHLyteMSonnenfeldG. Enhancement of in vitro growth of pathogenic bacteria by norepinephrine: importance of inoculum density and role of transferrin. Appl Environ Microbiol (2006) 72:5097–9.10.1128/AEM.00075-06

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1012

  KvetnanskyRSabbanELPalkovitsM. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol Rev (2009) 89:535–606.10.1152/physrev.00042.2006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1013

  Ribas RipollVRomayEBrunelliLPastorelliRGomaGNavasAet alMetabolite analysis in sepsis through conditional independence maps. Conf Proc IEEE Eng Med Biol Soc (2015) 2015:6477–80.10.1109/EMBC.2015.7319876

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1014

  SuLHuangYZhuYXiaLWangRXiaoKet alDiscrimination of sepsis stage metabolic profiles with an LC/MS-MS-based metabolomics approach. BMJ Open Respir Res (2014) 1:e000056.10.1136/bmjresp-2014-000056

  • CrossRef
  • Google Scholar

• 1015

  EggersAE. A suggestion about the cause of inflammation in acute atherosis complicating poor placentation in preeclampsia. Med Hypotheses (2015) 85:718–9.10.1016/j.mehy.2015.10.022

  • CrossRef
  • Google Scholar

• 1016

  D’AnnaRBavieraGScilipotiALeonardiILeoR. The clinical utility of serum uric acid measurements in pre-eclampsia and transient hypertension in pregnancy. Panminerva Med (2000) 42:101–3.

  • Pubmed Abstract
  • Google Scholar

• 1017

  WilliamsKPGalerneauF. The role of serum uric acid as a prognostic indicator of the severity of maternal and fetal complications in hypertensive pregnancies. J Obstet Gynaecol Can (2002) 24:628–32.10.1016/S1701-2163(16)30193-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1018

  RobertsJMBodnarLMLainKYHubelCAMarkovicNNessRBet alUric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension (2005) 46:1263–9.10.1161/01.HYP.0000188703.27002.14

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1019

  BainbridgeSARobertsJM. Uric acid as a pathogenic factor in preeclampsia. Placenta (2008) 29:S67–72.10.1016/j.placenta.2007.11.001

  • CrossRef
  • Google Scholar

• 1020

  KoopmansCMVan PampusMGGroenHAarnoudseJGVan Den BergPPMolBWJ. Accuracy of serum uric acid as a predictive test for maternal complications in pre-eclampsia: bivariate meta-analysis and decision analysis. Eur J Obstet Gynecol Reprod Biol (2009) 146:8–14.10.1016/j.ejogrb.2009.05.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1021

  AgarwalVGuptaBKVishnuAMamtatyagiShiprasolankiKiranJ. Association of lipid profile and uric acid with pre-eclampsia of third trimester in nullipara women. J Clin Diagn Res (2014) 8:CC04–07.10.7860/JCDR/2014/7901.4533

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1022

  PereiraKNKnoppkaCKDa SilvaJE. Association between uric acid and severity of pre-eclampsia. Clin Lab (2014) 60:309–14.

  • Pubmed Abstract
  • Google Scholar

• 1023

  LimKHFriedmanSAEckerJLKaoLKilpatrickSJ. The clinical utility of serum uric acid measurements in hypertensive diseases of pregnancy. Am J Obstet Gynecol (1998) 178:1067–71.10.1016/S0002-9378(98)70549-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1024

  CnossenJSDe Ruyter-HanhijarviHvan der PostJAMolBWKhanKSTer RietG. Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review. Acta Obstet Gynecol Scand (2006) 85:519–25.10.1080/00016340500342037

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1025

  PowersRWBodnarLMNessRBCooperKMGallaherMJFrankMPet alUric acid concentrations in early pregnancy among preeclamptic women with gestational hyperuricemia at delivery. Am J Obstet Gynecol (2006) 194:160–6.10.1016/j.ajog.2005.06.066

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1026

  ThangaratinamSIsmailKMSharpSCoomarasamyAKhanKSTests in Prediction of Pre-Eclampsia Severity Review, Group. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG (2006) 113:369–78.10.1111/j.1471-0528.2006.00908.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1027

  ChenQLauSTongMWeiJShenFZhaoJet alSerum uric acid may not be involved in the development of preeclampsia. J Hum Hypertens (2016) 30:136–40.10.1038/jhh.2015.47

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1028

  EltzschigHKSitkovskyMVRobsonSC. Purinergic signaling during inflammation. N Engl J Med (2012) 367:2322–33.10.1056/NEJMra1205750

  • CrossRef
  • Google Scholar

• 1029

  Kaddurah-DaoukRZhuHSharmaSBogdanovMRozenSGMatsonWet alAlterations in metabolic pathways and networks in Alzheimer’s disease. Transl Psychiatry (2013) 3:e244.10.1038/tp.2013.18

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1030

  McFarlandNRBurdettTDesjardinsCAFroschMPSchwarzschildMA. Postmortem brain levels of urate and precursors in Parkinson’s disease and related disorders. Neurodegener Dis (2013) 12:189–98.10.1159/000346370

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1031

  EsteveCJonesEAKellDBBoutinHMcdonnellLA. Mass spectral imaging shows major derangements in neurogranin and in purine metabolism in the triple-knockout 3xTg Alzheimer-like mouse model. Front Neurosci (Forthcoming 2016).

  • Google Scholar

• 1032

  MartinonF. Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev (2010) 233:218–32.10.1111/j.0105-2896.2009.00860.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1033

  LyngdohTVuistinerPMarques-VidalPRoussonVWaeberGVollenweiderPet alSerum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS One (2012) 7:e39321.10.1371/journal.pone.0039321

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1034

  OrengoJMLeliwa-SytekAEvansJEEvansBvan de HoefDNyakoMet alUric acid is a mediator of the Plasmodium falciparum-induced inflammatory response. PLoS One (2009) 4:e5194.10.1371/Journal.Pone.0005194

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1035

  KoolMSoullieTVan NimwegenMWillartMAMuskensFJungSet alAlum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med (2008) 205:869–82.10.1084/jem.20071087

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1036

  ChalcraftKR. Comprehensive Metabolomics Analysis of Peanut Allergy and Peanut-Induced Anaphylaxis [Ph.D. Thesis] Open Access Dissertations and Theses. Paper 7733. Hamilton, ON: McMaster University (2013).

  • Google Scholar

• 1037

  ChalcraftKRKongJWasermanSJordanaMMccarryBE. Comprehensive metabolomic analysis of peanut-induced anaphylaxis in a murine model. Metabolomics (2014) 10:452–60.10.1007/s11306-013-0589-7

  • CrossRef
  • Google Scholar

• 1038

  KongJChalcraftKMandurTSJimenez-SaizRWalkerTDGoncharovaSet alComprehensive metabolomics identifies the alarmin uric acid as a critical signal for the induction of peanut allergy. Allergy (2015) 70:495–505.10.1111/all.12579

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1039

  van DeventerSJHBüllerHRTen CateJWAardenLAHackCESturkA. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood (1990) 76:2520–6.

  • Pubmed Abstract
  • Google Scholar

• 1040

  JohnsonKAardenLChoiYDe GrootECreaseyA. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood (1996) 87:5051–60.

  • Pubmed Abstract
  • Google Scholar

• 1041

  American College of Chest Physicians. From the bench to the bedside: the future of sepsis research. Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop. Chest (1997) 111:744–53.

  • Google Scholar

• 1042

  PernerstorferTStohlawetzPHollensteinUDzirloLEichlerHGKapiotisSet alEndotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen. Arterioscler Thromb Vasc Biol (1999) 19:2517–23.10.1161/01.ATV.19.10.2517

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1043

  PernerstorferTHollensteinUHansenJBStohlawetzPEichlerHGHandlerSet alLepirudin blunts endotoxin-induced coagulation activation. Blood (2000) 95:1729–34.

  • Pubmed Abstract
  • Google Scholar

• 1044

  DellingerRP. Inflammation and coagulation: implications for the septic patient. Clin Infect Dis (2003) 36:1259–65.10.1086/374835

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1045

  SchoutenMWiersingaWJLeviMvan der PollT. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol (2008) 83:536–45.10.1189/jlb.0607373

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1046

  AnasAAWiersingaWJDe VosAFvan der PollT. Recent insights into the pathogenesis of bacterial sepsis. Neth J Med (2010) 68:147–52.

  • Pubmed Abstract
  • Google Scholar

• 1047

  SaraccoPVitalePScolfaroCPollioBPagliarinoMTimeusF. The coagulopathy in sepsis: significance and implications for treatment. Pediatr Rep (2011) 3:e30.10.4081/pr.2011.e30

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1048

  TsaoCMHoSTWuCC. Coagulation abnormalities in sepsis. Acta Anaesthesiol Taiwan (2015) 53:16–22.10.1016/j.aat.2014.11.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1049

  ArmstrongMTRicklesFRArmstrongPB. Capture of lipopolysaccharide (endotoxin) by the blood clot: a comparative study. PLoS One (2013) 8:e80192.10.1371/journal.pone.0080192

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1050

  Al-ofiECoffeltSBAnumbaDO. Fibrinogen, an endogenous ligand of toll-like receptor 4, activates monocytes in pre-eclamptic patients. J Reprod Immunol (2014) 103:23–8.10.1016/j.jri.2014.02.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1051

  ChatterjeeTMaitraDChakravartyTDattaAG. Studies on plasma fibrinogen level in pre-eclampsia and eclampsia. Experientia (1978) 34:562–3.10.1007/BF01936958

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1052

  MantenGTRSikkemaJMFranxAHameetemanTMVisserGHADe GrootPGet alIncreased high molecular weight fibrinogen in pre-eclampsia. Thromb Res (2003) 111:143–7.10.1016/j.thromres.2003.08.025

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1053

  ÜstünYEngin-ÜstünYKamacıM. Association of fibrinogen and C-reactive protein with severity of preeclampsia. Eur J Obstet Gynecol Reprod Biol (2005) 121:154–8.10.1016/j.ejogrb.2004.12.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1054

  SersamLW. Inflammatory markers in pre-eclampsia and related conditions. Int J Gynaecol Obstet (2009):69–70.10.1016/j.ijgo.2008.11.016

  • CrossRef
  • Google Scholar

• 1055

  SoganiSSarakarPD. Evaluation of plasma fibrinogen and plasma fibrin degradation product (FDP) in preeclampsia. J Clin Biomed Sci (2013) 3:201–3.

  • Google Scholar

• 1056

  PerryKGMartinJN. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia. Clin Obstet Gynecol (1992) 35:338–50.10.1097/00003081-199235020-00015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1057

  MetzJCincottaRFrancisMDerosaLBallochA. Screening for consumptive coagulopathy in preeclampsia. Int J Gynecol Obstet (1994) 46:3–9.10.1016/0020-7292(94)90301-8

  • CrossRef
  • Google Scholar

• 1058

  GilabertJEstellésAGranchaSEspañaFAznarJ. Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in pre-eclampsia. Hum Reprod (1995) 10(Suppl 2):121–31.10.1093/humrep/10.suppl_2.121

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1059

  HeSBremmeKBlombackM. Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia. Blood Coagul Firbinolysis (1997) 8:232–8.10.1097/00001721-199706000-00004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1060

  HladunewichMKarumanchiSALafayetteR. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol (2007) 2:543–9.10.2215/CJN.03761106

  • CrossRef
  • Google Scholar

• 1061

  KherABauersachsRNielsenJD. The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Thromb Haemost (2007) 97:505–13.10.1160/TH06-10-0606

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1062

  JahromiBNRafieeSH. Coagulation factors in severe preeclampsia. Iran Red Crescent Med J (2009) 11:321–4.

  • Google Scholar

• 1063

  Ducloy-BouthorsAS. Clotting disorders and preeclampsia (in French). Ann Fr Anesth Reanim (2010) 29:e121–34.10.1016/j.annfar.2010.03.012

  • CrossRef
  • Google Scholar

• 1064

  Martínez-ZamoraMATassiesDCarmonaFEspinosaGCerveraRReverterJCet alClot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies. J Reprod Immunol (2010) 86:133–40.10.1016/j.jri.2010.05.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1065

  DusseLMRiosDRAPinheiroMBCooperAJLwaleedBA. Pre-eclampsia: relationship between coagulation, fibrinolysis and inflammation. Clin Chim Acta (2011) 412:17–21.10.1016/j.cca.2010.09.030

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1066

  GodoiLCGomesKBAlpoimPNCarvalhoMDGLwaleedBASant’ana DusseLM. Preeclampsia: the role of tissue factor and tissue factor pathway inhibitor. J Thromb Thrombolysis (2012) 34:1–6.10.1007/s11239-012-0708-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1067

  BattinelliEMMarshallAConnorsJM. The role of thrombophilia in pregnancy. Thrombosis (2013) 2013:516420.10.1155/2013/516420

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1068

  HanLLiuXLiHZouJYangZHanJet alBlood coagulation parameters and platelet indices: changes in normal and preeclamptic pregnancies and predictive values for preeclampsia. PLoS One (2014) 9:e114488.10.1371/journal.pone.0114488

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1069

  KohSCLAnandakumarCMontanSRatnamSS. Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia. Gynecol Obstet Invest (1993) 35:214–21.10.1159/000292703

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1070

  KanekoTWadaH. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. J Clin Exp Hematop (2011) 51:67–76.10.3960/jslrt.51.67

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1071

  LeviMvan der PollT. Disseminated intravascular coagulation: a review for the internist. Int Emerg Med (2013) 8:23–32.10.1007/s11739-012-0859-9

  • CrossRef
  • Google Scholar

• 1072

  AsakuraH. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care (2014) 2:20.10.1186/2052-0492-2-20

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1073

  WadaHMatsumotoTYamashitaYHatadaT. Disseminated intravascular coagulation: testing and diagnosis. Clin Chim Acta (2014) 436:130–4.10.1016/j.cca.2014.04.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1074

  ZeerlederSHackCEWuilleminWA. Disseminated intravascular coagulation in sepsis. Chest (2005) 128:2864–75.10.1378/chest.128.4.2864

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1075

  XuMDongMQCaoFLLiuMLWangYXDongHYet alTanshinone IIA reduces lethality and acute lung injury in LPS-treated mice by inhibition of PLA2 activity. Eur J Pharmacol (2009) 607:194–200.10.1016/j.ejphar.2009.02.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1076

  SemeraroNAmmolloCTSemeraroFColucciM. Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. Mediterr J Hematol Infect Dis (2010) 2:e2010024.10.4084/MJHID.2010.024

  • CrossRef
  • Google Scholar

• 1077

  AcikgozSAkdumanDEskiciZMCanMMunganGGuvenBet alThrombocyte and erythrocyte indices in sepsis and disseminated intravascular coagulation. J Med Biochem (2012) 31:60–4.10.2478/v10011-011-0043-1

  • CrossRef
  • Google Scholar

• 1078

  WuLCLinXSunH. Tanshinone IIA protects rabbits against LPS-induced disseminated intravascular coagulation (DIC). Acta Pharmacol Sin (2012) 33:1254–9.10.1038/aps.2012.84

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1079

  IbaTItoTMaruyamaIJilmaBBrennerTMullerMCet alPotential diagnostic markers for disseminated intravascular coagulation of sepsis. Blood Rev (2016) 30:149–55.10.1016/j.blre.2015.10.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1080

  OkamotoKTamuraTSawatsubashiY. Sepsis and disseminated intravascular coagulation. J Intensive Care (2016) 4:23.10.1186/s40560-016-0149-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1081

  D’EliaAVFabbroDDriulLBarillariGMarchesoniDDamanteG. Plasminogen activator inhibitor-1 gene polymorphisms in pre-eclampsia. Semin Thromb Hemost (2011) 37:97–105.10.1055/s-0030-1270334

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1082

  BuurmaAJTurnerRJDriessenJHMooyaartALSchoonesJWBruijnJAet alGenetic variants in pre-eclampsia: a meta-analysis. Hum Reprod Update (2013) 19:289–303.10.1093/humupd/dms060

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1083

  MorganJABombellSMcguireW. Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review. PLoS One (2013) 8:e56907.10.1371/journal.pone.0056907

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1084

  KellDBPretoriusE. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Progr Biophys Mol Biol (2016).10.1016/j.pbiomolbio.2016.08.006

  • CrossRef
  • Google Scholar

• 1085

  KellDBPretoriusE. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. bioRxiv preprint. bioRxiv (2016) 054734.10.1101/054734

  • CrossRef
  • Google Scholar

• 1086

  AkassoglouKAdamsRABauerJMercadoPTsevelekiVLassmannHet alFibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci U S A (2004) 101:6698–703.10.1073/pnas.0303859101

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1087

  LeviMvan der PollTBullerHR. Bidirectional relation between inflammation and coagulation. Circulation (2004) 109:2698–704.10.1161/01.CIR.0000131660.51520.9A

  • CrossRef
  • Google Scholar

• 1088

  FlickMJLajeunesseCMTalmageKEWitteDPPalumboJSPinkertonMDet alFibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest (2007) 117:3224–35.10.1172/JCI30134

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1089

  JenneweinCPaulusPZacharowskiK. Linking inflammation and coagulation: novel drug targets to treat organ ischemia. Curr Opin Anaesthesiol (2011) 24:375–80.10.1097/ACO.0b013e3283489ac0

  • CrossRef
  • Google Scholar

• 1090

  JenneweinCTranNPaulusPEllinghausPEbleJAZacharowskiK. Novel aspects of fibrin(ogen) fragments during inflammation. Mol Med (2011) 17:568–73.10.2119/molmed.2010.00146

  • CrossRef
  • Google Scholar

• 1091

  SchuligaM. The inflammatory actions of coagulant and fibrinolytic proteases in disease. Mediators Inflamm (2015) 2015:437695.10.1155/2015/437695

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1092

  MirandaSOpazoCLarrondoLFMunozFJRuizFLeightonFet alThe role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer’s disease. Progr Neurobiol (2000) 62:633–48.10.1016/S0301-0082(00)00015-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1093

  Meyer-LuehmannMSpires-JonesTLPradaCGarcia-AllozaMDe CalignonARozkalneAet alRapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature (2008) 451:720–4.10.1038/nature06616

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1094

  RivalTPageRMChandraratnaDSSendallTJRyderELiuBet alFenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer’s disease. Eur J Neurosci (2009) 29:1335–47.10.1111/j.1460-9568.2009.06701.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1095

  LiuBMoloneyAMeehanSMorrisKThomasSESerpellLCet alIron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J Biol Chem (2011) 286:4248–56.10.1074/jbc.M110.158980

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1096

  MinterMRTaylorJMCrackPJ. The contribution of neuroinflammation to amyloid toxicity in Alzheimer’s disease. J Neurochem (2016) 136:457–74.10.1111/jnc.13411

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1097

  ÖzcanFTurakODurakAIşleyenAUçarFGinişZet alRed cell distribution width and inflammation in patients with non-dipper hypertension. Blood Press (2013) 22:80–5.10.3109/08037051.2012.707336

  • CrossRef
  • Google Scholar

• 1098

  HeilmannLMattheckCKurzE. Changes in blood rheology and their influence on oxygen diffusion in normal and pathological pregnancies. Arch Gynäkol (1977) 223:283–98.10.1007/Bf00667368

  • CrossRef
  • Google Scholar

• 1099

  StoeffSDikovIVretenarskaMJovtchevSTrifonovaNPenevM. Quantitative utility assessment of some biophysical and rheological tests used in hypertension research. 1. Relevance analyses of the test parameters. C R Acad Bulg Sci (2003) 56:95–100.

  • Google Scholar

• 1100

  KurtRKArasZSilfelerDBKuntCIslimyeMKosarO. Relationship of red cell distribution width with the presence and severity of preeclampsia. Clin Appl Thromb Hemost (2015) 21:128–31.10.1177/1076029613490827

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1101

  AbdullahiHOsmanARayisDAGasimGIImamAMAdamI. Red blood cell distribution width is not correlated with preeclampsia among pregnant Sudanese women. Diagn Pathol (2014) 9:29.10.1186/1746-1596-9-29

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1102

  McMahonCJHopkinsSVailAKingATSmithDIllingworthKJet alInflammation as a predictor for delayed cerebral ischemia after aneurysmal subarachnoid haemorrhage. J Neurointerv Surg (2013) 5:512–7.10.1136/neurintsurg-2012-010386

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1103

  SwanepoelACPretoriusE. Scanning electron microscopy analysis of erythrocytes in thromboembolic ischemic stroke. Int J Lab Hematol (2012) 34:185–91.10.1111/j.1751-553X.2011.01379.x

  • CrossRef
  • Google Scholar

• 1104

  BuysAVVan RooyMJSomaPVan PapendorpDLipinskiBPretoriusE. Changes in red blood cell membrane structure in type 2 diabetes: a scanning electron and atomic force microscopy study. Cardiovasc Diabetol (2013) 12:25.10.1186/1475-2840-12-25

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1105

  PretoriusELipinskiB. Iron alters red blood cell morphology. Blood (2013) 121:9.10.1182/blood-2012-09-454793

  • CrossRef
  • Google Scholar

• 1106

  PretoriusELipinskiB. Thromboembolic ischemic stroke changes red blood cell morphology. Cardiovasc Pathol (2013) 22:241–2.10.1016/j.carpath.2012.11.005

  • CrossRef
  • Google Scholar

• 1107

  LangFLangKSLangPAHuberSMWiederT. Mechanisms and significance of eryptosis. Antioxid Redox Signal (2006) 8:1183–92.10.1089/ars.2006.8.1183

  • CrossRef
  • Google Scholar

• 1108

  LangFGulbinsELercheHHuberSMKempeDSFöllerM. Eryptosis, a window to systemic disease. Cell Physiol Biochem (2008) 22:373–80.10.1159/000185448

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1109

  LangFLangEFollerM. Physiology and pathophysiology of eryptosis. Transfus Med Hemother (2012) 39:308–14.10.1159/000342534

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1110

  LangFQadriSM. Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purif (2012) 33:125–30.10.1159/000334163

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1111

  LangELangF. Triggers, inhibitors, mechanisms, and significance of eryptosis: the suicidal erythrocyte death. Biomed Res Int (2015) 2015:513518.10.1155/2015/513518

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1112

  LangEZelenakCEberhardMBissingerRRotteAGhashghaeiniaMet alImpact of cyclin-dependent kinase CDK4 inhibition on eryptosis. Cell Physiol Biochem (2015) 37:1178–86.10.1159/000430241

  • CrossRef
  • Google Scholar

• 1113

  QadriSMDonkorDABhaktaVEltringham-SmithLJDwivediDJMooreJCet alPhosphatidylserine externalization and procoagulant activation of erythrocytes induced by Pseudomonas aeruginosa virulence factor pyocyanin. J Cell Mol Med (2016) 20:710–20.10.1111/jcmm.12778

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1114

  LangEBissingerRGulbinsELangF. Ceramide in the regulation of eryptosis, the suicidal erythrocyte death. Apoptosis (2015) 20:758–67.10.1007/s10495-015-1094-4

  • CrossRef
  • Google Scholar

• 1115

  HanssonSRNäävÅErlandssonL. Oxidative stress in preeclampsia and the role of free fetal hemoglobin. Front Physiol (2014) 5:516.10.3389/fphys.2014.00516

  • CrossRef
  • Google Scholar

• 1116

  AskieLMDuleyLHenderson-SmartDJStewartLAParis Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet (2007) 369:1791–8.10.1016/S0140-6736(07)60712-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1117

  RobertsJMCatovJM. Aspirin for pre-eclampsia: compelling data on benefit and risk. Lancet (2007) 369:1765–6.10.1016/S0140-6736(07)60713-2

  • CrossRef
  • Google Scholar

• 1118

  RossiACMullinPM. Prevention of pre-eclampsia with low-dose aspirin or vitamins C and E in women at high or low risk: a systematic review with meta-analysis. Eur J Obstet Gynecol Reprod Biol (2011) 158:9–16.10.1016/j.ejogrb.2011.04.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1119

  VillaPMKajantieERäikkönenKPesonenAKHämäläinenEVainioMet alAspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO trial and a meta-analysis of randomised trials. BJOG (2013) 120:64–74.10.1111/j.1471-0528.2012.03493.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1120

  BujoldEMorencyAMRobergeSLacasseYForestJCGiguèreY. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can (2009) 31:818–26.10.1016/S1701-2163(16)34300-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1121

  RobergeSGiguereYVillaPNicolaidesKVainioMForestJCet alEarly administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol (2012) 29:551–6.10.1055/s-0032-1310527

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1122

  RobergeSDemersSBujoldE. Initiation of aspirin in early gestation for the prevention of pre-eclampsia. BJOG (2013) 120:773–4.10.1111/1471-0528.12170

  • CrossRef
  • Google Scholar

• 1123

  BergeronTSRobergeSCarpentierCSibaiBMccaw-BinnsABujoldE. Prevention of preeclampsia with aspirin in multiple gestations: a systematic review and meta-analysis. Am J Perinatol (2016) 33:605–10.10.1055/s-0035-1570381

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1124

  RobergeSSibaiBMcCaw-BinnsABujoldE. Low-dose aspirin in early gestation for prevention of preeclampsia and small-for-gestational-age neonates: meta-analysis of large randomized trials. Am J Perinatol (2016) 33:781–5.10.1055/s-0036-1572495

  • CrossRef
  • Google Scholar

• 1125

  HofmeyrGJBelizánJMVon DadelszenPCalcium Pre-Eclampsia Study Group. Low-dose calcium supplementation for preventing pre-eclampsia: a systematic review and commentary. BJOG (2014) 121:951–7.10.1111/1471-0528.12613

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1126

  LeslieKThilaganathanBPapageorghiouA. Early prediction and prevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol (2011) 25:343–54.10.1016/j.bpobgyn.2011.01.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1127

  ThangaratinamSLangenveldJMolBWKhanKS. Prediction and primary prevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol (2011) 25:419–33.10.1016/j.bpobgyn.2011.02.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1128

  GillonTEPelsAVon DadelszenPMacdonellKMageeLA. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One (2014) 9:e113715.10.1371/journal.pone.0113715

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1129

  CottrellECSibleyCP. From pre-clinical studies to clinical trials: generation of novel therapies for pregnancy complications. Int J Mol Sci (2015) 16:12907–24.10.3390/ijms160612907

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1130

  AltmanDCarroliGDuleyLFarrellBMoodleyJNeilsonJet alDo women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The magpie trial: a randomised placebo-controlled trial. Lancet (2002) 359:1877–90.10.1016/S0140-6736(02)08778-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1131

  DuleyL. Evidence and practice: the magnesium sulphate story. Best Pract Res Clin Obstet Gynaecol (2005) 19:57–74.10.1016/j.bpobgyn.2004.10.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1132

  PrattJJNiedlePSVogelJPOladapoOTBohrenMTunçalpÖet alAlternative regimens of magnesium sulfate for treatment of preeclampsia and eclampsia: a systematic review of non-randomized studies. Acta Obstet Gynecol Scand (2016) 95:144–56.10.1111/aogs.12807

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1133

  WilliamsonRDMcCarthyCKennyLCO’KeeffeGW. Magnesium sulphate prevents lipopolysaccharide-induced cell death in an in vitro model of the human placenta. Pregnancy Hypertens (2016).10.1016/j.preghy.2016.08.237

  • CrossRef
  • Google Scholar

• 1134

  KorenGPastuszakAItoS. Drugs in pregnancy. N Engl J Med (1998) 338:1128–37.10.1056/NEJM199804163381607

  • CrossRef
  • Google Scholar

• 1135

  EverettTRWilkinsonIBLeesCC. Drug development in preeclampsia: a ‘no go’ area?J Matern Fetal Neonatal Med (2012) 25:50–2.10.3109/14767058.2011.557791

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1136

  Martinez de TejadaB. Antibiotic use and misuse during pregnancy and delivery: benefits and risks. Int J Environ Res Public Health (2014) 11:7993–8009.10.3390/ijerph110807993

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1137

  ThinkhamropJHofmeyrGJAdetoroOLumbiganonPOtaE. Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity. Cochrane Database Syst Rev (2015) 1:CD002250.10.1002/14651858.CD002250.pub2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1138

  VazquezJCAbalosE. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database Syst Rev (2011) CD002256.10.1002/14651858.CD002256.pub2

  • CrossRef
  • Google Scholar

• 1139

  MathewDKhanKThorntonJGTodrosT. Antibiotics for preventing hypertensive diseases in pregnancy (protocol). Cochrane Database Syst Rev (2007) CD006841.10.1002/14651858.CD006841

  • CrossRef
  • Google Scholar

• 1140

  PoundMWMayDB. Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions. J Clin Pharm Ther (2005) 30:291–5.10.1111/j.1365-2710.2005.00631.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1141

  SeeSScottEKLevinMW. Penicillin-induced Jarisch-Herxheimer reaction. Ann Pharmacother (2005) 39:2128–30.10.1345/aph.1G308

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1142

  BelumGRBelumVRChaitanya ArudraSKReddyBS. The Jarisch-Herxheimer reaction: revisited. Travel Med Infect Dis (2013) 11:231–7.10.1016/j.tmaid.2013.04.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1143

  GuerrierGD’OrtenzioE. The Jarisch-Herxheimer reaction in leptospirosis: a systematic review. PLoS One (2013) 8:e59266.10.1371/journal.pone.0059266

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1144

  PrinsJMvan DeventerSJHKuijperEJSpeelmanP. Clinical relevance of antibiotic-induced endotoxin release. Antimicrob Agents Chemother (1994) 38:1211–8.10.1128/AAC.38.6.1211

  • CrossRef
  • Google Scholar

• 1145

  KirikaeTNakanoMMorrisonDC. Antibiotic-induced endotoxin release from bacteria and its clinical significance. Microbiol Immunol (1997) 41:285–94.10.1111/j.1348-0421.1997.tb01203.x

  • CrossRef
  • Google Scholar

• 1146

  HolzheimerRG. Antibiotic induced endotoxin release and clinical sepsis: a review. J Chemother (2001) 13(Spec No 1):159–72.10.1179/joc.2001.13.Supplement-2.159

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1147

  LepperPMHeldTKSchneiderEMBölkeEGerlachHTrautmannM. Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med (2002) 28:824–33.10.1007/s00134-002-1330-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1148

  AnderssonJAFittsECKirtleyMLPonnusamyDPenicheAGDannSMet alNew role for FDA-approved drugs in combating antibiotic-resistant bacteria. Antimicrob Agents Chemother (2016) 60:3717–29.10.1128/AAC.00326-16

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1149

  PostonLBrileyALSeedPTKellyFJShennanAH. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet (2006) 367:1145–54.10.1016/S0140-6736(06)68433-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1150

  LyCYockell-LelievreJFerraroZMArnasonJTFerrierJGruslinA. The effects of dietary polyphenols on reproductive health and early development. Hum Reprod Update (2015) 21:228–48.10.1093/humupd/dmu058

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1151

  LiangSTWongVCSoWWMaHKChanVToddD. Homozygous alpha-thalassaemia: clinical presentation, diagnosis and management. A review of 46 cases. Br J Obstet Gynaecol (1985) 92:680–4.10.1111/j.1471-0528.1985.tb01447.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1152

  TungwiwatWFucharoenSFucharoenGRatanasiriTSanchaisuriyaK. Development and application of a real-time quantitative PCR for prenatal detection of fetal alpha(0)-thalassemia from maternal plasma. Ann N Y Acad Sci (2006) 1075:103–7.10.1196/annals.1368.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1153

  SendenIPDe GrootCJSteegersEABertinaRMSwinkelsDW. Preeclampsia and the C282Y mutation in the hemochromatosis (HFE) gene. Clin Chem (2004) 50:973–4.10.1373/clinchem.2004.031591

  • CrossRef
  • Google Scholar

• 1154

  PerronNRBrumaghimJL. A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochem Biophys (2009) 53:75–100.10.1007/s12013-009-9043-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1155

  DoddJMMcleodAWindrimRCKingdomJ. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev (2010) CD006780.10.1002/14651858.CD006780.pub2

  • CrossRef
  • Google Scholar

• 1156

  LiYWuYGongXShiXQiaoFLiuH. Low molecular weight heparin decreases the permeability of glomerular endothelial cells when exposed to pre-eclampsia serum in vitro. Nephrology (Carlton) (2012) 17:754–9.10.1111/j.1440-1797.2012.01657.x

  • CrossRef
  • Google Scholar

• 1157

  DoddJMMcleodAWindrimRCKingdomJ. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev (2013) 7:CD006780.10.1002/14651858.CD006780.pub3

  • CrossRef
  • Google Scholar

• 1158

  ZhangYLiuFChenSZhongM. Low-molecular-weight heparin protects kidney through an anti-apoptotic mechanism in a rat pre-eclamptic model. Eur J Obstet Gynecol Reprod Biol (2015) 188:51–5.10.1016/j.ejogrb.2015.02.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1159

  Darmochwał-KolarzDKolarzBKorzeniewskiMKimber-TrojnarZPatro-MalyszaJMierzynskiRet alA prevention of pre-eclampsia with the use of acetylsalicylic acid and low-molecular weight heparin – molecular mechanisms. Curr Pharm Biotechnol (2016) 17:624–8.10.2174/1389201017666160301103312

  • CrossRef
  • Google Scholar

• 1160

  RobergeSDemersSNicolaidesKHBureauMCôtéSBujoldE. Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis. Ultrasound Obstet Gynecol (2016) 47:548–53.10.1002/uog.15789

  • CrossRef
  • Google Scholar

• 1161

  EggersAE. A hypothesis about how to achieve anticoagulation without bleeding. Med Hypotheses (2015) 85:720–2.10.1016/j.mehy.2015.10.021

  • CrossRef
  • Google Scholar

• 1162

  KellDB. How drugs pass through biological cell membranes – a paradigm shift in our understanding?Beilstein Mag (2016) 2. Available from: http://www.beilstein-institut.de/download/628/609_kell.pdf

  • Google Scholar

• 1163

  ParkKLeeSAhnHSKimD. Predicting the multi-modal binding propensity of small molecules: towards an understanding of drug promiscuity. Mol Biosyst (2009) 5:844–53.10.1039/b901356c

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1164

  Pérez-NuenoVIVenkatramanVMavridisLRitchieDW. Detecting drug promiscuity using Gaussian ensemble screening. J Chem Inf Model (2012) 52:1948–61.10.1021/ci3000979

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1165

  TarcsayAKeserüGM. Contributions of molecular properties to drug promiscuity. J Med Chem (2013) 56:1789–95.10.1021/jm301514n

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1166

  ArrowsmithCHAudiaJEAustinCBaellJBennettJBlaggJet alThe promise and peril of chemical probes. Nat Chem Biol (2015) 11:536–41.10.1038/nchembio.1867

  • CrossRef
  • Google Scholar

• 1167

  NiphakisMJLumKMCognettaABCorreiaBEIchuTAOluchaJet alA global map of lipid-binding proteins and their ligandability in cells. Cell (2015) 161:1668–80.10.1016/j.cell.2015.05.045

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1168

  MestresJGregori-PuigjanéEValverdeSSoléRV. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol Biosyst (2009) 5:1051–7.10.1039/b905821b

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1169

  HopkinsAL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol (2008) 4:682–90.10.1038/nchembio.118

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1170

  BergerSIIyengarR. Network analyses in systems pharmacology. Bioinformatics (2009) 25:2466–72.10.1093/bioinformatics/btp465

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1171

  van der GraafPHBensonN. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res (2011) 28:1460–4.10.1007/s11095-011-0467-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1172

  Cucurull-SanchezLSpinkKGMoschosSA. Relevance of systems pharmacology in drug discovery. Drug Discov Today (2012) 17:665–70.10.1016/j.drudis.2012.01.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1173

  PrenticeRLLangerRDStefanickMLHowardBVPettingerMAndersonGLet alCombined analysis of women’s health initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol (2006) 163:589–99.10.1093/aje/kwj079

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1174

  CouzinJ. Cholesterol veers off script. Science (2008) 322:220–3.10.1126/science.322.5899.220

  • CrossRef
  • Google Scholar

• 1175

  PetersonRT. Chemical biology and the limits of reductionism. Nat Chem Biol (2008) 4:635–8.10.1038/nchembio1108-635

  • CrossRef
  • Google Scholar

• 1176

  RobinsonJG. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am J Cardiol (2008) 101:1009–15.10.1016/j.amjcard.2007.11.060

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1177

  EndoA. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci (2010) 86:484–93.10.2183/pjab.86.484

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1178

  WagnerBKKitamiTGilbertTJPeckDRamanathanASchreiberSLet alLarge-scale chemical dissection of mitochondrial function. Nat Biotechnol (2008) 26:343–51.10.1038/nbt1387

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1179

  LibbyPAikawaM. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med (2002) 8:1257–62.10.1038/nm1102-1257

  • CrossRef
  • Google Scholar

• 1180

  LiaoJK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol (2002) 86:5–18.10.1016/S0167-5273(02)00195-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1181

  UndasABrozekJMusialJ. Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin Lab (2002) 48:287–96.

  • Pubmed Abstract
  • Google Scholar

• 1182

  Weitz-SchmidtG. Statins as anti-inflammatory agents. Trends Pharmacol Sci (2002) 23:482–6.10.1016/S0165-6147(02)02077-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1183

  Blanco-ColioLMTuñonJMartin-VenturaJLEgidoJ. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int (2003) 63:12–23.10.1046/j.1523-1755.2003.00744.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1184

  KwakBRMulhauptFMachF. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev (2003) 2:332–8.10.1016/S1568-9972(03)00049-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1185

  SteffensSMachF. Anti-inflammatory properties of statins. Semin Vasc Med (2004) 4:417–22.10.1055/s-2004-869599

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1186

  JainMKRidkerPM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov (2005) 4:977–87.10.1038/nrd1901

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1187

  AbelesAMPillingerMH. Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?Arthritis Rheum (2006) 54:393–407.10.1002/art.21521

  • CrossRef
  • Google Scholar

• 1188

  EndresM. Statins: potential new indications in inflammatory conditions. Atheroscler Suppl (2006) 7:31–5.10.1016/j.atherosclerosissup.2006.01.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1189

  LiJJZhengXLiJ. Statins may be beneficial for patients with slow coronary flow syndrome due to its anti-inflammatory property. Med Hypotheses (2007) 69:333–7.10.1016/j.mehy.2006.09.070

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1190

  MiraEManesS. Immunomodulatory and anti-inflammatory activities of statins. Endocr Metab Immune Disord Drug Targets (2009) 9:237–47.10.2174/187153009789044383

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1191

  DinarelloCA. Anti-inflammatory agents: present and future. Cell (2010) 140:935–50.10.1016/j.cell.2010.02.043

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1192

  BuDXGriffinGLichtmanAH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol (2011) 22:165–70.10.1097/MOL.0b013e3283453e41

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1193

  AntonopoulosASMargaritisMLeeRChannonKAntoniadesC. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des (2012) 18:1519–30.10.2174/138161212799504803

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1194

  LiappisAPKanVLRochesterCGSimonGL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis (2001) 33:1352–7.10.1086/323334

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1195

  TerblancheMAlmogYRosensonRSSmithTSHackamDG. Statins: panacea for sepsis?Lancet Infect Dis (2006) 6:242–8.10.1016/S1473-3099(06)70439-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1196

  FalagasMEMakrisGCMatthaiouDKRafailidisPI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother (2008) 61:774–85.10.1093/jac/dkn019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1197

  SunHYSinghN. Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. Clin Infect Dis (2009) 48:745–55.10.1086/597039

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1198

  KozarovEPadroTBadimonL. View of statins as antimicrobials in cardiovascular risk modification. Cardiovasc Res (2014) 102:362–74.10.1093/cvr/cvu058

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1199

  SandekAUtchillSRauchhausM. The endotoxin-lipoprotein hypothesis – an update. Arch Med Sci (2007) 3:S81–90.

  • Google Scholar

• 1200

  UkincKErsozHOEremCHacihasanogluABKartiSS. Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. Endocrine (2009) 35:380–8.10.1007/s12020-009-9157-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1201

  MascitelliLGoldsteinMR. Might the beneficial effects of statin drugs be related to their action on iron metabolism?QJM (2012) 105:1225–9.10.1093/qjmed/hcs204

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1202

  KanugulaAKGollavilliPNVasamsettiSBKarnewarSGopojuRUmmanniRet alStatin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms. FEBS J (2014) 281:3719–38.10.1111/febs.12893

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1203

  LecarpentierEMorelOFournierTElefantEChavatte-PalmerPTsatsarisV. Statins and pregnancy: between supposed risks and theoretical benefits. Drugs (2012) 72:773–88.10.2165/11632010-000000000-00000

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1204

  CostantineMMClearyKEunice Kennedy Shriver National Institute of Child, Health, Human Development Obstetric – Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol (2013) 121:349–53.10.1097/AOG.0b013e31827d8ad5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1205

  DowningJWBaysingerCLJohnsonRFPaschallRL. Review: potential druggable targets for the treatment of early onset preeclampsia. Pregnancy Hypertens (2013) 3:203–10.10.1016/j.preghy.2013.04.120

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1206

  CarverARTamayoEPerez-PoloJRSaadeGRHankinsGDVCostantineMM. The effect of maternal pravastatin therapy on adverse sensorimotor outcomes of the offspring in a murine model of preeclampsia. Int J Dev Neurosci (2014) 33:33–40.10.1016/j.ijdevneu.2013.11.004

  • CrossRef
  • Google Scholar

• 1207

  Cindrova-DaviesT. The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia. Front Pharmacol (2014) 5:119.10.3389/fphar.2014.00119

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1208

  GirardiG. Can statins prevent pregnancy complications?J Reprod Immunol (2014) 10(1–102):161–7.10.1016/j.jri.2013.07.005

  • CrossRef
  • Google Scholar

• 1209

  McDonnoldMTamayoEKechichianTGamblePLongoMHankinsGDVet alThe effect of prenatal pravastatin treatment on altered fetal programming of postnatal growth and metabolic function in a preeclampsia-like murine model. Am J Obstet Gynecol (2014) 210(542):e541–7.10.1016/j.ajog.2014.01.010

  • CrossRef
  • Google Scholar

• 1210

  RammaWAhmedA. Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. J Reprod Immunol (2014) 10(1–102):153–60.10.1016/j.jri.2013.12.120

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1211

  SaadAFKechichianTYinHSbranaELongoMWenMet alEffects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci (2014) 21:138–45.10.1177/1933719113492207

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1212

  StaffACJohnsenGMDechendRRedmanCWG. Preeclampsia and uteroplacental acute atherosis: immune and inflammatory factors. J Reprod Immunol (2014) 10(1–102):120–6.10.1016/j.jri.2013.09.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1213

  AhmedARammaW. Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?Br J Pharmacol (2015) 172:1574–86.10.1111/bph.12977

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1214

  BauerAJBanekCTNeedhamKGillhamHCapocciaSRegalJFet alPravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension (2013) 61:1103–10.10.1161/HYPERTENSIONAHA.111.00226

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1215

  CarverARAndrikopoulouMLeiJTamayoEGamblePHouZet alMaternal pravastatin prevents altered fetal brain development in a preeclamptic CD-1 mouse model. PLoS One (2014) 9:e100873.10.1371/journal.pone.0100873

  • CrossRef
  • Google Scholar

• 1216

  LefkouEMamopoulosAFragakisNDagklisTVosnakisCNounopoulosEet alClinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension (2014) 63:e118–9.10.1161/HYPERTENSIONAHA.114.03115

  • CrossRef
  • Google Scholar

• 1217

  BrownfootFCTongSHannanNJBinderNKWalkerSPCannonPet alEffects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension (2015) 66:687–97; discussion 445.10.1161/HYPERTENSIONAHA.115.05445

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1218

  ChaiworapongsaTRomeroRKorzeniewskiSJChaemsaithongPHernandez-AndradeESegarsJHet alPravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). J Matern Fetal Neonatal Med (2016) 29:855–62.10.3109/14767058.2015.1022864

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1219

  DowningJ. Sildenafil for the treatment of preeclampsia. Hypertens Pregnancy (2010) 29:248–50; author reply 251–2.10.3109/10641951003634766

  • CrossRef
  • Google Scholar

• 1220

  KakiganoATomimatsuTMimuraKKanayamaTFujitaSMinatoKet alDrug repositioning for preeclampsia therapeutics by in vitro screening: phosphodiesterase-5 inhibitor vardenafil restores endothelial dysfunction via induction of placental growth factor. Reprod Sci (2015) 22:1272–80.10.1177/1933719115574340

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1221

  RamesarSVMackrajIGathiramPMoodleyJ. Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague-Dawley rats. Eur J Obstet Gynecol Reprod Biol (2011) 157:136–40.10.1016/j.ejogrb.2011.03.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1222

  HerraizSPellicerBSerraVCauliOCortijoJFelipoVet alSildenafil citrate improves perinatal outcome in fetuses from pre-eclamptic rats. BJOG (2012) 119:1394–402.10.1111/j.1471-0528.2012.03430.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1223

  NassarAHMasrouhaKZItaniHNaderKAUstaIM. Effects of sildenafil in Nomega-nitro-L-arginine methyl ester-induced intrauterine growth restriction in a rat model. Am J Perinatol (2012) 29:429–34.10.1055/s-0032-1304823

  • CrossRef
  • Google Scholar

• 1224

  StanleyJLAnderssonIJPoudelRRueda-ClausenCFSibleyCPDavidgeSTet alSildenafil citrate rescues fetal growth in the catechol-O-methyl transferase knockout mouse model. Hypertension (2012) 59:1021–8.10.1161/HYPERTENSIONAHA.111.186270

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1225

  GeorgeEMPaleiACDentEAGrangerJP. Sildenafil attenuates placental ischemia-induced hypertension. Am J Physiol Regul Integr Comp Physiol (2013) 305:R397–403.10.1152/ajpregu.00216.2013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1226

  StanleyJLSulekKAnderssonIJDavidgeSTKennyLCSibleyCPet alSildenafil therapy normalizes the aberrant metabolomic profile in the comt(-/-) mouse model of preeclampsia/fetal growth restriction. Sci Rep (2015) 5:18241.10.1038/srep18241

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1227

  KarasuEKayacanNSadanGDincB. Different effects of different phosphodiesterase type-5 inhibitors in pre-eclampsia. Pregnancy Hypertens (2011) 1:231–7.10.1016/j.preghy.2011.04.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1228

  KarasuEKayacanNSadanGDincB. Endothelial dysfunction in the human umbilical artery due to preeclampsia can be prevented by sildenafil. Clin Exp Hypertens (2012) 34:79–85.10.3109/10641963.2011.628730

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1229

  GanzevoortWAlfirevicZVon DadelszenPKennyLPapageorghiouAVan Wassenaer-LeemhuisAet alSTRIDER: sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction – a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev (2014) 3:23.10.1186/2046-4053-3-23

  • CrossRef
  • Google Scholar

• 1230

  AbalosEDuleyLSteynDW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev (2014) 2:CD002252.10.1002/14651858.CD002252.pub3

  • CrossRef
  • Google Scholar

• 1231

  MahmudHFöllerMLangF. Stimulation of erythrocyte cell membrane scrambling by methyldopa. Kidney Blood Press Res (2008) 31:299–306.10.1159/000153250

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1232

  FirozTMageeLAMacdonellKPayneBAGordonRVidlerMet alOral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG (2014) 121:1210–8; discussion 1220.10.1111/1471-0528.12737

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1233

  MageeLANamouz-HaddadSCaoVKorenGVon DadelszenP. Labetalol for hypertension in pregnancy. Expert Opin Drug Saf (2015) 14:453–61.10.1517/14740338.2015.998197

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1234

  IshimaruTIshidaJNakamuraSHashimotoMMatsukuraTNakamuraAet alShort-term suppression of the renin-angiotensin system in mice associated with hypertension during pregnancy. Mol Med Rep (2012) 6:28–32.10.3892/mmr.2012.886

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1235

  MarshallTGLeeREMarshallFE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model (2006) 3:1.10.1186/1742-4682-3-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1236

  ZieglerEJFisherCJJrSprungCLStraubeRCSadoffJCFoulkeGEet alTreatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med (1991) 324:429–36.10.1056/NEJM199102143240701

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1237

  BaumgartnerJDGlauserMP. Immunotherapy of endotoxemia and septicemia. Immunobiology (1993) 187:464–77.10.1016/S0171-2985(11)80357-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1238

  DerkxBWittesJMccloskeyR. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis (1999) 28:770–7.10.1086/515184

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1239

  YentisSMSoniNRichesPG. In vitro effects of HA-1A (centoxin) on cytokine production in whole blood from intensive care unit patients. Br J Anaesth (1994) 73:805–11.10.1093/bja/73.6.805

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1240

  MarksL. The birth pangs of monoclonal antibody therapeutics: the failure and legacy of centoxin. MAbs (2012) 4:403–12.10.4161/mabs.19909

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1241

  HelmerhorstEJMaaskantJJAppelmelkBJ. Anti-lipid A monoclonal antibody centoxin (HA-1A) binds to a wide variety of hydrophobic ligands. Infect Immun (1998) 66:870–3.

  • Pubmed Abstract
  • Google Scholar

• 1242

  TanNSHoBDingJL. High-affinity LPS binding domain(s) in recombinant factor C of a horseshoe crab neutralizes LPS-induced lethality. FASEB J (2000) 14:859–70.10.1096/fj.1530-6860

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1243

  TanNSNgMLYauYHChongPKWHoBDingJL. Definition of endotoxin binding sites in horseshoe crab factor C recombinant sushi proteins and neutralization of endotoxin by sushi peptides. FASEB J (2000) 14:1801–13.10.1096/fj.99-0866com

  • CrossRef
  • Google Scholar

• 1244

  YauYHHoBTanNSNgMLDingJL. High therapeutic index of factor C sushi peptides: potent antimicrobials against Pseudomonas aeruginosa. Antimicrob Agents Chemother (2001) 45:2820–5.10.1128/AAC.45.10.2820-2825.2001

  • CrossRef
  • Google Scholar

• 1245

  LiPSunMWohlandTHoBDingJL. The molecular mechanism of interaction between sushi peptide and Pseudomonas endotoxin. Cell Mol Immunol (2006) 3:21–8.

  • Pubmed Abstract
  • Google Scholar

• 1246

  LiPSunMWohlandTYangDHoBDingJL. Molecular mechanisms that govern the specificity of sushi peptides for Gram-negative bacterial membrane lipids. Biochemistry (2006) 45:10554–62.10.1021/bi0602765

  • CrossRef
  • Google Scholar

• 1247

  DingJLLiPHoB. The sushi peptides: structural characterization and mode of action against Gram-negative bacteria. Cell Mol Life Sci (2008) 65:1202–19.10.1007/s00018-008-7456-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1248

  LeptihnSHarJYChenJHoBWohlandTDingJL. Single molecule resolution of the antimicrobial action of quantum dot-labeled sushi peptide on live bacteria. BMC Biol (2009) 7:22.10.1186/1741-7007-7-22

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1249

  LeptihnSGuoLFrecerVHoBDingJLWohlandT. One step at a time: action mechanism of sushi 1 antimicrobial peptide and derived molecules. Virulence (2010) 1:42–4.10.4161/viru.1.1.10229

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1250

  FrecerVHoBDingJL. De novo design of potent antimicrobial peptides. Antimicrob Agents Chemother (2004) 48:3349–57.10.1128/AAC.48.9.3349-3357.2004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1251

  BhattacharjyaS. De novo designed lipopolysaccharide binding peptides: structure based development of antiendotoxic and antimicrobial drugs. Curr Med Chem (2010) 17:3080–93.10.2174/092986710791959756

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1252

  BrantsaeterALMyhreRHaugenMMykingSSengpielVMagnusPet alIntake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study. Am J Epidemiol (2011) 174:807–15.10.1093/aje/kwr168

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1253

  GluckmanPBeedleAHansonM. Principles of Evolutionary Medicine. Oxford: Oxford University Press (2009).

  • Google Scholar

• 1254

  HemmingsDG. Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine. Naunyn Schmiedebergs Arch Pharmacol (2006) 373:18–29.10.1007/s00210-006-0046-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1255

  HemmingsDGHudsonNKHallidayDO’HaraMBakerPNDavidgeSTet alSphingosine-1-phosphate acts via rho-associated kinase and nitric oxide to regulate human placental vascular tone. Biol Reprod (2006) 74:88–94.10.1095/biolreprod.105.043034

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1256

  TeijaroJRWalshKBCahalanSFremgenDMRobertsEScottFet alEndothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell (2011) 146:980–91.10.1016/j.cell.2011.08.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1257

  OldstoneMBATeijaroJRWalshKBRosenH. Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection. Virology (2013) 435:92–101.10.1016/j.virol.2012.09.039

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1258

  MaceykaMSpiegelS. Sphingolipid metabolites in inflammatory disease. Nature (2014) 510:58–67.10.1038/nature13475

  • CrossRef
  • Google Scholar

• 1259

  OldstoneMBARosenH. Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule. Curr Top Microbiol Immunol (2014) 378:129–47.10.1007/978-3-319-05879-5_6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1260

  WalshKBTeijaroJRBrockLGFremgenDMCollinsPLRosenHet alAnimal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy. J Virol (2014) 88:6281–93.10.1128/JVI.00464-14

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1261

  ArishMHuseinAKashifMSaleemMAkhterYRubA. Sphingosine-1-phosphate signaling: unraveling its role as a drug target against infectious diseases. Drug Discov Today (2016) 21:133–42.10.1016/j.drudis.2015.09.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1262

  ZhangJDunkCELyeSJ. Sphingosine signalling regulates decidual NK cell angiogenic phenotype and trophoblast migration. Hum Reprod (2013) 28:3026–37.10.1093/humrep/det339

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1263

  NagamatsuTIwasawa-KawaiYIchikawaMKawanaKYamashitaTOsugaYet alEmerging roles for lysophospholipid mediators in pregnancy. Am J Reprod Immunol (2014) 72:182–91.10.1111/aji.12239

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1264

  RomanowiczLBańkowskiE. Altered sphingolipid composition in Wharton’s jelly of pre-eclamptic newborns. Pathobiology (2010) 77:78–87.10.1159/000278289

  • CrossRef
  • Google Scholar

• 1265

  RomanowiczLBańkowskiE. Lipid compounds of human Wharton’s jelly and their alterations in preeclampsia. Int J Exp Pathol (2010) 91:1–9.10.1111/j.1365-2613.2009.00675.x

  • CrossRef
  • Google Scholar

• 1266

  RomanowiczLBańkowskiE. Sphingolipids of human umbilical cord vein and their alteration in preeclampsia. Mol Cell Biochem (2010) 340:81–9.10.1007/s11010-010-0403-z

  • CrossRef
  • Google Scholar

• 1267

  BaigSLimJYFernandisAZWenkMRKaleASuLLet alLipidomic analysis of human placental syncytiotrophoblast microvesicles in adverse pregnancy outcomes. Placenta (2013) 34:436–42.10.1016/j.placenta.2013.02.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1268

  LiQPanZWangXGaoZRenCYangW. miR-125b-1-3p inhibits trophoblast cell invasion by targeting sphingosine-1-phosphate receptor 1 in preeclampsia. Biochem Biophys Res Commun (2014) 453:57–63.10.1016/j.bbrc.2014.09.059

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1269

  Carrillo-VicoALardonePJNajiLFernández-SantosJMMartín-LacaveIGuerreroJMet alBeneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. J Pineal Res (2005) 39:400–8.10.1111/j.1600-079X.2005.00265.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1270

  GittoEPellegrinoSGittoPBarberiIReiterRJ. Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. J Pineal Res (2009) 46:128–39.10.1111/j.1600-079X.2008.00649.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1271

  HobsonSRLimRGardinerEEAlersNOWallaceEM. Phase I pilot clinical trial of antenatal maternally administered melatonin to decrease the level of oxidative stress in human pregnancies affected by pre-eclampsia (PAMPR): study protocol. BMJ Open (2013) 3:e003788.10.1136/bmjopen-2013-003788

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1272

  WesthHLisbyGBreysseFBoddinghausBChomaratMGantVet alMultiplex real-time PCR and blood culture for identification of bloodstream pathogens in patients with suspected sepsis. Clin Microbiol Infect (2009) 15:544–51.10.1111/j.1469-0691.2009.02736.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1273

  YangBWangYQianPY. Sensitivity and correlation of hypervariable regions in 16S rRNA genes in phylogenetic analysis. BMC Bioinformatics (2016) 17:135.10.1186/s12859-016-0992-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1274

  KhamisARaoultDLa ScolaB. Comparison between rpoB and 16S rRNA gene sequencing for molecular identification of 168 clinical isolates of Corynebacterium. J Clin Microbiol (2005) 43:1934–6.10.1128/JCM.43.4.1934-1936.2005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1275

  AdékambiTDrancourtMRaoultD. The rpoB gene as a tool for clinical microbiologists. Trends Microbiol (2009) 17:37–45.10.1016/j.tim.2008.09.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1276

  RouxSEnaultFBronnerGDebroasD. Comparison of 16S rRNA and protein-coding genes as molecular markers for assessing microbial diversity (bacteria and archaea) in ecosystems. FEMS Microbiol Ecol (2011) 78:617–28.10.1111/j.1574-6941.2011.01190.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1277

  LiuWLiLKhanMAZhuF. Popular molecular markers in bacteria. Mol Gen Microbiol Virol (2012) 27(3):103–7.10.3103/S0891416812030056

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1278

  VětrovskýTBaldrianP. The variability of the 16S rRNA gene in bacterial genomes and its consequences for bacterial community analyses. PLoS One (2013) 8:e57923.10.1371/journal.pone.0057923

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1279

  DasSDashHRMangwaniNChakrabortyJKumariS. Understanding molecular identification and polyphasic taxonomic approaches for genetic relatedness and phylogenetic relationships of microorganisms. J Microbiol Methods (2014) 103:80–100.10.1016/j.mimet.2014.05.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1280

  CodyAJMcCarthyNDJansen Van RensburgMIsinkayeTBentleySDParkhillJet alReal-time genomic epidemiological evaluation of human Campylobacter isolates by use of whole-genome multilocus sequence typing. J Clin Microbiol (2013) 51:2526–34.10.1128/JCM.00066-13

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1281

  LazarLRigóJJrNagyBBaloghKMakóVCervenakLet alRelationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia. BMC Med Genet (2009) 10:120.10.1186/1471-2350-10-120

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1282

  GalbiatiSCausaranoVPinzaniPFrancescaSOrlandoCSmidMet alEvaluation of a panel of circulating DNA, RNA and protein potential markers for pathologies of pregnancy. Clin Chem Lab Med (2010) 48:791–4.10.1515/CCLM.2010.160

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1283

  MirandaMLMacherHCMunoz-HernandezRVallejo-VazAMoreno-LunaRVillarJet alRole of circulating cell-free DNA levels in patients with severe preeclampsia and HELLP syndrome. Am J Hypertens (2013) 26:1377–80.10.1093/ajh/hpt187

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1284

  OudejansCBM. Maternal plasma RNA sequencing. Clin Biochem (2015) 48:942–7.10.1016/j.clinbiochem.2015.03.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1285

  HudecovaI. Digital PCR analysis of circulating nucleic acids. Clin Biochem (2015) 48:948–56.10.1016/j.clinbiochem.2015.03.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1286

  CoatesARMHuY. New strategies for antibacterial drug design: targeting non-multiplying latent bacteria. Drugs R D (2006) 7:133–51.10.2165/00126839-200607030-00001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1287

  HuYShamaei-TousiALiuYCoatesA. A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infections. PLoS One (2010) 5:e11818.10.1371/journal.pone.0011818

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1288

  CoatesARHallsGHuY. Novel classes of antibiotics or more of the same?Br J Pharmacol (2011) 163:184–94.10.1111/j.1476-5381.2011.01250.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1289

  LaxminarayanRDuseAWattalCZaidiAKWertheimHFSumpraditNet alAntibiotic resistance – the need for global solutions. Lancet Infect Dis (2013) 13:1057–98.10.1016/S1473-3099(13)70318-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1290

  HuYLiuAOrtega-MuroFAlameda-MartinLMitchisonDCoatesA. High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo. Front Microbiol (2015) 6:641.10.3389/fmicb.2015.00641

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1291

  BarberMTaitRCScottJRumleyALoweGDStottDJ. Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. J Thromb Haemost (2004) 2:1873–8.10.1111/j.1538-7836.2004.00993.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1292

  MurthySBJawaidAQureshiSUSchulzPESchulzPE. The apolipoprotein 2 allele in Alzheimer’s disease: suggestions for a judicious use of antiplatelet and anticoagulant medications. J Am Geriatr Soc (2009) 57:1124–5.10.1111/j.1532-5415.2009.02284.x

  • CrossRef
  • Google Scholar

• 1293

  AhnHJGlickmanJFPoonKLZamolodchikovDJno-CharlesOCNorrisEHet alA novel abeta-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer’s disease mice. J Exp Med (2014) 211:1049–62.10.1084/jem.20131751

  • CrossRef
  • Google Scholar

• 1294

  KrishnanRTsuberyHProschitskyMYAspELuluMGileadSet alA bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies. J Mol Biol (2014) 426:2500–19.10.1016/j.jmb.2014.04.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1295

  AnkarcronaMWinbladBMonteiroCFearnsCPowersETJohanssonJet alCurrent and future treatment of amyloid diseases. J Intern Med (2016) 280:177–202.10.1111/joim.12506

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 1296

  MarshallBJ. Helicobacter pylori. Am J Gastroenterol (1994) 89:S116–28.

  • Google Scholar